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According to the World Health Organization (WHO) world malaria report released in 2017, 
about 445,000 malaria deaths were recorded in 2016, a similar mortality as that recorded in the 
preceding year (446,000 deaths in 2015). Once effective and cheap drugs such as chloroquine 
and sulfadoxine-pyrimethamine have suffered widespread drug resistance. Additionally, 
despite the remarkable effectiveness of the currently recommended first line treatment, the 
artemisinin combination therapies (ACTs), resistance to artemisinin and the partner drugs is 
beginning to emerge in South East Asia. Furthermore, the current portfolio of medicines, both 
in clinical use and development has several other shortfalls which need redress. In addition, 
prevention of transmission and relapse with better safety profiles than current medicines are 
some of the important features that should be a prioritized characteristic of new medicines. 
Most importantly, these new regimens should be able to offer chemoprotection and prevent 
reinfection. Thus, there is need for constant research efforts aimed at identifying and 
developing novel chemotherapeutic agents for malaria, which are structurally diverse with 
novel mechanisms of action. 
In this PhD thesis, the medicinal chemistry 
optimization of two antimalarial chemotypes, 
the imidazopyridazines and aminopyrazines, is 
reported. In earlier studies, Le Manach and co-
workers reported the impressive in vitro 
antiplasmodial activity and in vivo antimalarial efficacy of the imidazopyridazine lead 
compound 19 (Figure 1). However, this compound was plagued by poor solubility and a 
cardiotoxicity risk as shown from its inhibition of the hERG (human ether-a-go-go-related 
gene)-encoded potassium channel. Further medicinal chemistry optimization led to 
identification of other derivatives which, albeit exhibiting complete cure of P. berghei-infected 
mice, still displayed poor solubility and hERG inhibition issues. In this project, chemical 
modification approaches such as the introduction of water solubilizing groups, disruption of 
molecular planarity and making subtle changes (SAR 1 – 6, Figure 1) were adopted towards 
improving the solubility and countering hERG inhibition of this class of molecules. 
Through the thesis work undertaken, analogues with a combination of reduced hERG inhibition 
(IC50 = 7.8 – 32 μM) and submicromolar antiplasmodial activity (NF54, IC50 = 0.15 – 0.92 μM) 
were identified. Likewise, the modifications made delivered analogues with moderate to high 
 
SAR 1, 
3, 5 & 6 SAR 2, 
4 & 6 




solubility (60 – 200 μM) while exhibiting submicromolar antiplasmodial potency (NF54, IC50 
= 0.14 – 0.99 μM). Furthermore, cytotoxicity assessment of selected analogues against the 
Chinese Hamster Ovarian (CHO) cell line revealed that most analogues were relatively non-
cytotoxic (selectivity indices in the range 72 - > 874). Selected compounds were also screened 
against gametocyte and liver stage parasites in order to assess transmission blocking and 
chemoprotection potential, respectively. In this regard, analogues with good gametocytocidal 
activity (IC50 = 0.098 – 0.75 μM) against late stage gametocytes and potent liver stage activity 
(IC50 = 0.045 μM) were identified. 
On the other hand, aminopyrazines have 
also recently shown potential as new 
antimalarial agents exhibiting promising in 
vivo efficacy in animal models of malaria 
infection with one analogue having 
progressed to an optimised late lead stage. 
However, this aminopyrazine lead 
compound 24 (Figure 2) as well as the first generation aminopyridine human Phase 2a clinical 
candidate MMV390048 showed sub-optimal solubility. In this aspect of the project, chemical 
modifications mainly focusing on replacing the two aromatic rings with fully and partially 
saturated heterocyclic systems, hypothesized to potentially disrupt intermolecular π – π 
stacking thereby improving aqueous solubility, were introduced. The first set of analogues 
corresponded to the replacement of the trifluoromethylpyridyl ring with partially and fully 
saturated heterocyclic rings as well as the 4-carboxyphenyl ring while keeping the 4-
methylsulfonylphenyl group on the right-hand side portion of the aminopyrazine core scaffold 
fixed (SAR 1). In SAR 2, the trifluoromethylpyridyl group was fixed on the left-hand side of 
the aminopyrazine core scaffold while introducing partial and full saturation on the right-hand 
side of the core. SAR 3 analogues with both aromatic groups simultaneously replaced with 
partially and fully saturated heterocyclic rings were further generated. 
Compared to the lead compound 24 (NF54, IC50 = 0.008 μM), the introduced modifications 
drastically reduced antiplasmodial potency with only one analogue retaining submicromolar 
activity (NF54, IC50 = 0.51 μM). However, the introduced molecular features positively 
influenced solubility with the new analogues showing 4 - > 20-fold increase in aqueous 
solubility compared to the lead compound 24. 
 
SAR 2 SAR 1 
Dual modification 





For both imidazopyridazines and aminopyrazines, docking studies on a homology model of 
PfPI4K (P. falciparum phosphatidylinositol 4‑kinase) were retrospectively undertaken. In both 
cases, the docking experiments showed that the introduction of the new molecular features was 
accompanied by loss of key binding interactions to the ATP binding pocket. This was in 
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INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Chapter Overview 
In this chapter, malaria as a disease, is introduced in the context of its brief history, 
epidemiology and aetiology. The chapter then covers malaria control and prevention strategies 
such as vector control, chemoprophylaxis, vaccination and mass drug administration (MDA) 
programmes. The status and challenges of current malaria treatment options as well as 
antimalarials in the drug development pipeline are also discussed. A survey of the emerging 
malaria eradication agenda with accompanying newly defined target product profiles (TPPs) 
for the next generation of antimalarials is presented. Furthermore, the importance of drug 
solubility and the need to profile drug candidates against drug antitargets such as the human 
ether-a-go-go-related gene (hERG) potassium ion channel is highlighted. Commonly 
employed strategies to optimize solubility and counter hERG inhibition are also summarised. 
This is followed by a literature survey of biological properties of imidazopyridazines and 
aminopyrazines which were a subject of this thesis research. The chapter concludes with an 
introduction of the overall research programme, detailing the justification of the study, research 
questions, objective and specific aims. 
   
1.2 Malaria: History and Introduction 
There are over 125 different types of malaria parasite species that infect mammals, birds and 
reptiles. The disease is known to be one of the most ubiquitous and has probably ravaged 
humanity throughout its evolutionary history.1 However, the symptoms matching those of 
malaria were first historically reported around 1550 BC by the ancient Egyptians who noted 
the association between fevers and wet gounds.1 The association of malaria with wet ground 
or stagnant waters later prompted Romans to embark on drainage programmes which marked 
one of the first preventive measures aimed at halting malaria in the Roman Empire.2 In Europe 
and Africa, malaria has been a major public health problem for many centuries, and its spread 
has been encouraged by travelling tradesmen, settlers and conquering forces. Particularly, the 
spread of malaria to the New World has been thought to result from the over 400 years of slave 
trade which also resulted in the deaths of millions of Africans from the disease.2 Although 
malaria generally thrives in tropical regions, the early settlers of America suffered a 
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pronounced impact with incidences peaking in 1875 and more than 600,000 cases being 
reported in 1914.2 
Ground-breaking advances in medicine and dedicated efforts of individual scientists have 
helped in the shift of the understanding of the disease from the ancient mythology-based 
approach to a clear scientific insight. Malaria parasites in the blood of infected patients were 
first discovered by Charles Louis Alphonse Laveran, a French Army surgeon.3 An Italian 
neurophysiologist, Camillo Golgi, later established a positive correlation between fever 
symptoms and the rupture and release of merozoites into the blood stream.3 In 1898-1899, 
Giovanni Batista Grassi and co-workers showed that the female Anopheles mosquito was 
responsible for the transmission of malaria from one human to the other.3  
Reports on the origins of malaria, particularly, Plasmodium falciparum malaria, the most 
virulent form of the disease, have been contradictory. P. falciparum DNA (deoxyribonucleic 
acid) has been detected in Egyptian mummified remains dating as far back as 1500 – 500 BC4 
while other studies suggest the disease originated from Gorillas and was probably transmitted 
to humans from these apes.5 Still other reports indicate that a bird parasite whose descendants 
include both the human-infecting P. falciparum and the chimpanzee-infecting P. reichenowii 
could have been the origin of falciparum malaria.6 
         
1.3 Epidemiology of Malaria 
Approximately 50% of the world’s population was at risk of malaria in 2016.7 In the same year, 
ongoing malaria transmission was reported in 91 mainly tropical countries and regions (Figure 
1.1). In 2004, malaria deaths were reported to peak at 1.82 million and declined to 1.24 million 
in 2010 according to the Institute for Health Metrics and Epidemiology (IHME).8 According 
to the WHO world malaria report released in 2017, about 445,000 malaria deaths were recorded 
in 2016, a similar mortality as that recorded in the preceding year (446,000 deaths in 2015). A 
disproportionately high share of this global malaria burden is carried by the WHO African 
region (Figure 1.1). In this regard, 90% of malaria cases and 91% of malaria deaths in 2016 
occurred in this region. Additionally, 80% of the global malaria burden was accounted for by 
some 15 countries all of which, except India, are in sub-Saharan Africa.7 




Figure 1.1: Malaria-endemic countries in 2000 and 2016.7 
 
Great strides have been made in the fight against malaria in the period between 2000 and 2015. 
In this period, a 41 and 62% reduction in malaria incidence rates and mortality respectively 
have been recorded.7 In 2000, 108 countries were considered malaria endemic while only 91 
countries and territories were considered so at the beginning of 2016 (Figure 1.1). The wide-
spread deployment of malaria control interventions can partly explain such successes. 
According to the WHO, malaria is considered to have been eliminated in a particular country 
if that country registers zero indigenous cases in three consecutive years. Although Tajikistan 
has not yet had 3 consecutive years of zero indigenous malaria cases, no country in the WHO 
European region reported indigenous cases in 2015.7 Unfortunately, for South East Asia, Africa 
and the Western Pacific, the decline in mortality for all age groups appears to have stalled.7 
However, the understanding of the malaria control programme success is complicated by the 
uncertainties in the number of cases and deaths reported. In this regard, 31 countries, including 
the high burden countries like India and Nigeria, out of the 55 countries were the burden was 
estimated, have a malaria reporting rate of less than 50%.7 
The risk of contracting and developing severe malaria is considerably higher in some 
population groups than others. Amongst the high-risk groups are infants, children under 5 years 
of age, pregnant women, HIV/AIDS patients, non-immune migrants, mobile populations and 
travellers. Accordingly, such vulnerable population groups need special protection against 
malaria infection by national malaria control programmes.7 Children under the age of 5 years 
CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
4 
 
are particularly vulnerable to malaria infections in areas with high transmission with over 70% 
of all deaths occurring in this age group.7 Indeed, malaria remains a major cause of morbidity 
in under 5 children taking the life of a child every two minutes. 
 
1.4 Aetiology of Malaria 
1.4.1 Parasite Species Responsible for Malaria 
Human malaria is caused by mainly four species of protozoan parasites of the genus 
Plasmodium which include P. falciparum, P. vivax, P. malariae and P. ovale.9 Disturbingly, 
P. knowlesi, a malaria parasite strain known to infect monkeys and occurring in certain forested 
areas of South East Asia, has recently been shown to infect humans.10 P. falciparum accounts 
for the largest burden of disease followed by P. vivax.11 Sub-Saharan Africa, New Guinea and 
Hispaniola are predominated by P. falciparum while P. vivax affects the Americas and the 
Western Pacific the most. However, in the Indian sub-continent, Eastern Asia and Oceania, 
these two species exhibit approximately equal prevalence.12–14 Endemic sub-Saharan African 
countries also harbour P. malariae the most although it is rare. P. ovale accounts for under 1% 
of isolates and is relatively unusual outside of the African continent.15 Using molecular 
methods, the species P. knowlesi which is morphologically similar to P. malariae has been 
identified in patients in Malaysia, the Philippines, Thailand and Myanmar. However, human-
to-mosquito transmission of P. knowlesi has not yet been demonstrated and it appears a monkey 
reservoir may be required to infect mosquitoes.10     
 
1.4.2 Malaria Parasite Life Cycle 
As malaria drug discovery efforts evolve, with focus on designing antimalarials that inhibit 
parasite growth at multiple stages of development,16 understanding the parasite life cycle 
becomes important. Of the parasites that infect humans, the life cycle of P. falciparum is the 
most studied and best understood.17 
Two types of hosts are infected with malaria parasites – the humans and the female Anopheles 
mosquitoes. However, the mosquito vector does not suffer from the presence of the parasites 
unlike the human host.18 The parasite life cycle is summarized in figure 1.2.18 Parasites, in the 
form of sporozoites, are introduced into the human host during a blood meal of an infected 
female Anopheles mosquito. Sporozoites then invade the liver cells, developing into schizonts 
which rupture and release merozoites. During the liver stage, particularly in P. vivax and P. 
ovale infections, dormant forms of the parasites (hypnozoites) can develop and persist in the 
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liver resulting in relapses weeks or years later. The initial replication in the liver, also referred 
to as exo-erythrocytic schizogony, is followed by asexual multiplication in the erythrocytes in 
a process known as erythrocytic schizogony. It is this blood-stage infection cycle that is 
associated with the clinical manifestation of malaria.18 Upon parasitizing red blood cells, 
merozoites develop into trophozoites, which subsequently mature into schizonts. The rapture 
of schizonts releases more merozoites, which infect new red blood cells thereby perpetuating 
the blood-stage infection cycle. Some trophozoites differentiate into sexual erythrocytic forms 
(gametocytes) which are then ingested by a mosquito during its blood meal.18 
 
Figure 1.2: Malaria parasite life cycle.18  
 
Parasite development in the mosquito, known as the sporogonic cycle, starts with the ingestion 
of male and female gametocytes during a blood meal by an Anopheles mosquito (figure 1.2).18 
In the mosquito’s stomach, the male and female gametes fuse together to form zygotes. The 
zygotes then develop into ookinetes, which are elongated and motile. The ookinetes then 
migrate to the midgut wall of the mosquito and further develop into oocysts. The oocysts then 
mature and rupture releasing sporozoites which in turn invade the mosquito’s salivary glands. 
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The malaria life cycle is perpetuated by the inoculation of the sporozoites into the human host 
during the next blood meal. 
 
1.5 Malaria Control, Prevention and Treatment 
Amongst some employed approaches to malaria control include preventive strategies such as 
vector management and control, chemoprophylaxis, vaccination (ongoing research efforts), 
and mass drug administration. Most importantly, case management requires the deployment of 
antimalarial drugs. 
  
1.5.1 Preventive Strategies 
1.5.1.1 Vector Management and Control 
The focus of mosquito vector control is to reduce the mosquito population. These strategies 
include the use of household insecticide indoor residual spraying (IRS), insecticide-treated nets 
(ITNs) and larval control by environmental management.15 Genetic control methods are still a 
subject of research. IRS and ITNs have become pivotal in vector control owing to the advent 
of effective insecticides against adult Anopheles mosquitoes.15 
IRS involves spraying the insecticide on residential walls and ceilings whose effect can last for 
extended periods depending on the insecticide and surface.15 Organochlorine insecticides like 
dichlorodiphenyltrichloroethane (DDT) require only once to twice applications per year while 
organophosphates like malathion require more frequent application - three or more times per 
year.19 Insecticide-treated surfaces are generally lethal to the mosquito upon contact while sub-
lethal exposure drives the mosquito outside the house. In an ideal case, the mosquito is killed 
or repelled before it can feed on humans within the house.20 Malaria elimination, achieved over 
half a century ago, in many regions including the Southern United States, most Caribbean 
islands, Southern Europe, most of the former USSR and Taiwan was facilitated by IRS 
programmes employing DDT. Malaria prevalence in South Asia, Southern Africa, South 
America and Zanzibar has also been reduced with IRS programmes involving DDT.14,21,22 
However, environmental and wildlife toxic effects of DDT led the WHO, in mid-2009, to issue 
a recommendation to phase out DDT while replacing it with other insecticides.15 
Before insecticides were available for use against adult mosquitoes, vector control efforts were 
aimed at making potential breeding sites unconducive for Anopheles larvae. Such vector 
control measures are exemplified by two famous historical cases – the fluctuation of the water 
CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
7 
 
levels in the reservoir of the Tennessee Valley Authority and the draining of the Pontine 
Marshes near Rome.23 Furthermore, village ponds and wells can be stocked with larvivorous 
fish species like Gambusia and Poecilia which are avid feeders on mosquito larvae.24 In a series 
of villages in South India, no malaria cases were detected after the implementation of this 
strategy from 1998 to 2003.23,25 In another approach, the larva-to-pupa-to-adult metamorphosis 
can be arrested by treating water-filled pits with insect growth regulators such as pyriproxyfen. 
In the 1960s, Sri Lanka nearly eradicated malaria when this approach was used. Regrettably, 
these eradication efforts where frustrated by gem mining which left more pits filled with rain 
water thereby providing new breeding ground for malaria vectors.26 
In a genetic control strategy, adult male mosquitoes can be genetically modified by irradiation 
to carry sterilizing factors such as dominant lethal mutations. Mating such sterile male insects 
with a population of females produces eggs and larvae incapable of hatching and surviving 
respectively.27 Although its application to Anopheles mosquitoes is limited, this technique has 
been successfully used to eradicate other pests.28 
 
1.5.1.2 Chemoprophylaxis 
Another strategy employed in the prevention of malaria is chemoprophylaxis. In this strategy, 
development of malaria is prevented by use of antimalarial drugs. Chemoprophylaxis is 
normally recommended for travellers to malaria-endemic countries and not for residents of 
such countries.29 Depending on the malaria parasite species and the drug resistance landscape 
in a country, the choice of chemoprophylactic agents varies. There are two phases of 
chemoprophylaxis in the context of malaria prevention – primary and terminal prophylaxis.  
In primary prophylaxis, a traveller starts taking antimalarial drugs at recommended doses 2 – 
20 days prior to departure for a malarious zone and continues throughout their stay and for 1 – 
4 weeks after return. Primary prophylaxis may either be causal or suppressive. Causal 
prophylaxis involves administration of drugs which inhibit the pre-erythrocytic schizogony 
thereby disrupting the establishment of liver stage infection. Such causal prophylactic drugs 
include primaquine and proguanil. However, the use of primaquine for such a purpose has been 
precluded due to potential adverse effects associated with long term use and its limited 
availability. On the other hand, suppressive prophylaxis offers protection against clinical 
illness by administering schizonticidal drugs which inhibit the blood stage forms of the malaria 
parasites. However, hypnozoites from P. vivax and P. ovale infections may cause relapse in 
which case terminal prophylaxis may be necessary.  
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In order to clear the hypnozoites associated with P. vivax and P. ovale infections, which can 
trigger relapses, primaquine is administered for two weeks after returning from a malarious 
zone in a strategy called terminal prophylaxis.29 
 
1.5.1.3 Vaccination 
To date and, despite decades of intense research, there is no effective antimalarial vaccine albeit 
over 20 candidates are under clinical development or are in advanced preclinical 
development.30 The most advanced injectable vaccine which is being considered for pilot 
programmes before full deployment is RTS,S/AS01 (RTS,S) also known as Mosquirix. The 
vaccine has been developed against the deadliest form of human malaria, P. falciparum and is 
known to partially protect young children against malaria.9,30 The vaccine is currently 
undergoing evaluation in sub-Saharan Africa to determine its potential to complement, and not 
replace, the core preventive, diagnostic and treatment measures recommended by the WHO.9 
In 2015, the European Medicines Agency (EMA), a stringent medicines regulatory body, gave 
a positive opinion on the vaccine, and three months later in the same year, pilot implementation 
of the vaccine in a limited number of African countries was recommended by two WHO 
advisory teams. WHO adopted these recommendations, and in November 2016, announced 
that the vaccine would be launched in pilot programmes in three sub-Saharan African 
countries.9 The initial phase of the programme has secured funding already and vaccinations 
are scheduled to begin in 2018. If safety and effectiveness are considered acceptable, these 
pilot programmes could pave way to large-scale deployment of the vaccine. 
   
1.5.1.4 Mass Drug Administration Programmes 
In low transmission settings, especially in areas threatened by the emergence of P. falciparum 
resistance, MDA is another tool which can rapidly reduce malaria parasitemia. For instance, in 
Zambia, an 87% reduction in parasite prevalence was observed in low-transmission areas when 
dihydroartemisinin – piperaquine was administered in two doses in a randomized controlled 
trial.31 However, in high transmission areas, such an effect was not observed. Another variant 
of MDA involves the identification of asymptomatic individuals via rapid diagnostic tests 
(RDTs) followed by targeted treatment of such a population. This strategy is exemplified by a 
recent elimination of nearly 70% of asymptomatic carriers in Zanzibar, a low-transmission area 
for P. falciparum. In this case, all individuals residing within 300 to 1000 meters of individuals 
with positive RDT also received antimalarial drug treatment.32 
CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
9 
 
However, the application of MDA campaigns to eradicate malaria requires caution. This is 
because the development of drug resistance has been thought to be greatly influenced by the 
malaria eradication efforts anchored on MDA programmes.33,34 These programmes are known 
to exert a considerable degree of drug pressure. Although MDA programmes, such as the use 
of iodinated salt, have registered remarkable success in contributing to the decline of endemic 
goitre, chloroquinized salt programmes are thought to have fuelled the emergence of 
chloroquine-resistant strains of P. falciparum.34 Failure to ensure each individual consumes an 
adequate dose of salt is one apparent shortfall of such a strategy. Such exposure of the parasite 
to sub-therapeutic levels of the drug subsequently encouraged the emergence of chloroquine-
resistant strains.35 
 
1.5.2 The Status and Challenges of Malaria Treatment 
1.5.2.1 Current Treatment Regimens and Challenges 
Malaria infections are treated and prevented mostly by antimalarial drugs. The erythrocytic 
stage of malarial infection, a parasite development stage associated with the symptoms of 
malaria, is the target of most antimalarial drugs. Chloroquine (Figure 1.3), a drug which was 
the first to be manufactured on a large scale for treatment and prevention of malaria, exhibits 
activity against the blood stages of P. ovale, P. malariae and susceptible strains of P. vivax and 
P. falciparum.36 However, although it remains effective in the treatment of P. ovale, P. 
malariae and, in most regions, P. vivax infections, widespread resistance in most malaria-
endemic countries has led to decline in its use for the treatment of P. falciparum malaria.37 
Other treatment options have been devised for the treatment of both uncomplicated and 
complicated malaria. In uncomplicated cases of falciparum malaria, where there is no evidence 
of vital organ dysfunction and parasitemia is less than 5%,38 the WHO has recommended 
artemisinin combination therapies (ACTs) as the first line drugs. Artemisinin derivatives which 
are administered in combination with other antimalarial drugs (lumefantrine, amodiaquine, 
mefloquine, sulfadoxine-pyrimethamine and piperaquine) include artesunate, artemether and 
dihydroartemisinin (Figure 1.3).38 In cases of complicated falciparum malaria, where advanced 
signs of organ dysfunction and high levels of parasitemia (> 5%) are evident,36,39 the cinchona 
alkaloids (quinine and quinidine) or the artemisinin derivatives (artesunate, artemether and 
artemotil) (Figure 1.3) are generally considered as treatment options.36 
 
 




Figure 1.3: Chemical structures of some antimalarial drugs in clinical use. 
 
For pregnant women in areas with medium and high malaria transmission, intermittent 
preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine has been 
recommended. In this strategy, at least three doses of sulfadoxine-pyrimethamine are 
administered to pregnant women ideally at each of three antenatal care visits during the second 
and third trimesters.40,41 Apart from suppressing and clearing asymptomatic infections from the 
placenta, each dose of sulfadoxine-pyrimethamine provides prophylaxis up to six weeks after 
treatment. Furthermore, this preventive treatment approach also protects women against 
adverse birth outcomes associated with sexually transmitted and reproductive tract infections.42 
Despite the remarkable effectiveness of ACTs, emergence of resistance to artemisinin and the 
partner drugs is continuously threatening.43 For instance, resistance to amodiaquine, one of the 
partner drugs in ACTs, has already been reported in some countries.44 Moreover, in the Thai-
Cambodia and, more recently, the Thai-Myanmar border regions, signs of artemisinin 
resistance manifested in loss of susceptibility have been documented.45–47 Furthermore, the 
current portfolio of medicines, both in clinical use and development, has several other shortfalls 
which need redress. For instance, single-dose cure regimens as opposed to current three-day 
treatments are needed. In addition, prevention of transmission and relapse with better safety 
profiles than current medicines are some of the important features that should be a prioritized 
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chemoprotection and prevent reinfection.43 Thus, there is need for constant research efforts 
aimed at identifying and developing novel chemotherapeutic agents for malaria which are 
affordable, structurally diverse with novel mechanisms of action. 
 
1.5.2.2 Current Antimalarials: Classification Based on Life Cycle Stage Targeted 
Classification of antimalarial drugs can be based on their structure or the parasite life cycle 
stage targeted. Based on structure, current antimalarials fall into one of these classes of 
molecules: aryl amino alcohols, 4-aminoquinolines, 8-aminoquinolines, folate synthesis 
inhibitors, antimicrobials, peroxides, naphthoquinones and iron chelating agents. Respectively, 
one example of each of these classes is quinine, chloroquine, primaquine, pyrimethamine, 
doxycycline, artemether, atovaquone and desferrioxamine.48 The classification based on 
parasite life cycle stage targeted will be discussed in greater detail in the following sub-
sections. 
 
1.5.2.2.1 Tissue Schizontocides 
The target stages of this class of drugs are the pre-erythrocytic stages of the parasite in the liver 
cells. Proguanil and pyrimethamine (Figure 1.3) are the less toxic members of this group and 




These drugs, among which, primaquine (Figure 1.3) and some other 8-aminoquinolines are the 
only examples found to be effective in man, kill the hypnozoites which are the dormant liver 
stages of the parasite. Therefore, in P. vivax and P. ovale infections, these drugs are used to 
prevent relapse associated with infections from these two parasite strains.49 
 
1.5.2.2.3 Blood Schizontocides 
These antimalarials are generally used in therapy and are quick acting only on the erythrocytic 
stage of parasite development.49 Examples include chloroquine and quinine (Figure 1.3) with 
chloroquine being one of the less toxic members of this family. They are used to prevent the 
progression of malaria infection to disease by acting as suppressive prophylactics. Although 
they are not potent on the mature gametocytes of P. falciparum, these drugs are potent against 
gametocytes of P. vivax, P. ovale and P. malariae. In addition to acting at other stages, drugs 
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such as pyrimethamine, proguanil, sulphonamides, antibiotics, and to a lesser extent, 
primaquine (Figure 1.3) also possess blood-schizontocidal efficacy.49 
 
1.5.2.2.4 Gametocytocides 
These drugs kill the blood stage sexual forms of the parasite as well as the mature gametocytes 
of P. falciparum. A typical example of a drug used for this purpose, among other 8-
aminoquinoline drugs, is primaquine.49 
  
1.5.2.2.5 Sporontocides 
Generally, this refers to drugs or their metabolites which interfere with oocyst or sporozoite 
development in the mosquito following a blood meal. Sporontocidal drugs, exemplified by 
pyrimethamine, also inhibit oocyst and sporozoite development when fed directly to 
mosquitoes.49 
 
1.6 Current Antimalarials in Clinical Development 
The Medicines for Malaria Venture (MMV), a public-private partnership with the goal of 
fostering development of new malaria treatments archives and updates, every 3 months, a 
comprehensive list of most of new compounds under development across the globe.50 Table 
1.1, adapted from the MMV’s summary, shows antimalarial compounds, including those 
supported by MMV at different phases of clinical development. Following pre-clinical 
evaluation, clinical development of a drug candidate constitutes three phases. In phase I trials, 
the safety, tolerability and dosing in healthy adult volunteers are determined. The drug 
candidate is then progressed to phase II where it is tested in a limited number of patients to 
demonstrate the proof-of-concept and further evaluate safety. Phase III trials involve a large 
cohort of patients in endemic countries and are aimed at comparing efficacy with the standard 
of care as well as reconfirm safety before the product is licensed. 
Table 1.1: Summary of antimalarial drug candidates at different phases of development.a 
Translational Product Development 
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Table 1.1: Summary of antimalarial drug candidates at different phases of development.a 
Translational Product Development 






























































































aAdapted from MMV’s summary of the global portfolio of antimalarial candidates in clinical development.50 




Over the past decade, new chemical entities have entered clinical development transforming 
the portfolio of malaria medicines (Table 1.1).51 In this section, brief backgrounds for selected 
drug candidates from table 1.1 are outlined. 
Currently, radical cure for P. vivax infections relies on primaquine which is administered for 
fourteen days to completely clear P. vivax parasites from the body. Unfortunately, primaquine 
is incompatible with patients with G6PD (glucose 6‑phosphate1‑dehydrogenase) deficiency 
posing a significantly high risk of haemolysis.52 Although not structurally novel, tafenoquine 
(structure in figure 1.4), currently in clinical development (Table 1.1), represents a promising 
alternative to primaquine with clinical studies showing a single dose could clear P. vivax 
parasites.53,54 This is a significant improvement from primaquine which takes 14 days of 
treatment. Regrettably, like primaquine, tafenoquine will require a point of care G6PD 
diagnostic test owing to its haemolytic liabilities.51 
Although the cornerstone of current antimalarial therapy are artemisinin derivatives like 
artesunate, the fact that the raw material is still derived from plants still hampers access to such 
regimens especially in resource-constrained settings. The 1.5 years lead time between demand 
for the raw material and supply has occasionally led to devastating changes in prices – the past 
decade has seen a variation in artesunate prices by as much as 4-fold.51 In response to this 
supply problem, MMV, in collaboration with other partners, launched a campaign to synthesize 
endoperoxide derivatives as effective and affordable as artesunate at its best price ($400 per 
kg). Such efforts have culminated in the synthesis of OZ277 which was subsequently called 
Rbx11160 or arterolane (Figure 1.4). Compared to the high price of artesunate triggered by 
supply problems, the synthesis was cheaper costing $800 per kg although there is still room for 
further reduction of this figure to $400 per kg. Comparison of arterolane with the marketed 
artemether-lumefantrine fixed dose combination (Coartem), in clinical studies demonstrated 
its non-inferior efficacy.55 Arterolane, in combination with piperaquine (Table 1.1), under the 
trade name Synriam, has received approval in India and later in seven African countries 
following a limited phase III study albeit more stringent regulatory bodies and the WHO are 
yet to approve the medicine.51 Efforts to generate a next-generation compound that could solve 
artesunate price fluctuations with a potentially longer half-life have also delivered OZ439 (also 
known as artefenomel, figure 1.4) which is now undergoing evaluation in combination with 
piperaquine in a phase IIb study (Table 1.1).51 




Figure 1.4: Chemical structures of some new antimalarial clinical candidates. 
 
Using target-based approaches, another noteworthy compound DSM265 (Figure 1.4), 
belonging to the triazolopyrimidine class, was discovered and commenced phase IIa (Table 
1.1) monotherapy studies in Peru at the beginning of 2015. DSM265 exerts its antimalarial 
efficacy by inhibiting Plasmodium falciparum dihydroorotate dehydrogenase.56 On the other 
hand, phenotypic-based approaches have recently furnished KAE609 (Figure 1.4) also known 
as cipargamin, a spiroindolone which holds immense promise as a structurally novel 
antimalarial.57,58 Medicinal chemistry optimization of the initial hit led to the lead KAE609 
which progressed rapidly through phase I59 and the first studies in human patients have so far 
been concluded in Thailand (Table 1.1).60 Interestingly, apart from maintaining a plasma 
concentration above the MIC value for several days, KAE609 kills even faster than artesunate. 
Furthermore, it is 40- and 7-fold more potent than 4-aminoquinolines and artesunate 
respectively and required relatively low doses (30 – 75 mg) in total during clinical studies. 
Therefore, KAE609 has potential to be cheaper than current therapies and could potentially 
cure malaria in a single dose. It was anticipated that by 2017, KAE609 would be submitted for 
approval.61 Other notable drug candidates with the same molecular target as KAE609 include 
SJ557733 (also known as SJ733) (Figure 1.4) which entered the first-in-human studies in 2016 
(Table 1.1) sponsored by St Jude Children’s Research Hospital and Rutgers University.62 
The recent contribution of the African continent in discovering new chemotherapeutic remedies 
is also worth mentioning. In this regard, a team led by the University of Cape Town in South 
Tafenoquine OZ277 (Arterolane) OZ439 (Artefenomel) 
KAE609 SJ557733 MMV390048 
Artemisone 
Ferroquine AQ13 DSM265 
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Africa have employed phenotypic approaches to develop a clinical candidate MMV390048 
(Figure 1.4) belonging to the aminopyridine class.63 As the compound progressed to preclinical 
development, the target was identified to be the lipid P. falciparum phosphatidylinositol-4‑OH 
kinase (PfPI4K).64 MMV390048 has successfully completed phase I studies65 and is currently 
undergoing proof-of-concept studies in P. vivax- and P. falciparum-infected patients (Table 
1.1).66 
The global antimalarial portfolio also contains other candidates derived from known chemical 
scaffolds. These include the endoperoxide artemisone,67 derived from artesunate, the 4-
aminoquinolines (ferroquine68,69 and AQ1370) (Figure 1.4), NPC1161B (an 8-
aminoquinoline)71 and DM1157 (a chloroquine derivative)72 (structures for NPC1161B and 
DM1157 are not shown but developmental status is captured in table 1.1). Additionally, the 
antimalarial development pipeline also has a significant proportion of new formulations and 
combinations of existing drugs as captured in table 1.1. Additional new antimalarial clinical 
candidates at different stages of development (Table 1.1) include SAR121, AN13762,73 
UCT943 (an aminopyrazine alternative to MMV390048),74 MK4815,50,75 M5717,76 
MMV253,77 SC83288,78 KAF15679 and several others.80–87 
 
1.7 Malaria Eradication Agenda 
About 10 years ago, the WHO and the Bill and Melinda Gates Foundation announced the long-
term goal of malaria eradication. The 60 and 37% significant reduction in mortality and 
morbidity respectively recorded in the past nearly two decades has been partly driven by the 
use of existing therapy.88 The malaria community has now defined clear road maps on the types 
of new medicines89 while the WHO has committed to reducing morbidity and mortality by a 
further 90% by 2030.90 Clear goals for new therapy have been set by proposals on the types of 
medicines [target product profiles (TPPs)] needed.91 During drug discovery and development, 
TPPs act as strategic tools by providing guidance.16 In this subsection, the TPPs of new 
medicines needed to eliminate and eradicate malaria are discussed. 
 
1.7.1 Newly Defined Target Product Profiles for Malaria Elimination and Eradication 
1.7.1.1 Antimalarials with Multi-Stage Antimalarial Activity 
The blocking of transmission and prevention of relapse is pivotal to the realization of the 
malaria eradication agenda. In this regard, an ideal combination therapy should contain 
compounds with activity on hypnozoites and sexual stages in the human host and mosquito 
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vector in addition to the erythrocytic stage-killing activity.51,91 Although primaquine remains a 
gold standard for treating P. vivax relapses and transmission blocking, the treatment is lengthy 
and it is unsafe in G6PD-deficient patients. Therefore, an ideal combination needs to 
demonstrate a single-dose radical cure and should be devoid of the haemolytic effects 
associated with primaquine.91 
    
1.7.1.2 Resistance-Proof Chemotypes 
As much as possible, molecules with pan-activity across the five human-infecting parasite 
species (P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi) should be prioritized.91–
93 However, due to issues associated with accessibility to parasites and culture conditions, a 
more realistic approach is to focus on P. falciparum and in limited cases P. vivax. As a second 
priority, new antimalarials need to demonstrate lack of cross-resistance against laboratory 
adapted strains as well as clinical isolates from geographical regions known for antimalarial 
drug resistance. Such an assessment serves as a measure of the molecule’s tendency to develop 
resistance.91 Indeed, a number of chemotypes incapable of resistance selection in vitro have 
been identified from recent studies on compounds from the open-access Malaria Box.94,95 
Consequently, optimization and subsequent progress will prioritize interesting scaffolds from 
within this set.16 
 
1.7.1.3 Single Dose Regimens to Simplify Treatment 
The ideal medicine needed for eradication of malaria has been termed the SERCaP (single 
exposure radical cure and prophylaxis). Such a medicine would be critical in eliminating and 
eradicating malaria in urban or remote rural areas with substandard health systems because 
only a single encounter with a healthcare provider and the patient would be necessary.96 
Additionally, this ideal medicine could foster compliance since it could easily be administered 
as directly observed therapy (DOT).91 A SERCaP treatment should demonstrate a radical cure 
and must be suitable for MDA programmes. Additionally, such an ideal treatment should offer 
prophylaxis for a minimum of one month post-treatment. Although the development of a drug 
with such a stringent TPP would be protracted, chances of malaria eradication could still be 
drastically improved if new drugs that bear some of these criteria are developed.96 Admittedly, 
towards the development of such an ideal medicine, compromises will have to be made.91 
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1.7.1.4 Safe Drugs to Wide Range of Patient Populations 
Safe and well tolerated medicines in vulnerable and a wide range of populations will ultimately 
be required to realize malaria elimination. Such vulnerable populations include pregnant 
women in their first trimester,97 asymptomatics,98 infants,99 malnourished individuals and 
patients co-infected with other pathogens such as human immunodeficiency virus (HIV) and 
tuberculosis (TB).16 Once again, developing a medicine that meets the needs of all these groups 
will be a challenge. For instance, due to ethical issues surrounding the recruitment of pregnant 
women into clinical trials, safety data in pregnant women is currently collected passively. For 
the artemether-lumefantrine combination, it has taken 20 years after regulatory approval to 
gather enough safety data to warrant a WHO-recommendation for use in first-trimester 
pregnancy.100–104 Above all, the ideal medications need to be affordable to guarantee wide 
coverage to the many victims of malaria in resource-constrained countries.91 
 
1.8 Importance of Solubility in Drug Design and Development 
To attain optimal concentration of the drug in systemic circulation for desired therapeutic 
effect, solubility, the phenomenon of dissolution of a solute in a solvent to give a homogenous 
system, is a very important factor that needs to be optimised.105 The low aqueous solubility of 
a drug candidate can result in low and variable oral bioavailability leading to variability in 
clinical response. Despite considerable efforts dedicated to improving solubility during lead 
optimization campaigns, an estimated 40% of drugs on the market and most candidates in the 
drug development pipeline remain poorly water soluble.106 For a drug in clinical development, 
appropriate physical techniques can be employed to address solubility problems107 although, 
realistically speaking, enhancement of solubility and absorption through such approaches is 
severely limited.108 Thus, it is crucial that drug candidates have their solubility improved upon 
by chemical-modification means early on at the drug discovery stage.108 These chemical-
modification approaches are presented in subsection 1.8.1 below and, where appropriate, 
examples cited from literature are illustrated schematically in figure 1.5. 
 
1.8.1 Strategies to Improve Solubility 
1.8.1.1 Introduction of Ionizable Groups and Salt Formation 
Solubility can be improved upon by the installation of water solubilizing and ionizable groups 
at a position in the core-scaffold in such a way that does not negatively impact other 
properties.109 For instance, the discovery of amlodipine (a calcium channel blocker),110 
CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
19 
 
tamoxifen (an estrogen receptor modulator)111 and farnesoid X receptor (FXR) agonists112 all 
involved the introduction of alkoxy amines to the core pharmacophore with concomitant 
pronounced improvement in solubility compared to the original leads. The latter case is 
illustrated by an example in figure 1.5. When administered to the mouse using the standard 
suspension formulation (2% Tween 80 with 0.5% methylcellulose), the lead compound FXR-
450 exhibited low solubility (0.014 mg/mL) in this dosing vehicle which translated to sub-
optimal oral bioavailability (21%). By introducing an ionizable centre (a basic amine), a next-
generation molecule, candidate (B) was identified which demonstrated a ~ 18- and 423-fold 
increase in solubility as a free base and hydrochloride salt respectively. The improved solubility 
in the dosing vehicle along with improved metabolic stability resulted in high oral 
bioavailability (53%).     
Indeed, ionizable groups in new drug molecules, whether cationic or anionic, offer an 
opportunity to generate salt forms with superior biopharmaceutical properties to the parent 
molecule.113 The rate of dissolution and oral absorption can be enhanced by appropriate salt 
forms. Potential merits of salt formation are evident in drugs like diclofenac whose sodium or 
potassium salt forms are > 400-fold more water-soluble114 than the free form.115 A similar trend 
also holds true for weakly basic drugs which constitute the largest fraction of ionizable drug 
molecules. A typical example in this class is enalapril which has inferior aqueous solubility as 
a free base (~ 0.21 mg/mL) compared to its maleate form (~ 25 mg/mL).116 Depending on the 
preferred route of administration, it is wise to prioritise counter ions with prior clinical 
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Figure 1.5: Examples of chemical modification approaches to improve solubility. 
 
1.8.1.2 Reduction of Lipophilicity 
Reduction of lipophilicity, another approach employed in optimizing solubility, may involve 
replacing phenyl rings with pyridyl rings and other heteroaromatic rings with hydrogen 
bonding capability.119 In addition, structure-property relationship (SPR) investigations on 
solubility have shown that removing and/or replacing halogen atoms leads to a decrease in 
lipophilicity and, therefore, enhanced solubility.120–122 Furthermore, aqueous solubility could 
significantly be improved upon by decreasing the length of alkyl groups as well as completely 
eliminating them from the structure.120,123 
 
1.8.1.3 Prodrug Approaches  
Improving solubility of poorly-soluble drugs, promoting their oral absorption, and enabling 
safe and effective intravenous (IV) formulations often involves employing prodrug 
strategies.124,125 Sulindac is one typical example of a prodrug that achieves better oral delivery 
due to its water-solubilizing effect of the sulfoxide group which gets metabolized through a 
reduction to the active sulphide (Figure 1.5).126 The sulfoxide prodrug exhibits 100-fold higher 
solubility (3.0 mg/mL) than sulindac sulphide (0.03 mg/mL) at pH 7.127 Being more polar, the 
sulfoxide prodrug interacts with aqueous media more effectively than the reduced sulphide. 
Additionally, sulindac does not inhibit prostaglandin synthetase activity as strongly as sulindac 
sulphide and, therefore, is less locally irritating.126  
Other prodrug approaches aimed at increasing solubility involve the linking of the parent 
molecule to an ionizable promoiety. However, because charged molecules are associated with 
decreased membrane permeability, there is need to exercise caution to avoid increasing water 
solubility at the expense of permeability. In particular, phosphate esters introduced at an 
alcohol functionality of parent molecules have been shown to effectively enhance delivery of 
water-insoluble parent drug molecules following oral delivery.125 As the phosphate (R–
OPO3Na2) prodrug rapidly dissolves in the gastrointestinal fluid, it undergoes enzymatic 
cleavage mediated by alkaline phosphatase to release the free drug (R-OH). The free drug then 
crosses the enterocyte membrane ending up in systemic circulation. Such a process functions 
like a semi-coupled metabolism/transport event.125 Others have noted some limitations to such 
an approach including the possibility of precipitation of R-OH following rapid cleavage.128 
Nevertheless, there have been successful examples of the application of this approach as 
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evident in prodrugs such as  fosfluconazole, fosphenytoin and fosamprenavir, which have 
demonstrated substantially higher solubility compared to parent drugs.125 
 
1.8.1.4 Disrupting Molecular Planarity 
Generally, improving aqueous solubility involves reduction of lipophilicity by introduction of 
hydrophilic groups into molecules. However, such a classical and general approach is not 
universally effective sometimes because interference with the target protein-drug interaction 
can result from the introduced hydrophilic substituents thereby compromising drug efficacy.108 
It should also be noted that in scenarios where both solubility and hydrophobicity need to be 
increased, such an approach proves ineffective. The disruption of molecular planarity and 
symmetry has recently been reviewed as an alternative strategy for improving aqueous 
solubility.108 Such a strategy has been rationalized in both quantitative and qualitative terms. 
In 1980, the general solubility equations (GSEs), derived on the basis of semi-empirical 
analysis, were presented by Yalkowsky.129 For instance, solubility, lipophilicity and melting 
point are related by the following equation:130 
Log[solubility (M)] = 0.5 – (log P) – 0.01{[melting point (⁰C)] – 25} 
Therefore, from the above equation, the solubility of a solute in water is a function of two 
factors: the crystallinity of the solute and the ability of the solute to interact with water. In this 
case, melting point is related to crystallinity and crystal packing energies while log P is a 
measure of the interaction of the solute with water. Therefore, disruption of crystal packing 
which results in reduction in melting point would be an alternative approach of enhancing 
aqueous solubility. Moreover, a concomitant decrease in crystal packing efficiency and melting 
point would be expected with disruption of molecular planarity and symmetry. A relatively 
recent survey revealed a decrease in the melting point with an increase in the fraction of sp3 
hybridized carbons in the drug and clinical candidate database.131 
Specific examples of disruption of planarity/symmetry approach include removal of 
aromaticity (increasing saturation in the aromatic system).132 In this case, in their efforts to 
develop vanilloid receptor 1 antagonists, Wang and co-workers identified the clinical candidate 
AMG 517 (Figure 1.5) which exhibited sub-optimal thermodynamic solubility [< 1 μg/mL in 
phosphate buffered saline (PBS) or 0.01 M HCl]. Partial saturation of the phenyl ring which 
was hypothesized to reduce structural planarity as well as disrupt crystal stacking potential led 
to the identification of a second-generation clinical candidate with a 13-fold improved 
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thermodynamic solubility (13 μg/mL in 0.01 M HCl). Calculated lipophilicity (cLog P) 
indicates AMG 517 has a higher lipophilicity than the partially saturated analogue indicating 
the reduction in lipophilicity, in addition to disruption of planarity, could be contributing to the 
observed increase in solubility.108 Moreover, the hypothesis that a reduction in planarity 
contributes to the enhanced solubility is supported by the fact that AMG 517 has a higher 
melting point than the second-generation clinical candidate.108,132,133 
Molecular planarity can also be reduced by the introduction of substituents in a bicyclic 
structure in such a way that increases the dihedral angle. Ishikawa et al., employed this strategy 
to substantially increase aqueous solubility (84.6 μg/mL) of the aryl hydrocarbon receptor 
(AhR) agonist β-naphthoflavone (Figure 1.5). Monomethylation at ortho position increased 
thermodynamic aqueous solubility by 4-fold (262 μg/mL) while ortho dimethylation increased 
solubility by an even greater margin (1270 μg/mL, 15-fold improvement).108 Calculations using 
density functional theory showed an increase in the dihedral angle in both the monomethylated 
(37.9°) and dimethylated (70.0°) analogues compared to the unsubstituted parent molecule 
(17.8°).108 These derivatizations were also accompanied by increase in hydrophobicity and 
decrease in melting points. This result demonstrates that, indeed, the introduced substituents 
led to disruption of planarity with concomitant reduction in crystal packing energy which 
positively impacts solubility.108  
Other strategies which have been shown to improve solubility include the introduction of 
substituents into the benzylic position where feasible;134 and twisting of fused rings (e.g. subtle 
positional change of the nitrogen atom within the fused ring system).135 
In this PhD project, some of these chemical-modification-based approaches were used to 
improve the aqueous solubility of imidazopyridazine and aminopyrazine analogues. 
              
1.9 Cardiotoxicity: A Major Reason for Drug Withdrawals 
Cardiovascular toxicity represents the most encountered serious adverse reaction and is a major 
contributor to withdrawal of marketed drugs.136 According to Stevens and Baker,137 about 45% 
of total post-approval drug withdrawals from the market are attributed to cardiovascular safety 
liabilities while hepatic safety liabilities account for 32% of such withdrawals. Cardiotoxicity 
issues have also prompted severe restrictions on the availability of marketed drugs. Examples 
of drugs which have suffered complete withdrawals or restrictions in availability include 
terfenadine, astemizole, grepafloxacin, terodiline, droperidol, lidoflazine, sertindole, 
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levomethadyl and cisapride.138 Strangely, of the total drug attrition during phase I clinical 
development, only 9% is attributed to cardiovascular toxicity.139 Such a discrepancy highlights 
the fact that the accuracy of predicting drug-induced cardiotoxicity in preclinical and early 
clinical stages is highly questionable. As such, in order to avoid delivering drug candidates 
with a high cardiotoxicity risk into late clinical development and marketing approval phases, 
there is need to more accurately de-risk projects early on in preclinical and early clinical 
stages.136 
     
1.9.1 Underlying Mechanisms of Cardiotoxicity: Inhibition of the human ether-a-go-go-
related gene (hERG) K+ Channel 
At cellular level, the efflux of potassium ions (K+) from the myocytes is mainly responsible for 
the repolarization phase of the myocytes.140 The heart harbours various K+ current subtypes 
with the delayed rectifier current, IKr (rapid) and IKs (slow) being known to play a role in 
ventricular repolarisation.140 The action potential may be prolonged by the blockade of either 
of these two outward potassium currents with IKr being more prone to pharmacological 
interference. The pore-forming α subunits of the channel for the IKr current is encoded by the 
human ether-a-go-go-related gene (hERG).141 The pro-arrhythmic effects of drugs can be 
attributed almost exclusively to the blockade of the IKr. Clinically, the blockade of the IKr 
current is manifested in the prolongation of the QT interval and the presence of other T or U 
wave anomalies on the surface electrocardiogram (ECG).140 Particularly, torsades de pointes 
(TdP), a rare but life-threatening form of cardiac arrhythmia arising from QT prolongation has 
been the main safety issue that has prompted the withdrawal of already marketed drugs.142 
 
1.9.2 Strategies to Counter hERG Activity 
In 2006, Jamieson et al.,143 conducted a survey of literature on different reports of medicinal 
chemistry optimization campaigns where hERG/IKr activity have successfully been detuned. 
As opposed to developing statistically validated models or 3D pharmacophore information, the 
authors analysed the literature SAR data on hERG with the aim of devising simplified and user-
friendly guidelines on detuning hERG activity that would be useful to a medicinal chemistry 
practitioner. The authors categorized the optimizations based on similarities in the chemical 
modification approach employed. These approaches which include discrete structural 
modifications, formation of zwitterions, control of log P and attenuation of pKa will be 
discussed in greater detail in subsequent sub-sections. However, the authors caution, there is 
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no such thing as a “one size fits all” solution to minimizing hERG activity and different groups 
employ different approaches to address this liability.143 
 
1.9.2.1 Discreet Structural Modifications 
A survey of published SAR information against the hERG channel suggest that π-stacking and 
hydrophobic interactions between aromatic residues lining the large cavity of the channel and 
aromatic moieties favourably oriented in a drug molecule are the major determinants of hERG-
drug interactions.144,145 Thus, these putative interactions and affinity for the hERG channel can 
potentially be disrupted if such molecular features in a drug molecule are subtly or drastically 
modified.143 Additionally, introducing constraint in the molecule as well as varying 
stereochemistry, where pertinent, is one other approach in this category with potential to 
mitigate hERG activity.143  
In one approach utilizing subtle modifications, Bell and co-workers have successfully 
diminished hERG potency of novel pyrrolidinone-based farnesyltransferase inhibitors (FTIs) 
by varying stereochemistry.146,147 Although compound 1 (Figure 1.6) was amongst the most 
potent FTIs (IC50 = 0.15 nM) in the series, it was also one of the strongest inhibitors of hERG 
(IP = 0.08 μM) where IP represents the inflection point in the dose-response hERG inhibition 
curve. When tested in the anaesthetized dog, at a plasma concentration of 2.4 μM, compound 
1 induced a 10% increase in the QTc (corrected QT) interval which was considered 
unacceptable. Reversing stereochemistry at one chiral centre gave compound 2 with nearly 60-
fold reduction in hERG potency (IP = 4.7 μM).147 Additionally, compound 3, derived from 
compound 1 by cyclopentyl-to-cyclohexyl ring expansion (Figure 1.6), exhibited one of the 
highest potencies and selectivity over hERG (hERG IP = 7 μM; FT IC50 < 1 nM).
147 Other 
examples of structural modifications employed which have successfully diminished hERG 
activity include positional change of the carbonyl group, removal of the chlorine from the 
phenyl ring, N-methylation,147 acetylation of the amino functionality, methylsulfonamide-to-
ethylsulfonamide change,148 trifluoromethylation of the phenyl ring,149 tert-butyl-to-sec-butyl 
group conversion,150 deletion of methyl groups,151 and ortho-to-para positional change.152 For 
additional examples, the reader is referred to the perspective article by Jamieson et al.143 




Figure 1.6: Examples of chemical modification approaches to diminish hERG activity. 
 
1.9.2.2 Zwitterion Approach 
Formation of zwitterions is also considered another approach to minimizing hERG activity. 
Such zwitterionic species are physically limited with respect to membrane permeability and, 
therefore, this prevents access of the drug molecule to the transmembrane binding site. Any 
potential interactions with hERG are, therefore, minimized. Unfortunately, the zwitterion 
approach has apparent shortfalls: Suboptimal oral bioavailability attributed to poor 
absorption.153,154 
The story of terfenadine (Figure 1.6), a second-generation antihistamine, represents a very good 
example and one of the earliest applications of the zwitterion approach to minimize hERG 
activity. After its launch in 1982, post-marketing investigations implicated terfenadine in a few 
TdP-related cases. The elevated plasma concentrations of terfenadine, when administered 
concomitantly with food or drugs that inhibit CYP3A4 (cytochrome P450 3A4), were found to 
cause QT interval prolongation.155 Although the US Food and Drug Administration (FDA) 
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issued a black box warning following incidents of cardiac side effects, cases of cardiac 
arrhythmia continued which led to the eventual withdrawal of terfenadine from the market 15 
years after its launch. However, it was discovered that the carboxyl metabolite, which was later 
marketed as fexofenadine (Figure 1.6), was responsible for the therapeutic efficacy of 
terfenadine and demonstrated a substantially minimized hERG inhibition (IC50 = 23 μM) while 
displaying no effects on the QT interval. The zwitterionic nature of fexofenadine, which 
discourages membrane permeability and access to the intracellular cavity of the channel, could 
explain the reduced hERG binding.143 Following these observations, the zwitterionic strategy 
has found application in many studies to detune hERG activity. The difference in hERG activity 
could also be explained by differences in the conformations of the two compounds as suggested 
by recent molecular modelling studies.145 
In another approach, workers at Merck reported the generation of zwitterionic compounds 
which were virtually inactive on hERG. In their more recent work on biaryl-β-
methylphenylalanine DPPIV (dipeptidyl peptidase IV) inhibitors,156 the team generated the 
carboxylic acid-containing derivative 5 which was 16-fold less potent on hERG compared to 
the parent carboxamide 4 (Figure 1.6). However, as anticipated, oral bioavailability was 
compromised by 4-fold (cf. 5, F = 16%; 4, F = 67%). There are other examples, in literature, 
of the application of the zwitterionic approach where a carboxylic acid153,157 or its 
bioisosteres154 have been incorporated into the amino-containing parent molecule. 
 
1.9.2.3 Control of Log P 
Quite often, a positive correlation between hERG blocking and measures of lipophilicity such 
as log P is evident in SAR data. Such observations have been rationalised by evidence revealing 
the existence of a lipophilic ligand binding site in the hERG ion channel.144,158 Therefore, 
interaction with the lipophilic binding site of the channel can be disrupted when the polarity of 
a drug molecule is increased. A number of optimization campaigns aimed at decreasing hERG 
activity have utilized this strategy.143 
In one approach, workers at Bristol-Myers Squibb reported a significant improvement of 
selectivity over IKr following reduction of cLog P by eliminating a phenyl ring from the 
structure.159 In this regard, when the phenyl ring in compound 6 (cLog P = 7.06, hERG IC50 = 
0.16 μM, Figure 1.6) was deleted, the decrease in lipophilicity was accompanied by a nearly 
11-fold reduction in hERG activity as shown in compound 7 (cLog P = 5.29, hERG IC50 = 1.7 
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μM, Figure 1.6).159 A reduction in hERG accompanying such a molecular change is expected 
since a phenyl ring is considered a key pharmacophore for hERG potency.143 
In another related strategy, Cooper et al.,160 replaced the terminal fluorinated phenyl ring in an 
NK1 (neurokinin-1) receptor antagonist 8 with a saturated spiroether system as shown in 
analogue 9 (Figure 1.6). Such a reduction in lipophilicity was accompanied by over 50-fold 
reduction in IKr activity with preservation of activity at the primary target. Many other studies 
have utilized the reduction of cLog P to minimize hERG activity. As summarized by Jamieson 
et al.,143 these include installation of a carboxamide group,157 introducing polar hydrogen-
bonding groups,150,161 deletion of the phenethyl group, replacing the naphthyl with a pyridyl or 
cyclohexyl group162 and replacing the phenyl ring with a methyl group.163 
 
1.9.2.4 Attenuation of pKa 
Attenuation of pKa for drug candidates containing basic nitrogens is another approach to 
address hERG liabilities. A basic nitrogen moiety that is likely to be protonated at physiological 
pH is a common feature of many ligands that block the hERG channel.143 The ligand binding 
affinity for such basic nitrogen-containing compounds is thought to be enhanced by the π-
cation interactions between the protonated nitrogen of the amine and aromatic residues within 
the cavity of the hERG channel.144,145 Therefore, the proportion of protonated molecules at 
physiological pH can substantially be reduced by lowering the pKa of a basic nitrogen with 
concomitant disruption of any putative π-cation interactions with the channel. Conversely, 
introduction of alkoxy/hydroxyl groups at the β-position relative to the amine may shield the 
protonatable centre thereby compromising the π-cation interactions and hence lowering affinity 
for hERG.154 
In their attempts to optimize a series of compounds for the primary target (5-HT2A receptor) 
while trying to improve selectivity over hERG, Fletcher and co-workers164 identified 
compound 10 (Figure 1.6) which elicited an over 10% QT interval prolongation at doses of 3 
and 10 mg/kg/h in the anesthetised ferret. Among various modifications made to diminish 
hERG activity, the installation of the ketone at β position relative to the amine (compound 11, 
Figure 1.6) was accompanied by noteworthy success. A corresponding reduction in IKr activity 
was observed with such a pKa-reducing structural modification. As anticipated, the hERG 
optimized analogue was also devoid of QT-prolongation effects when administered at doses up 
to 10 mg/kg/h in the anesthetized ferret model. However, compound 11 could not be moved 
forward due to its instability in polar solvents such as methanol which was attributed to the 
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presence of the ketone moiety.152 The authors then explored other means of attenuating the 
basicity without the involvement of the keto group. In this respect, the introduction of the 
fluorine into the piperidine ring resulted in the reduction of pKa and a concomitant reduction 
in hERG inhibition as reflected in analogue 12 (Figure 1.6) which was also devoid of QT 
prolongation in anesthetized dogs at plasma concentrations up to 148 μΜ. 
          
1.10 Pharmacological Properties of Imidazopyridazines and Aminopyrazines 
1.10.1 Imidazopyridazines 
The imidazopyridazine scaffold is made up of the imidazo and the pyridazine ring systems 
fused together. This scaffold has been associated with various biological activities (see some 
examples in figure 1.7). For instance, imidazopyridazine compounds have shown potential 
application in the treatment of the common cold as demonstrated by their potent activity on a 
broad spectrum of rhinoviruses,165 the most important aetiologic agents of the common 
cold.166–170 
 
Figure 1.7: Examples of imidazopyridazines with various pharmacological properties. 
 
Recently, five tyrosine kinase inhibitors have been approved for the treatment of cancers by 
the US FDA.171 Amongst these new anticancer drugs is an imidazopyridazine-containing 
compound ponatinib (AP24534) which has been approved for the treatment of chronic, 
accelerated or blast-phase chronic myeloid leukaemia. Additionally, other imidazopyridazine 
compounds have been found to exhibit potent inhibition of different targets relevant to cancer 
including mTOR (mechanistic target of rapamycin),172 PIM kinases,173 TRK (tropomyosin 
receptor kinase) receptors,174 PI3Ks (phosphatidylinositol 3-kinases)175 and others.176–181 
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activity on the enzyme reverse transcriptase (RT) of HIV-1 as well as excellent potency in 
cellular assays.182 Furthermore, imidazopyridazine derivatives possess a range of other 
pharmacological effects including antiToxoplasma gondii,183 antialzheimer,184 antiHCV 
(hepatitis C virus),185 antiseizure,186 and antiinflammatory activities as well as potential to treat 




The aminopyrazine scaffold or its derivative is found in several clinically-established drugs 
(Figure 1.8). These include sulfalene (an antibacterial sulphonamide),188 mirfentanil (a fentanyl 
analogue selective for the μ opioid receptor)189 and amiloride the diuretic.190   
A literature survey revealed that aminopyrazines have been extensively explored as anticancer 
agents. In a recent study, Osborne et al.,191 have identified an oral anticancer pre-clinical 
candidate (CCT245737, Figure 1.8) targeting a kinase responsible for cell growth and division 
– the checkpoint kinase 1 (CHK1). Moreover, the preclinical candidate exhibited low predicted 
doses and exposures in humans, a characteristic which could mitigate other off-target activities 
such as hERG inhibition. In another recent article,192 workers at AstraZeneca have employed a 
structure-guided approach to identify an irreversible mutant-EGFR (epidermal growth factor 
receptor) kinase inhibitor (Figure 1.8) which exhibited in vivo antitumor efficacy albeit 
liabilities with regard to other physical properties remained unresolved. Recently, and in a 
space of two years only (from 2013 to 2014), over 10 patents193–200 on the application of 
aminopyrazines as anticancers targeting the ATR (ataxia telangiectasia and Rad3-related) 
kinase have been granted to researchers at Vertex Pharmaceuticals, Inc (USA). When tested in 
vivo, the most promising compound, VE-822 (Figure 1.8), of this class demonstrated effective 
treatment of non-small cell lung cancer and pancreatic cancer.201,202 Additionally, other studies 
have documented the pharmacological effects of aminopyrazines against different types of 
cancers.203–207 




Figure 1.8: Examples of aminopyrazines with various pharmacological properties. 
 
Aminopyrazines have also shown potential for treatment of cardiovascular diseases. Examples 
in this therapeutic area include the aminopyrazine drug, selexipag, (Figure 1.8) which is 
currently being developed as a pulmonary arterial antihypertensive.208 Selexipag and its active 
metabolite are known to cause vasodilation in the pulmonary circulation by their agonist 
interaction at the PGI2 (prostaglandin I2) receptor.
208 Other pharmacological properties 
exhibited by aminopyrazines include antitrypanosomal,209 antitubercular,210 antidiabetic,211,212 
and antiobesity213 (see examples in figure 1.8). Additional applications of aminopyrazines, both 
as clinically established drugs and as early phase drug leads or clinical candidates, are 
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1.11 Antimalarial Properties of Imidazopyridazines and Aminopyrazines 
1.11.1 Imidazopyridazines 
Although imidazopyridazines have been extensively explored in other disease indications such 
as cancer (see subsection 1.10.1), a literature search revealed only limited exploration of this 
chemotype with respect to antimalarial therapy. In an article published in 2016, Bhatt et al.,216 
have reported the antiplasmodial evaluation of two imidazopyridazine derivatives bearing 
substituents at positions 2 and 6 of the core-scaffold. The two identified analogues, 13 and 14 
(Figure 1.9), only exhibited modest antiplasmodial activity – IC50 = 1.57 and 1.87 μΜ 
respectively against P. falciparum parasites. However, the authors did not state what parasite 
strain of P. falciparum was used in their assays. More recently, Bendjeddou and co-workers217 
have evaluated imidazopyridazines in biochemical assays involving a panel of kinases which 
included the Plasmodium falciparum Cdc2-like kinase 1 (PfCLK1). In this study, the 3,6-
disubstituted imidazopyridazine analogue 15 (Figure 1.9) was found to potently inhibit 
PfCLK1 (IC50 = 0.032 μM). Nevertheless, cellular assays to assess the translatability of this 
potency were not performed. 
 
Figure 1.9: Examples of imidazopyridazines with antimalarial properties. 
 
In another recent article, Green et al.,218 have reported the antiplasmodial activity of 3,6-
disubstirtuted imidazopyridazines. The authors reported imidazopyridazine analogues with 
potent activity in both the cyclic GMP (cGMP)-dependent protein kinase (PKG) inhibition 
assay and cellular assays. The authors further demonstrated that mutations in PKG resulted in 
13: R1 = CF3; P. f, IC50: 1.57 μM 
14: R1 = Cl; P. f, IC50: 1.87 μM 
15 
PfCLK1, IC50: 0.032 μM 
16 
PfPKG, IC50: 0.002 μM 
P. f, 3D7, EC50: 0.034 μM 
17 
PfCDPK1, IC50: 0.012 μM 
P. f, 3D7, EC50: 0.080 μM 
In vivo P. berghei (po) at 
4 × 50 mg/kg: 51% 
18 (KAI715) 
P. f, 3D7, IC50: 0.0039 μM 
P. yoelii, IC50: 0.009 μM 
19 
P. f, NF54, IC50: 0.0073 μM 
P. f, K1, IC50: 0.0063 μM 
In vivo P. berghei (po) at 4 × 
50 mg/kg: 98% 
Solubility, pH 6.5: < 5 μM 
hERG IC50: 0.9 μM 
20 
P. f, NF54, IC50: 0.0011 μM 
In vivo P. berghei (po) at 4 × 50 
mg/kg: 99.8%, 3 out of 3 mice 
cured 
Solubility, pH 6.5: < 5 μΜ; pH 
2: 61 μM 
21 
P. f, NF54, IC50: 0.006 μM 
In vivo P. berghei (po) at 4 
× 50 mg/kg: 99.8%, 3 out of 
3 mice cured 
Solubility, pH 6.5: < 5 μΜ 
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reduced potency of imidazopyridazines on this kinase. Similarly, reduced potency in cellular 
assays was observed when mutant strains bearing a modified PKG were used, further 
suggesting this class of molecules exert their activity primarily by inhibition of PKG. 
Compound 16 (Figure 1.9), a representative example, was highly potent against PKG (IC50 = 
0.002 μM) and the plasmodium parasites 3D7 (EC50 = 0.034 μM). 
In a structure-based approach, which employed a homology model of Plasmodium falciparum 
calcium-dependent protein kinase 1 (PfCDPK1), Chapman and co-workers219 have reported 
optimization of potency for a series of imidazopyridazines. Although the most promising 
compound, 17 (Figure 1.9), exhibited potent activity against PfCDPK1 (IC50 = 0.012 μM) and 
whole-cell P. falciparum 3D7 parasites (EC50 = 0.080 μM), only modest in vivo efficacy (51% 
reduction in parasitemia at 4 × 50 mg/kg) was observed in the P. berghei-infected mouse 
model. Further exploration of imidazopyridazines as potent inhibitors of PfCDPK1 has been 
reported in two other papers.220,221 
Imidazopyridazines have also been shown to inhibit the malaria parasite kinase P. falciparum 
protein kinase 7 (PfPK7). PfPK7 represents an emerging malarial drug target which lacks a 
human homologue and is expressed at several stages of the parasite life cycle including both 
the sexual and asexual stages in man as well as in the mosquito.222 Bouloc et al.,223 have 
reported imidazopyridazine inhibitors of this enzyme whose whole-cell parasite inhibition was 
only modest. Furthermore, using quantitative structure-activity relationship (QSAR) as well as 
docking studies, Sahu and co-workers have further shed more light on the structural 
requirements for inhibitory activity of the imidazopyridazines on PfPK7 and the amino acid 
residues involved in the imidazopyridazine-PfPK7 enzyme interactions.224,225 
In another notable study,226 a group of researchers identified analogues, among them, an 
imidazopyridazine compound 18 (Figure 1.9) which exhibited activity on P. falciparum 
asexual blood stage 3D7 parasites (IC50 = 0.0039 μM) and liver-stage schizonts of the rodent 
parasite P. yoelii (IC50 = 0.009 μM). The authors also showed that this class of compounds 
exert their therapeutic effect by inhibitory interaction with the adenosine triphosphate (ATP)-
binding pocket of a lipid kinase, phosphatidylinositol-4-OH kinase (PI4K).                     
More specifically, work on imidazopyridazines documented in this PhD thesis, was motivated 
by a series of recent studies undertaken by Le Manach et al119,227,228 where promising diaryl-
imidazopyridazines demonstrating in vivo efficacy where plagued by poor solubility and a 
hERG inhibition liability. This series of imidazopyridazines, named SFK52, was identified 
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from a recent high throughput screening (HTS) campaign of a commercial SoftFocus kinase 
library.229 Amongst the 488 diaryl-imidazopyridazines identified, 153 compounds exhibited > 
80% inhibition at the screening concentration of 1.82 µM.227 Medicinal chemistry optimization 
of the most promising analogues led to the identification of a highly potent lead 19 (Figure 1.9) 
against both the multidrug resistant, K1 (IC50 = 0.0063 μM) and the drug sensitive, NF54 (IC50 
= 0.0073 μM) strains of P. falciparum parasites along with good metabolic stability. In the in 
vivo model of P. berghei-infected mice, 19 demonstrated a relatively impressive 98% 
suppression of parasitemia at an oral dose of 4 × 50 mg/kg. At much lower doses (4 × 1.4 
mg/kg and 4 × 15 mg/kg), the lead compound 19 was somewhat ineffective although it 
exhibited very good potency (90% suppression in parasitemia) in the P. falciparum humanised 
SCID mouse model at a dose of 4 × 1.5 mg/kg. Additionally, compound 19 exhibited poor 
aqueous solubility (< 5 μΜ at pH 6.5) and a serious hERG liability (IC50 = 0.9 μM).
227  
In an attempt to address the solubility issue and hERG inhibition risk while maintaining 
potency and metabolic stability, further SAR explorations were undertaken resulting in the 
identification of analogue 20 (Figure 1.9).119 This analogue represented the first derivative of 
this imidazopyridazine series to demonstrate complete cure at an oral dose of 4 × 50 mg/kg. At 
much lower doses, 4 × 10 mg/kg and 4 × 3 mg/kg, reduction of parasitemia was quite 
significant, 99.6 and 98% respectively. Regrettably, hERG inhibition studies revealed that the 
sulfoxide-to-sulfone metabolism of 20 gave a sulfone metabolite which was highly active in 
the hERG assay (IC50 = 0.4 µM). Consequently, the prodrug sulfoxide 20 was considered to 
carry a potential hERG inhibition risk due to anticipated biotransformation in vivo. Moreover, 
its aqueous solubility remained sub-optimal at pH 6.5 (< 5 μM) albeit a slight improvement 
was observed at lower pH (61 μΜ at pH 2).119 In a more recent paper,228 analogue 20 was 
scaffold-hoped to give a pyrazolopyridine lead 21 (Figure 1.9) with the two substituents on the 
two phenyl rings being retained. It was hoped such a modification would improve selectivity 
over hERG, pharmacokinetics and in vivo efficacy. Unfortunately, the scaffold-hoped analogue 
still retained a hERG liability and sub-optimal solubility (< 5 μM) despite being able to 
completely cure P. berghei-infected mice at oral doses of 4 × 50 mg/kg.  
In this project, other strategies of mitigating hERG liability and improving solubility while 
trying to maintain good in vitro activity, metabolic stability as well as in vivo efficacy for this 
class of molecules were further explored. 
 




Apart from two published papers74,230, there is no literature precedence with respect to 
exploration of aminopyrazines as antimalarial agents. Work on aminopyrazines in this thesis 
was motivated by the impressive antimalarial properties of the 3,5-diaryl-2-aminopyrazines 
reported in the above mentioned papers. A schematic representation of a series of medicinal 
chemistry optimization steps which led to the identification of potent aminopyrazines is 
captured in figure 1.10. Using an image-based assay,231 a HTS performed on 36,608 
compounds from a commercial SoftFocus kinase library232 identified 442 compounds which 
exhibited > 50% inhibition of both the 3D7 and Dd2 P. falciparum strains at a test concentration 
of 1.82 μΜ.63 The 3,5-diaryl-2-aminopyridine compound, 22 (Figure 1.10), which was amongst 
the most potent hits exhibiting > 80% inhibition at the screening concentration of 1.82 μM was 
chosen as a starting point for further medicinal chemistry optimization programmes. Despite 
being potent in vitro against both the NF54 and K1 P. falciparum strains (IC50 = 0.049 μM), 
the hit compound only demonstrated moderate metabolic stability with a projected hepatic 
extraction ratio (EH) of 0.48 when tested in human liver microsomes. Accordingly, the authors 
did not anticipate good performance in vivo for this metabolically labile compound. In their 
efforts to address this liability, the authors replaced the methoxyphenyl moiety with the 
methoxypyridyl group leading to the identification of compound 23 (Figure 1.10) with 
preserved in vitro antiplasmodial potency (NF54 and K1, IC50 = 0.051 μM) and improved 
metabolic stability (EH = 0.26). Compound 23 also cured animals when administered orally at 


























Figure 1.10: A schematic of medicinal chemistry optimization leading to identification of antimalarial 
aminopyrazines. 
bH2L, hit to lead; LO, lead optimization. 
 
The encouraging result demonstrated by compound 23 prompted a hit to lead (H2L) and lead 
optimization (LO) campaign which culminated in the identification of the clinical candidate 
MMV390048 (Figure 1.10). This aminopyridine compound was highly potent in vitro across 
the NF54 and K1 parasite strains [IC50: (K1) = 0.025 μΜ; (NF54) = 0.028 μΜ] and completely 
cured P. berghei-infected mice with a single oral dose of 30 mg/kg. As pointed out earlier in 
section 1.6, MMV390048 successfully completed phase I studies and is currently undergoing 
phase II proof-of-concept studies in P. vivax- and P. falciparum-infected patients.66 
Unfortunately, the solubilities of MMV390048 (16.0 – 31.8 μM, pH 6.5)63 and an 
aminopyrazine analogue 24 (< 5 μΜ, pH 6.5), which was identified in later studies74,230 via a 
scaffold-hoping approach, have remained sub-optimal which might pose challenges during 
development. Interestingly, chemical-modification-based solubility optimization strategies 
employed in later studies74 led to the identification of a second-generation pre-clinical 
candidate UCT943 with improved aqueous solubility at pH 6.5 (163 μM) (Figure 1.10). 
BioFocus DPI  
SoftFocus kinase 
library  
   
HTS 
22 




















P. f, NF54, IC
50
: 0.028 μM 
P. f, K1, IC
50
: 0.025 μM 
Solubility, pH 6.5: 16.0 – 31.8 μM 
In vivo P. berghei (po) at 1 x 30 
mg/kg: 99.3%, complete cure 
  
24 
P. f, NF54, IC
50
: 0.01 μM 
P. f, K1, IC
50
: 0.0084 μM 
Solubility, pH 6.5: < 5 μM 
In vivo P. berghei (po) at 4 x 10 
mg/kg: 99.3%, complete cure 
UCT943 
P. f, NF54, IC
50
: 0.0054 μM 
P. f, K1, IC
50
: 0.0052 μM 
Solubility, pH 6.5: 163 μM 
In vivo P. berghei (po) at 4 × 10 
mg/kg: > 99.9%, complete cure 
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UCT943 has a combination of improved solubility, good efficacy and pharmacokinetics as 
well as good selectivity over hERG channel inhibition. Preclinical safety assessment of 
UCT943 was scheduled to be completed by end of 2017.233       
 
1.12 Research Programme 
1.12.1 Justification of the Study 
The exploration of imidazopyridazines and aminopyrazines as potential novel antimalarial 
therapies is warranted for several reasons. Firstly, once effective and cheap treatment regimens 
such as chloroquine and sulfadoxine-pyrimethamine have been beset by emergence of 
widespread resistance which has hampered malaria control and eradication.234–237 Secondly, 
although the current standard of first line malaria treatment, the ACTs, has been remarkably 
effective, resistance to artemisinin in the Thai-Cambodia and Thai-Myanmar border regions 
has been reported.45–47 Additionally, in some countries, resistance to partner drugs such as 
amodiaquine has already been observed.44 Therefore, because drug resistance seems an 
inevitable outcome of antimalarial chemotherapy, there is a critical need to continuously 
replenish the drug development pipeline with new antimalarial drug candidates with 
structurally diverse and novel chemical scaffolds.  
Thirdly, the malaria eradication agenda requires new therapies which can: deliver a single dose 
radical cure to simplify treatment; target parasite development at multiple stages; be 
administered to a wide range of patient populations. The new therapies also need to 
demonstrate zero propensity to development of resistance. Current treatment options are far 
from this ideal TPP. Therefore, efforts towards the development of such an ideal medicine need 
to continue. 
Fourthly, imidazopyridazines and aminopyrazines are a new antimalarial chemotype which 
could offer an opportunity to target the malaria parasite through novel mechanisms of action. 
Therefore, these chemotypes could potentially be less prone to resistance mechanisms that have 
rendered current drugs ineffective. 
Lastly, as detailed in section 1.10, imidazopyridazines and aminopyrazines have exhibited a 
wide range of pharmacological properties. Thus, the imidazopyridazine and aminopyrazine 
scaffolds have proven potential to pharmacologically interfere with a wide range of pathogens 
as well as non-communicable diseases. Therefore, further investigations into these two classes 
of chemotypes as novel antimalarial agents is warranted. Investigations into the aminopyrazine 
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class was motivated by the need to identify second-generation analogues with improved 
physicochemical properties (mainly solubility). On the other hand, the imidazopyridazine 
aspect of this project was meant to design analogues devoid of the hERG liability with 
improved solubility which have been identified as the two major issues in recent 
studies.119,227,228 
        
1.12.2 Research Question 
The research question is whether it will be possible to identify antimalarial imidazopyridazine 
and aminopyrazine analogues with favourable safety, physico-chemical and drug metabolism 
and pharmacokinetic (DMPK) properties. 
 
1.12.3 Objective 
To utilise imidazopyridazines and aminopyrazines as templates for the design and synthesis of 
potential novel antimalarial agents. 
 
1.12.4 Specific Aims 
i) To synthesise various analogues of imidazopyridazines and aminopyrazines and study 
their in vitro antiplasmodial structure-activity relationship. 
ii) To profile the synthesized analogues with respect to solubility, cytotoxicity and hERG 
inhibition in vitro. 
iii) To investigate factors influencing solubility and deduce relationships. 
iv) To evaluate potent, non-cytotoxic, hERG-de-risked and metabolically stable 
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DESIGN, SYNTHESIS AND CHARACTERIZATION OF TARGET COMPOUNDS 
 
2.1 Chapter Overview 
In this chapter, the rationale behind the design of target compounds is presented. This is 
followed by brief descriptions of the chemistry employed, mechanisms of the reactions (some 
mechanisms the author considers trivial have been left out) and characterization of 
intermediates as well as target compounds. The two chemotypes, the imidazopyridazines and 
aminopyrazines, covered in this thesis are dealt with in separate sub-sections.   
 
2.2 Rationale for Design of Target Compounds 
2.2.1 Imidazopyridazines 
As noted in subsection 1.11.1 of the preceding chapter, imidazopyridazines have recently been 
recognized to possess in vitro antiplasmodial activity in the low nanomolar range and 
impressive in vivo efficacy.1–3 Despite the impressive antimalarial activity, frontline 
compounds were associated with poor solubility and hERG inhibition liabilities. In this project, 
various chemical modification strategies aimed at generating analogues with potentially 
improved aqueous solubility and hERG inhibition profiles were employed. 
Figure 2.1 shows a summary of the target compounds classed according to the chemical 
modification approach used. In designing the target compounds, the right-hand side portion of 
the molecule was fixed as a 4-methylsulfinylphenyl group (SARs 1 and 3) since such a 
sulfoxide-containing group is characterized by enhanced solubility relative to the sulfone 
counterpart.2 Such sulfoxide analogues would also act as prodrugs by being metabolized to 
corresponding sulfones in vivo. Le Manach and co-workers have recently employed such a 
prodrug strategy by synthesizing solubility-enhancing sulfoxides that were shown to be 
metabolized to the corresponding sulfones.2 





Figure 2.1: Chemical structures of target imidazopyridazine compounds. 
 
By fixing the right-hand portion of the imidazopyridazine core scaffold as 4-
methylsulfinylphenyl moiety, analogues 25, 27 - 30, 36 – 45 and 58 (SARs 1 and 3) were 
synthesized. For comparison purposes, two sulfone analogues (26 and 31) bearing a 4-
methylsulfonylphenyl substructure on the right-hand side portion were synthesized. The first 
generation imidazopyridazines, 19 and 58, possessed a sulfone and sulfoxide group 
respectively at the meta position of the left-hand side phenyl ring. A positional change of these 
two groups on the left-hand side phenyl ring resulted in analogues 25 – 27. While substitution 
with a sulfoxide in 25 and 26 served to enhance solubility,2 the accompanying meta-to-para 
positional changes in the two analogues as well as that in 27 have potential to attenuate hERG 
inhibition. Such subtle modifications have been applied by different research groups to 
successfully diminish hERG binding.4,5 Additional analogues such as 35, and 50 – 54 (SARs 2 





























and 6), resulting from subtle peripheral changes, were also designed to exploit such a hERG-
attenuating strategy. Comparison among the different positional isomers generated would also 
shed more light on the importance of substituent position on antiplasmodial activity. 
Furthermore, 19, the lead compound previously reported1,2 to possess impressive antimalarial 
properties but marred by poor aqueous solubility and hERG inhibition liabilities, was 
resynthesized to serve as a control in biological assays.  
The regioisomeric analogues (28 – 30) were designed to explore the effect of relative positions 
of substituents on the aromatic ring. Moreover, the incorporation of the basic side chain in 
compound 45 was also motivated by the presence of such molecular features in clinically 
established antimalarial drugs exemplified by amodiaquine (Figure 2.1). Incorporation of such 
basic side chains was also envisaged to facilitate salt formation in formulation efforts meant to 
improve physico-chemical properties. Analogues 32 – 34 (SAR2), with basic side chains on 
the right-hand side phenyl ring, were also inspired by the same rationale. Another important 
approach employed to improve aqueous solubility of drug molecules containing biaryl systems 
is the introduction of groups at the ortho or 2 position to increase the dihedral angle. This has 
the potential to disrupt molecular planarity and, therefore, discourage crystal packing which 
may result in improved aqueous solubility.6 In designing compounds 28 and 32 with 
substitution in the ortho position, this strategy was employed. 
Because lipophilic binding pockets in the hERG K+ ion channel are known to be crucial to drug 
binding via interaction with the suitably positioned lipophilic substructures in drug molecules, 
increasing the polarity of the molecule can potentially disrupt such lipophilic interactions.7,8 
Capitalizing on this strategy, the hydrophilic aminated analogues 36 – 45 (SAR3) were 
designed and synthesized. It was also hypothesized that introduction of an amino linker into 
the analogues could also potentially result in improved aqueous solubility – the NH linker could 
facilitate hydrogen bonding interactions with water molecules. In another set of molecules 
synthesised by amination on the imidazole ring (46 - 49) (SAR4), this strategy was also utilized. 
Indeed, such a strategy, anchored on changes in lipophilicity, has been successfully employed 
to minimize hERG inhibition by a number of medicinal chemistry optimization programs.9–14  
Amodiaquine, a Mannich-base 4-aminoquinoline drug was once actively used 
prophylactically.15 Unfortunately, the hepatotoxicity and agranulocytosis associated with its 
chronic use has led to its withdrawal.16–20 However, amodiaquine still finds use as a partner 
drug in artemisinin-based combination therapies for treatment of uncomplicated malaria, 




particularly in Africa. It is also a drug of choice for treatment of acute malaria if the potential 
for drug toxicity is considered less important compared to the risk of infection.21 The 
bioactivation of amodiaquine to its quinoneimine reactive metabolite (Figure 2.1) has been 
implicated in amodiaquine-induced hepatotoxicity.22 Its disruption of cell functions has been 
thought to arise from the irreversible binding of such electrophilic reactive metabolites to 
proteins.23 Comfortingly, subsequent studies have circumvented the formation of amodiaquine 
reactive metabolites by replacing the hydroxyl with a fluoro group as well as designing 
isoquine, an isomer of amodiaquine resulting from interchanging the positions of the hydroxyl 
and the Mannich base side chain.24,25 In this regard, analogue 44 (a fluoro version of the 
Mannich base side chain) was designed to avoid the opportunity for formation of such reactive 
metabolites. However, the Mannich base analogue, 45, was also included for comparison 
purposes. It is also possible that 45 may not form reactive metabolites. Thus, evaluation through 
metabolite trapping experiments would be necessary. The derivative 44, differing from 30, only 
in the presence of an NH linker between two aryl systems was designed to evaluate the 
influence of such a hydrophilic spacer on pharmacological properties. The non-basic NH spacer 
would also shed more light on its influence of physico-chemical parameters and hERG potency. 
Furthermore, because phenyl rings are known to be pharmacophoric moieties for hERG 
binding,26,27 three analogues (41 - 43), with saturated cyclic substituents were also designed. 
These could potentially discourage π - π interactions with phenyl-containing amino acid 
residues in the hERG channel. Replacement of phenyl rings with saturated molecular features 
also has the potential to discourage intermolecular π - π stacking and, thereby, potentially 
enhancing solubility.6  
Within the context of introducing novelty to the new target compounds, selected silicon-
containing derivatives 55 – 57 (SAR5) were generated. This bio-organosilicon chemistry 
approach also has potential to generate novel silicon-containing bioisosteres with 
pharmacologically relevant properties.28 Once again, compounds 56 (sulfoxide) and 55 
(sulfone) will bring to the fore any significant influence of the sulfone and sulfoxide groups on 
pharmacological and physico-chemical properties. Such a comparison of sulfoxide and sulfone 
groups also inspired the design of other pairs of analogues bearing the sulfoxide and sulfone at 
the point of variation (e.g., analogues 25 vs 27, 36 vs 37, 38 vs 39, 46 vs 49 and 47 vs 48). 
Lastly, the design of the target compounds in figure 2.1 was also inspired by the need to expand 
the scope of SAR around imidazopyridazines. 
 





SAR explorations aimed at improving solubility of the antimalarial aminopyrazines have led 
to the identification of the preclinical candidate UCT94329 (see subsection 1.11.2 of chapter 
1). However, the modifications pursued in this initial SAR where, to a large extent, peripheral 
in nature – i.e., involving the introduction of water solubilizing substituents on the phenyl ring 
at position 5 of the aminopyrazine core-scaffold. In this PhD project, the disruption-of-
molecular-planarity approach, by replacing the two aromatic rings at positions 3 and 5 with 
saturated ring systems was adopted (Figure 2.2). In SAR1, the trifluoromethylpyridyl ring was 
replaced with partially as well as fully saturated heterocyclic ring systems while fixing a 
methylsulfonylphenyl ring at position 5. Similar modifications were made in SAR2 while 
keeping the trifluoromethylpyridyl ring fixed at position 3. In SAR3, both aromatic rings were 
replaced with partially and fully saturated heterocyclic ring systems. These modifications have 
potential to improve aqueous solubility by discouraging intermolecular π – π stacking 
interactions.6 Using this approach, analogues 59 – 68 and 70 – 72 were designed. It was also 
envisaged that the basic piperidine and piperazine moieties introduced would facilitate 
hydrogen bonding thereby improving aqueous solubility. Such basic molecular features would 
also act as sites for potential salt formation in formulation efforts. A lone analogue 69 bearing 
a water-solubilizing benzoic acid moiety was also synthesized. The analogues were also 
designed in such a way that would probe the effect of partial saturation on both antiplasmodial 
activity and solubility (e.g., 59 vs 60, 63 vs 64 and 70 vs 71). Additionally, while some 
analogues served to draw comparisons between the pharmacological activity of N-boc-
protected derivatives and free amines (60 vs 61 and 64 vs 65), others were designed to give 
insight into the pharmacological effect of N-mesylation (61 vs 62, 65 vs 66 and 67 vs 68). 





Figure 2.2: Chemical structures of target aminopyrazine compounds. 
 
2.3 Chemistry: Imidazopyridazine Analogues 
2.3.1 Synthesis of Imidazopyridazine Analogues 
2.3.1.1 Synthesis of Analogues 19, 26 – 34, 36 – 45, 51 – 54 and 58 
Compounds 19, 26 – 34, 36 – 45, 51 – 54 and 58 (Figure 2.1) were synthesized following a 
generic synthetic approach outlined in scheme 2.1. A condensation/cyclization of 
commercially available 6-chloropyridazin-3-amine (1a) with bromoacetaldehyde diethylacetal 
in presence of hydrobromic acid (HBr) gave the chloroimidazopyridazine intermediate 2a.1 
Regioselective electrophilic aromatic iodination, with N-iodosuccinimide (NIS) being the 
source of electrophilic iodine, afforded the iodinated intermediate, 3a, in 81% yield.1,30,31 The 
intermediate, 3a, was then subjected to sequential Suzuki-Miyaura cross coupling reactions32,33 
to deliver the diaryl-imidazopyridazines (19, 26 – 34, 51 – 54 and 58) in 13 – 80% yield. 
Finally, a palladium-mediated Buchwald-Hartwig amination34,35 of the chloro-bearing 





- Partial and full saturation to 
disrupt π – π stacking and 
potentially improve solubility 
- Piperidine, piperazine and 
benzoic acid moieties to 
encourage H-bonding 





Scheme 2.1: General synthetic approach for analogues 19, 26 – 34, 36 – 45, 51 – 54 and 58. 
Reagents and reaction conditions: (i) BrCH2CH(OEt)2, aq HBr, EtOH/H2O, reflux, 103 ⁰C, 22 h; (ii) 
NIS, DMF, rt (21 ⁰C), 5 d; (iii) appropriate boronic acid or boronic acid pinacol ester, Pd(PPh3)2Cl2, 1 
M aq K2CO3, DMF, 80 ⁰C, 3.5 - 46 h; (iv) appropriate boronic acid or boronic acid pinacol ester, 
Pd(PPh3)2Cl2, 1 M aq K2CO3, DMF, 100 ⁰C, 4 – 21 h; (v) R3NH2, Pd2(dba)3, (R)-BINAP for 39, 
BrettPhos for 36, 44 & 45, XPhos for 37, 38 & 40 – 43, K2CO3 for 39, Cs2CO3 for 36, 44 & 45, NaOt-
Bu for 37, 38 & 40 - 43, toluene/1,4-dioxane for 39, 1,4-dioxane for all other analogues, 100 °C for 42, 
120 ⁰C for all other analogues, sealed tube, inert atmosphere (N2), 6 – 43 h. 
 
Table 2.1 summarizes the target compounds and isolated yields obtained via scheme 2.1. 
 














2a 1a 4a – 4g 
37 – 77% 
4a: n = 1; 4b: n = 2 
 
4c: n = 1; 4d: n = 2 
 
4e: X = 2F; 4f: X = 3F 
 
4g 
36 – 45 
8 – 30% 
19, 26 – 34, 51 – 54 & 58 
13 – 80% 
(i) (ii) (iii) (v) 
(iv) 














































































































2.3.1.2 Synthesis of the Aniline Precursor 5d Required for Synthesis of Analogue 44 
The aniline precursor, 5d, required for the synthesis of analogue 44 (table 2.1), could not be 
sourced commercially and, therefore, was prepared in-house according to scheme 2.2. The 
commercially available alcohol starting material (5a) was tosylated in the presence of sodium 
hydroxide. The obtained tosylated intermediate (5b) was then treated with diethylamine to 
afford the amino-substituted intermediate 5c in 87% yield.36 The aniline precursor, 5d, was 
then realized in quantitative yield following reduction of the nitro group to the amino 
functionality in presence of acidified stannous chloride (SnCl2).
36 
 
Scheme 2.2: Synthetic approach for aniline starting material 5d. 
Reagents and reaction conditions: (i) aq NaOH, p-toluenesulfonyl chloride, THF, 0 - 11 ⁰C, 2 h; (ii) 
Et2NH, Et3N, 1,4-dioxane, 55 ⁰C, 5 h; (iii) SnCl2, aq HCl, THF, reflux, 66 ⁰C, 29 h. 
 
2.3.1.3 Synthesis of the Phenolic Precursor 5h Required for Synthesis of Analogue 45 
The phenolic starting material (5h), a precursor for the Buchwald-Hartwig amination towards 
analogue 45, was realized via a three-step synthetic sequence from commercially available 4-
aminophenol (5e) as captured in scheme 2.3. Anilines are extremely reactive towards 
electrophilic aromatic substitution reactions, leading to undesirable polysubstitution side 
products.37,38 Such side reactions are considerably circumvented by acetylating the amino 
group to form the acetanilide derivative. In this regard, the acetylated intermediate (5f) was 
synthesized by reacting the commercially available 4-aminophenol (5e) with acetic anhydride 
under reflux. A Mannich base side chain was then introduced via electrophilic aromatic 
substitution in the presence of formaldehyde and diethylamine. The amino group was 
5a 











subsequently deacetylated by refluxing in aqueous HCl to afford the Mannich base 
intermediate 5h in 43% yield, which was later utilized in a Buchwald-Hartwig amination 
reaction. 
 
Scheme 2.3: Synthetic approach for phenolic starting material 5h. 
Reagents and reaction conditions: (i) Acetic anhydride, THF, reflux, 60 ⁰C, 1.75 h; (ii) aq HCHO, 
Et2NH, ethanol, microwave irradiation, 80 ⁰C, 1.5 h; (iii) aq HCl, reflux, 80 ⁰C, 2 h. 
  
2.3.1.4 Synthesis of Analogues 25, 35 and 46 – 50 
Analogues 25, 35 and 46 – 50 (see structures in figure 2.1) were realized using the synthetic 
approach shown in scheme 2.4. Analogues 50 and 25 have the same nature and pattern of 
substitution on their two phenyl rings. While analogue 50 is meta-substituted with a sulfone on 
both phenyl rings, analogue 25 bears sulfoxide substituents at the para position of both phenyl 
rings. Since the same boronic acid was required for the coupling reaction on both reaction sites 
of the dihalogenated intermediate 3a, the two analogues were realized by a simple one pot 
Suzuki-Miyaura cross coupling32,33 using an excess (2.2 eq) of the respective boronic acids 
(Scheme 2.4A). Although another analogue, 35, could have been obtained using the same one 
pot synthetic approach, it was synthesized from a different available bromo-intermediate (6b) 
in a single step Suzuki-Miyaura cross coupling32,33 reaction (Scheme 2.4B). 
Analogues 46 – 49 were synthesised according to scheme 2.4B. The previously synthesized 
chlorinated intermediate 2a was subjected to a Suzuki-Miyaura cross coupling32,33 to afford the 
phenylated intermediate 6a in low yield (48%). Regioselective electrophilic aromatic 
bromination using N-bromosuccinimide (NBS) afforded the brominated intermediate 6b in 
moderate yield (59%).2 The aminated analogues 46 – 49 were then obtained in poor yields (9 
– 17%) via a Buchwald-Hartwig amination reaction.34,35 
5e 












Scheme 2.4: General synthetic approach for analogues 25, 35 and 46 – 50. 
Reagents and reaction conditions: (i) appropriate boronic acid (excess, 2.2 eq), Pd(PPh3)2Cl2, 1 M aq 
K2CO3, DMF, 100 ⁰C, 15 h for 25 and 24 h for 50; (ii) 3-methylsulfinylphenylboronic acid, 
Pd(PPh3)2Cl2, 1 M aq K2CO3, DMF, 100 ⁰C, 3.25 h; (iii) NBS, DMF, rt (23 ⁰C), 22 h; (iv) 3-
methylsulfinylphenylboronic acid, Pd(PPh3)2Cl2, 1 M aq K2CO3, DMF, 100 ⁰C, 20 h; (v) R4-NH2, 
Pd2(dba)3, BrettPhos, Cs2CO3, 1,4-dioxane, 120 ⁰C, sealed tube, 5 – 39 h. 
 
The synthesized analogues are summarized in table 2.2 below. 
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2.3.1.5 Synthesis of Silylamide Analogues 55 – 57 
The silylamide imidazopyridazine derivatives were synthesized via a synthetic protocol 
involving carboxylic acid intermediates (Scheme 2.5). The chloroiodoimidazopyridazine 
intermediate 3a was regioselectively coupled with the commercially available 4-
carboxyphenylboronic acid in a Suzuki-Miyaura cross coupling32,33 step to afford intermediate 
7a in 56% yield. A subsequent Suzuki-Miyaura cross coupling32,33 of intermediate 7a with 
appropriate arylboronic acids furnished the carboxylic acid intermediates 7b and 7c in 95 and 
54% yields respectively. Intermediate 7d was obtained in a low 39% yield following a Suzuki-
Miyaura cross coupling using a different intermediate 7e (7e synthesized by Le Manach et al2). 
The target compounds (55 – 57) were realized by an EDCI (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide)- and DMAP (4-dimethylaminopyridine)-mediated acid-
amine coupling.39 
 


























Reagents and reaction conditions: (i) 4-Carboxyphenylboronic acid, Pd(PPh3)2Cl2, 1 M aq K2CO3, 
DMF, 80 ⁰C, 27 h; (ii) arylboronic acid, Pd(PPh3)2Cl2, 1 M aq K2CO3, DMF, 100 ⁰C, 22 – 30 h; (iii) 
(trimethylsilyl)methylamine, EDCI.HCl, DMAP, DCM/DMF for 55, DCM for 57, DMF for 56, rt for 
55 and 56, 36 ⁰C for 57, 20 – 60 h.  
 
2.3.2 Proposed Mechanistic Details and Characterization 
In this subsection, mechanisms accompanying the reactions carried out are proposed with an 
attempt being made to back up such mechanisms with literature information. Once again, 
mechanisms considered trivial are left out. Intermediate compounds were characterised using 
1H-NMR (proton nuclear magnetic resonance) and/or HPLC-MS (high pressure liquid 
chromatography mass spectrometry) while final target compounds were fully characterised by 
these two techniques as well as 13C-NMR (carbon-13 NMR). For compounds 30 and 57, the 
13C-NMR spectra could not be acquired due to insufficient material. In addition to the 1H-NMR 
and 13C-NMR spectra, which are presented for representative compounds, the HPLC 
chromatograms and mass spectra showing the observed quasi-molecular ion peaks are also 
presented for final compounds. 
  
2.3.2.1 Ring Closure and Aromatization: Step (i), Scheme 2.1 
Acetals are deprotected in presence of catalytic amounts of BrØnsted acids to afford their 
carbonyl versions.40,41 Therefore, the formation of intermediate 2a, most likely, commences 
with the deprotection of bromoacetaldehyde diethylacetal (Scheme 2.6). A protonation step 
followed by an intramolecular elimination gives a resonance-stabilized oxonium ion. 
 















The relatively more electrophilic oxonium ion is then attacked by a water molecule giving a 
protonated intermediate, which further undergoes intramolecular elimination after internal 
proton transfer to give the protonated aldehyde. A deprotonation step gives the free aldehyde, 
in the process, regenerating the acid catalyst in form of a hydronium ion. A nucleophilic 
addition of 6-chloropyridazin-3-amine to the protonated aldehyde gives the hydroxyl 
intermediate which, upon intramolecular proton transfer, undergoes elimination to form the 
iminium ion. A neutral imine is subsequently formed via a deprotonation step. A nucleophilic 
substitution reaction involving a pyridazine nitrogen leads to a cyclized ionic intermediate. A 
final aromatization step leads to the formation of intermediate 2a while the BrØnsted acid is 
regenerated. This intermediate was confirmed by HPLC-MS: APCI+/ESI+-m/z found 154.0 [M 
+ H]+ (calculated exact mass = 153.0094), tr = 1.1 min. 
 
2.3.2.2 Electrophilic Aromatic Iodination: Step (ii), Scheme 2.1 
The formation of the dihalogenated intermediate 3a involves electrophilic aromatic iodination 
mediated by NIS (Scheme 2.7). The π electrons of the imidazo ring system attack the iodine in 
NIS with the succinimide anion acting as a leaving group.42,43 The succinimide anion 
deprotonates the heteroarenium ion intermediate giving the iodinated heteroaromatic 
compound 3a with succimide being formed as a by-product. 





Scheme 2.7: Reaction mechanism for electrophilic aromatic iodination. 
 
The regioselectivity of this reaction can be explained by careful examination of the 
heteroarenium ion intermediates that would form from potential electrophilic attack at various 
positions. Electrophilic attack at position 3 is the most favoured because it gives rise to a 
heteroarenium ion intermediate with the largest number of resonance contributors (Scheme 
2.7). With the positive charge resident on carbon atoms, which can better accommodate it, 
these resonance contributors are also the most stable. On the contrary, electrophilic attack at 
positions 2, 6 or 7 gives rise to heteroarenium ion intermediates with a limited number of 
resonance contributors. In these cases, highly unstable resonance contributors with the positive 
charge residing on the electronegative nitrogen renders substitution at these positions not 
feasible.  
Successful synthesis of the dihalogenated intermediate 3a was confirmed by HPLC-MS 
(ESI+/APCI+: m/z [M + H]+ = 279.8, calculated exact mass = 278.9060, tr = 3.0 min). 
1H-NMR 
spectroscopy also confirmed the successful synthesis of 3a (Figure 2.3) with protons H2 and 
H3 coupling to each other and appearing as doublets at chemical shifts δ 7.92 and 7.14 ppm 
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Figure 2.3: 1H-NMR spectrum of 3a at 300 MHz in CDCl3. 
 
2.3.2.3 Suzuki-Miyaura Cross-coupling: Step (iii), Scheme 2.1 
The next step in the synthetic protocol in scheme 2.1 involved a Suzuki-Miyaura cross coupling 
of the dihalogenated precursor 3a with various arylboronic acids as well as arylboronic acid 
pinacol esters. The reaction mechanism has been postulated to occur as outlined in scheme 
2.8.43,44 The first step involves the oxidative addition of the heteroarylhalide (3a) to the Pd0 
catalyst to form the Pd2+ complex. The halide (in this case iodine) is then replaced by a 
nucleophilic attack of one carbonate (CO3
2-) ion on the palladium complex. The boronic acid 
or the pinacol ester equivalent is also activated or rendered more nucleophilic by the 
nucleophilic addition of a carbonate anion on the electrophilic boron atom. A transmetalation 
step follows in which the now more nucleophilic Ar group bonds to the palladium complex 
while the eliminated carbonate anion bonds to the boronic centre. The biaryl bond is then 
formed in a reductive elimination step, which also regenerates the Pd0 catalytic species for the 







δ/ppm     Multiplicity        J/Hz        H 
7.92                 d                   9.41        H2 
7.88                 s                      -           H1 









Scheme 2.8: Reaction mechanism for the Suzuki-Miyaura cross-coupling reaction.43,44  
 
The intermediates arising from the first Suzuki-Miyaura cross-coupling reaction, as captured 
in step (iii) of scheme 2.1, were characterized by 1H-NMR and, in most cases, HPLC-MS. For 
each class of intermediates, a representative 1H-NMR spectrum is shown. 
For the sulfoxide-containing intermediate 4a, characterization by HPLC-MS revealed a 
characteristic quasi-molecular ion peak [M + H]+ at m/z 292.0 (calculated exact mass = 
291.0233). The successful incorporation of the 4-methylsulfinylphenyl moiety was also evident 
in the 1H-NMR spectrum (Figure 2.4) with an upfield singlet signal (δ = 2.81 ppm) 
corresponding to the relatively shielded three methyl protons (H4) of the methylsulfinyl group. 
The two sets of protons, H2 and H3, were observed as two doublets, integrating for two protons 
each, in the downfield aromatic region. Two other doublets, integrating for one proton each, 
were attributed to protons H5 and H6, while proton H1 corresponded to a one-proton singlet 
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Figure 2.4: 1H-NMR spectrum of 4a at 300 MHz in CDCl3. 
 
The first Suzuki-Miyaura cross-coupling reaction [step (iii) in scheme 2.1] also gave rise to 
regioisomeric biaryl intermediates with basic side chains on the phenyl ring (4e – g). As 
expected, two of these regioisomeric intermediates, whose formation was monitored by HPLC-
MS, exhibited the same quasi-molecular ion peak [M + H]+ at m/z 333.1 (calculated exact mass 
= 332.1204). Common to all three regioisomeric intermediates is the diethylaminomethyl 
group attached to the benzene ring. As anticipated, in addition to aromatic protons resonating 
in the aromatic region (δ = 7.00 – 8.25 ppm), the 1H-NMR spectra of these intermediates were 
characterized by three signals in the aliphatic region (see representative spectrum in figure 2.5). 
The highly shielded methyl protons resonated upfield giving a triplet at around δ = 1.13 ppm 
which integrated for 6 protons of the two methyl groups of the basic side chain. A 4-proton 
quartet signal, corresponding to the 4 hydrogens on the two methylene groups adjacent to the 
methyl groups, was also observed at approximately δ = 2.65 ppm. The non-coupled aliphatic 
protons of the comparatively deshielded methylene carbon bonded to the nitrogen and the 
benzene ring resonated as a singlet at around δ = 3.70 ppm. A representative 1H-NMR spectrum 
for this class of intermediates is shown in figure 2.5. 
 
δ/ppm     Multiplicity        J/Hz        H 
8.24                 d                   8.19        H2 
8.18                 s                      -           H1 
8.11                 d                   9.41        H5 
7.82                 d                   8.01        H3 
7.22                 d                   8.83        H6 
















Figure 2.5: 1H-NMR spectrum of 4e at 300 MHz in CDCl3. 
 
2.3.2.4 Suzuki-Miyaura Cross-coupling: Step (iv), Scheme 2.1 
Diaryl-imidazopyridazine analogues were obtained following a second Suzuki-Miyaura cross 
coupling as captured in scheme 2.1. For the reaction mechanism of this and other Suzuki-
Miyaura cross-coupling reactions in this thesis, refer to scheme 2.8. The final target compounds 
representing this class are shown in table 2.1. For all diphenylated analogues containing either 
the sulfone or sulfoxide groups on both phenyl rings (19, 26, 27, 50 – 54 and 58), the number 
of aromatic protons was constant. This was consistent with all the corresponding 1H-NMR 
spectra which exhibited aromatic signals integrating for 11 protons in total. The 1H-NMR 
spectrum for the representative analogue 26 is shown in figure 2.6.  
A well resolved 1H-NMR multiplicity pattern was observed. As anticipated, the more shielded 
sulfinylmethyl protons (H9) resonated as a singlet relatively upfield (δ = 2.84 ppm) while the 
less shielded sulfonylmethyl protons (H4) resonated as a singlet relatively downfield at δ = 
3.15 ppm. The splitting pattern of the protons attached to the imidazopyridazine core (H1, H5 
and H6) was similar to that observed for the intermediate 4e (Figure 2.5). Four distinct doublets 
corresponding to the four pairs of phenyl protons were observed. In this regard, protons H2 
resonated at δ = 8.41 ppm integrating for two protons while showing coupling to a two-proton 
 
δ/ppm        Multiplicity        J/Hz          H 
8.23-8.10            m                    -          H1, H2 
8.00                     d                  9.41          H8 
7.40-7.30            m                    -          H3, H4 
7.12                     d                  9.41          H9 
3.70                     s                     -             H5 
2.65                     q                  7.11          H6 

















signal for H3 (J ~ 8.8 Hz). In like manner, coupling was observed for protons H7 and H8 which 
were associated with the same coupling constant (J ~ 8.7 Hz) at chemical shifts δ = 8.19 and 
7.88 ppm respectively. 
 
Figure 2.6: 1H-NMR spectrum of 26 at 400 MHz in CDCl3. 
 
The 13C-NMR spectrum for the representative compound 26 is shown in figure 2.7. 
Heteronuclear Single Quantum Coherence (HSQC) spectroscopy, a 2-D NMR technique 
facilitated the unambiguous assignment of signals arising from carbons attached to protons. As 
anticipated, two signals appearing in the aliphatic region at δ = 44.00 and 44.58 ppm 
corresponded to C9 and C4 respectively. Also notable are signals corresponding to C5 and C6 
which resonated at δ = 126.65 and 116.66 ppm respectively with virtually the same peak 
intensity. As expected, chemically equivalent phenyl carbons such as C2, C3, C7 and C8 gave 
relatively intense signals in the range δ = 128.08 - 124.49 ppm. Carbon C1 was also 
unambiguously assigned to a signal at δ = 134.52 ppm. The relatively weak signals observed 
in the range δ = 151.23 - 137.92 ppm and at δ = 133.74 ppm, in addition to intense signals, 
were attributed to quaternary carbons. Additionally, two other quaternary carbons resonated 
together with C7 (128.08 ppm) and C3 (127.97 ppm) as is evident from the pronounced peak 
intensity of signals at these two chemical shifts. 
 
δ/ppm     Multiplicity        J/Hz        H 
8.41                 d                   8.82        H2 
8.27                 s                      -           H1 
8.24                 d                   9.54        H5 
8.19                 d                   8.69        H7 
8.13                 d                   8.79        H3 
7.88                 d                   8.70        H8 
7.70                 d                   9.49        H6 
3.15                 s                      -           H4 
















Figure 2.7: 13C-NMR spectrum of 26 at 101 MHz in CDCl3. 
 
HPLC-MS analysis of these analogues further confirmed their successful synthesis with 
pseudo-molecular ion [M + H]+ m/z peaks observed for all the compounds. For a representative 
analogue 26 (calculated exact mass = 411.0711), a pseudo-molecular ion [M + H]+ was 
























2 × C3 + 1 quaternary C 2 × C7 + 1 quaternary C 

























Figure 2.8: HPLC Chromatogram and APCI+ mass spectrum of 26. 
 
The second Suzuki-Miyaura cross-coupling reaction on the chloro-substituted intermediates 
(step iv, scheme 2.1) also delivered other biaryl analogues such as the regioisomeric analogues 
28 – 30 (Table 2.1). Additionally, 31 (Table 2.1), an analogue with a pro-drug-like relationship 
 
 26 
Exact mass: 411.0711 
Molecular weight: 411.49  
 
 
[M + H]+: 412.1 
APCI+ Mass Spectrum 
HPLC Chromatogram at λ = 280 nm 




with compound 29, was also synthesized. The 1H-NMR spectra of these analogues were 
generally of a similar pattern with 4 characteristic signals in the aliphatic region corresponding 
to the four different classes of aliphatic protons. The spectrum for analogue 30 (Figure 2.9) is 
shown as a representative example. The relatively highly shielded methyl protons H12 were 
observed as a triplet at δ = 1.14 ppm and coupled to the neighbouring H11 protons. The slightly 
more deshielded four H11 protons resonated as a quartet at δ = 2.67 ppm and, as expected, 
exhibiting the same coupling constant (J = 7.07 Hz) as that of the H12 triplet. However, for 
analogues 28 and 31, the expected quartet at around the same chemical shift was not well 
resolved, and all attempts at manipulating the samples to get the desired multiplicity proved 
futile. Very sharp singlet peaks corresponding to the uncoupled H4 and H10 protons were also 
observed at δ = 2.81 and 3.78 ppm respectively. Notable multiplicity patterns in the aromatic 
region include the unusual multiplet at δ = 7.20 ppm. Although this peak, corresponding to 
proton H8, has a typical triplet appearance, attempts to calculate the corresponding coupling 
constant were unsuccessful. Furthermore, 1H-NMR-processing software also recognized this 
signal as a multiplet. This is hardly surprizing because proton H8 could be experiencing 
unequal coupling from proton H7 and the adjacent fluorine. Similarly, a signal that appears as 
a doublet of doublet of doublets (ddd) at δ = 7.92 ppm could not be recognized as such due to 
unequal long-range couplings between proton H9 and the fluorine atom. More sophisticated 
NMR experiments, such as the two-dimensional Correlation Spectroscopy (COSY) and HSQC 
also gave insight into such fluorine-coupling behaviour. On the other hand, protons H2 and H3 
were observed as two doublets at δ = 8.37 and 7.80 ppm respectively with exactly equal 
coupling constants (J = 8.65 Hz). As expected, the other regioisomeric analogues, including 
the sulfone 31, gave different aromatic multiplicity patterns attributable to the different 
positions of the fluoro and diethylaminomethyl groups on the phenyl ring.  





Figure 2.9: 1H-NMR spectrum of 30 at 300 MHz in CDCl3. 
 
Further characterization by HPLC-MS of these analogues confirmed their molecular weights. 
The isomeric analogues exhibited the same m/z values corresponding to their quasi-molecular 
ions [M + H]+ (30: m/z = 437.1, calculated exact mass = 436.1733; 28: m/z = 437.1, calculated 
exact mass = 436.1733 and 29: m/z = 437.2, calculated exact mass = 436.1733). With a 
calculated exact mass of 452.1682, the sulfone, 31, also exhibited a quasi-molecular ion at m/z 
= 453.1. For the representative analogue 30, the HPLC chromatogram and mass spectrum are 








δ/ppm        Multiplicity        J/Hz          H 
8.37                     d                  8.65          H2 
8.23                     d                  6.57          H9 
8.17                     s                     -             H1 
8.11                     d                  9.48          H5 
7.98-7.87            m                    -             H7 
7.80                     d                  8.65          H3 
7.63                     d                  9.41          H6 
7.25-7.15            m                    -             H8 
3.78                     s                     -            H10 
2.81                     s                     -             H4 
2.67                     q                  7.07         H11 
1.14                     t                   7.12         H12 
 
H12 








































Figure 2.10: HPLC Chromatogram and APCI+ mass spectrum of 30.  
 
Keeping the left-hand portion of the imidazopyridazine core-scaffold as 3-
methylsulfinylphenyl moiety while introducing basic side chains on the right portion gave rise 




Exact mass: 436.1733 





HPLC Chromatogram at λ = 280 nm 
[M + H]+: 437.1 
APCI+ Mass Spectrum 




so are they to derivatives 28 - 30 (Table 2.1). Therefore, the 1H-NMR signal pattern remained 
essentially the same for these sets of regioisomers. As observed for the other regioisomers, the 
expected splitting pattern for two of these analogues (32 and 33) was not observed. In this 
regard, the expected 4-proton quartet signal for the 4 methylene protons of the two carbons 
directly bonded to the nitrogen atom of the basic side chain was not observed. Compound 32 
gave a broad singlet while 33 gave a broad doublet for these protons. On the contrary, a well 
resolved multiplicity was observed for 34 and the solved 1H-NMR spectrum for this 
representative compound is shown in figure 2.11 below. 
 
Figure 2.11: 1H-NMR spectrum of 34 at 300 MHz in CDCl3. 
 
Noteworthy splitting patterns in the 1H-NMR spectrum is the doublet of triplets (dt) at δ = 8.25 
ppm. This signal was attributed to proton H12 whose short range (J3) coupling to H11 accounts 
for one large coupling constant (J = 7.39 Hz). The second, and relatively smaller coupling 
constant (J = 1.56 Hz), arises from long range coupling (J4) to H10 and H13. COSY and HSQC 
NMR correlation experiments were employed to gain insight into such coupling behaviour. 
Again, employing such correlation experiments, the well resolved 1-proton signal splitting as 
a doublet of doublet of doublets (ddd) was attributed to proton H3. In this regard, a short-range 
coupling to H4, and two unequal long-range couplings to fluorine and H2 resulted in such a 
 
δ/ppm        Multiplicity        J/Hz                   H 
8.39-8.29            m                    -                 H2, H13 
8.25                    dt             7.39, 1.56             H12 
8.16-8.07            m                    -                  H1, H8 
8.00                   ddd      8.36, 4.92, 2.36          H3 
7.80-7.66            m                    -                H11, H10 
7.61                     d                 9.48                   H9 
7.25-7.15            m                    -                     H4 
3.80                     s                     -                     H5 
2.82                     s                     -                    H14 
2.68                     q                 7.08                   H6 





















splitting pattern. As observed previously for analogue 30, H4 was recognized as a multiplet 
albeit exhibiting an appearance of a triplet. This, once again, may be attributed to unequal 
couplings to H3 and the adjacent fluorine atom. 
Furthermore, all the 24 carbon atoms in compound 34 were accounted for in the 13C-NMR 
spectrum shown in figure 2.12. The two highly shielded equivalent carbon atoms, C11, 
resonated at the most upfield chemical shift (δ = 11.58 ppm). C22 connected to a less 
electronegative atom (sulfur) resonated relatively upfield (δ = 44.13 ppm) compared to C10 (δ 
= 46.97 ppm) and C9 (δ = 49.88 ppm) carbons which are directly connected to a more 
electronegative atom (nitrogen). The aromatic C14 resonated at δ = 115.04 ppm which is 
consistent with the chemical shift (δ = 116.66 ppm) observed for the same carbon in compound 
26 (see figure 2.7). However, the neighbouring carbon (C13) resonates significantly downfield 
(δ = 133.60 ppm) compared to the same carbon in analogue 26 (δ = 126.65 ppm). Interestingly, 
C7 resonated as a doublet at δ = 115.61 ppm with a large coupling constant (J = 22.94 Hz) 
which is typical of J2 coupling to the fluorine attached to the adjacent carbon atom, C6.45 As 
expected, the quaternary carbon C6 directly attached to the fluorine atom was highly deshielded 
resonating as a weak signal at δ = 162.23 ppm. It is also worth noting that, for aromatic carbons 
bonded to hydrogens, those on the sulfoxide-substituted phenyl ring (C17 – C19 and C21) 
including the imidazo C1 all resonated as strong signals. On the contrary, C4, C7 and C8 
attached to the fluoro- and diethylaminomethyl-substituted phenyl ring were relatively weaker. 
As expected, all the remaining seven quaternary carbons resonated as seven weak signals (see 
unassigned signals). 





Figure 2.12: 13C-NMR spectrum of 34 at 101 MHz in CDCl3. 
 
When further subjected to molecular weight confirmation by HPLC-MS, the three analogues 
(32 - 34) exhibited the same quasi-molecular ion [M + H]+ at m/z = 437.2, calculated exact 
mass = 436.1733. The three regioisomers also exhibited almost the same retention times (tr ~ 
2.5 min). The HPLC chromatogram and the mass spectrum of the representative analogue 34 
































































Figure 2.13: HPLC Chromatogram and APCI+ mass spectrum of 34. 
 
2.3.2.5 Buchwald-Hartwig Amination: Step (v), Scheme 2.1 
As opposed to the Suzuki-Miyaura cross-coupling, which leads to carbon-carbon bond 
formation, the Buchwald-Hartwig amination furnishes compounds containing carbon-nitrogen 
 
 34 
Exact mass: 436.1733 





HPLC Chromatogram at λ = 280 nm 
[M + H]+: 437.2 
APCI+ Mass Spectrum 




bonds. In some aspects, the catalytic cycle by which this reaction occurs is similar to that for 
the Suzuki-Miyaura cross-coupling. In this reaction, an aryl halide is cross-coupled with an 
amine in presence of a palladium catalyst and a base. The reaction’s catalytic cycle is depicted 
in scheme 2.9.46–48 In the first step, the aryl halide oxidatively adds to the palladium after which 
the amine coordinates to the palladium metal centre. Deprotonation of the amine by the base 
(e.g., Cs2CO3), generates the highly nucleophilic amide ion, which then substitutes the chloro 
group. The final aminated product is then formed via a reductive elimination step with the 
palladium catalyst being regenerated. 
 
Scheme 2.9: Catalytic cycle for the Buchwald-Hartwig amination.46–48  
 
This reaction afforded analogues with an amino (NH) linker between the core 
imidazopyridazine scaffold and the aromatic/aliphatic substituents (36 – 45, Table 2.1). 
Consistent with the newly introduced NH linker, the 1H-NMR spectra of all the analogues, save 
for 45, showed a diagnostic signal corresponding to the NH proton. Except for analogue 45 
whose 1H-NMR spectrum was acquired in deuterated methanol (CD3OD), all 
1H-NMR spectra 
for the remainder of the aminated analogues were acquired in deuterated dimethylsulfoxide 
(DMSO-d6) and chloroform (CDCl3) in the case of 44. Therefore, the absence of an NH signal 
in the spectrum for 45 could be, most likely, due to protium-deuterium (H-D) isotopic exchange 
which is common48 when 1H-NMR spectra are acquired in CD3OD for compounds containing 
exchangeable hydrogens. For analogues appended with aromatic amines (36 - 40, 44 and 45), 













the aliphatic-attached nitrogen in the remainder of the analogues resonated relatively upfield at 
around δ = 7.0 ppm. In the case of 44 and 45, such a coupling reaction was accompanied by 
the appearance of aliphatic-region 1H-NMR signals corresponding to the basic side chain in 
these compounds.  
A representative 1H-NMR spectrum for analogue 37 is captured in figure 2.14. Two diagnostic 
signals were observed. These include a signal arising from the highly deshielded NH (H7) 
proton which appears as a singlet at δ = 9.81 ppm. Successful installation of a 
methylsulfinylaniline moiety was also accompanied by the appearance of an extra signal at δ 
= 2.73 ppm integrating for three protons of the methylsulfinyl group. Some other noteworthy 
splitting patterns arising from the newly introduced group include a singlet with a triplet-like 
appearance which was not well resolved at δ = 8.11 ppm. This corresponded to proton H11 
whose triplet-like shape could be arising from long range J4 coupling to protons H8 and H10. 
Proton H8 resonated as a doublet of doublets signal at δ = 7.77 ppm integrating for one proton. 
Short range coupling (J3 = 8.09 Hz) to H9 as well as long range coupling (J4 = 1.30 Hz) to H10 
explains this splitting pattern. A well-defined one-proton triplet signal (δ = 7.57 ppm, J = 7.89 
Hz) and doublet (δ = 7.31 ppm, J = 7.66 Hz) were attributed to protons H9 and H10 
respectively. Short range coupling to two neighbours (H8 and H10) accounts for the splitting 
pattern of the H9 signal while coupling to H9 accounts for the H10 doublet. 





Figure 2.14: 1H-NMR spectrum of 37 at 400 MHz in DMSO-d6. 
 
The aminated analogues were also confirmed by 13C-NMR and figure 2.15 shows a 
representative spectrum for the aniline analogue 37. The signals in the spectrum were generally 
well resolved with minimal overlap. Notable chemical shift values arising from the introduced 
aniline motif include those from the hydrogen-containing carbons such as 43.83 ppm (C18); 
113.50 ppm (C17); 117.01 ppm (C15); 121.14 ppm (C13) and 130.32 ppm (C14) which were, 













δ/ppm        Multiplicity        J/Hz            H 
9.81                    s                      -               H7 
8.28                    d                   8.51            H2 
8.11                    s                      -              H11 
8.05                    s                      -               H1 
8.03                    d                   9.66            H5 
7.85                    d                   8.48            H3 
7.77                   dd              8.09, 1.30       H8 
7.57                    t                    7.89            H9 
7.31                    d                   7.66           H10 
7.02                    d                   9.69            H6 
2.82                    s                       -              H4 
2.73                    s                       -             H12 
 
H2O in DMSO-d6 
37 
H6 





Figure 2.15: 13C-NMR spectrum of 37 at 101 MHz in DMSO-d6. 
 
When subjected to HPLC-MS analysis, analogue 37 exhibited a quasi-molecular ion (m/z [M 
+ H]+ = 411.0, exact mass = 410.0871 at tr = 2.636 min) under APCI



























































Figure 2.16: HPLC Chromatogram and APCI+ mass spectrum of 37. 
 
The 1H-NMR spectrum of 43 is shown in figure 2.17 to represent analogues possessing 
aliphatic amines. With the installation of the saturated cyclic amine substructure, there was a 
concomitant and expected decrease in the number of aromatic signals while aliphatic signals 
corresponding to the aliphatic protons of the piperidyl ring appeared. Notable diagnostic signals 
 
 37 
Exact mass: 410.0871 





HPLC Chromatogram at λ = 280 nm 
[M + H]+: 411.0 
APCI+ Mass Spectrum 




include the NH proton (H7) which experiences coupling to proton H8 and, therefore, resonates 
as a doublet (J = 6.54 Hz, δ = 7.16 ppm). Since the piperidine ring predominantly assumes the 
chair conformation, the equatorial (e) and axial (a) protons resonated at different chemical 
shifts. Generally, the more deshielded pair of protons, H10e and H10a, appeared relatively 
downfield compared to the less deshielded H9e and H9a protons. COSY and HSQC 
experiments were also instrumental in facilitating accurate assignment of the two pairs of 
protons. Due to a multiplicity of coupling including geminal (J2) and vicinal (J3) coupling, 
which was also evident from COSY and HSQC experiments, the piperidyl protons resonated 
as multiplets. The H10e protons appeared slightly downfield at δ = 3.60 ppm as a multiplet 
while H10a resonated as a multiplet further upfield at δ = 3.01 ppm. Axial protons in chair 
conformations of piperidine are indeed known to be more shielded than their equatorial 
counterparts.49 The same is true for protons H9e and H9a. Another multiplet signal integrating 
for one proton was observed at δ = 3.82 ppm, which was attributed to proton H8. As expected, 
an extra aliphatic singlet signal (δ = 2.94 ppm) integrating for three protons was unambiguously 
attributed to H11. 
 
Figure 2.17: 1H-NMR spectrum of 43 at 400 MHz in DMSO-d6. 
 
δ/ppm        Multiplicity        J/Hz            H 
8.41                    d                  8.6               H2 
8.04                    s                    -                 H1 
7.87-7.74           m                   -              H3, H5 
7.16                    d                  6.5               H7 
6.76                    d                  9.7               H6 
3.90-3.75           m                   -                 H8 
3.67-3.55           m                   -                H10e 
3.07-2.97           m                   -                H10a 
2.94                    s                    -                 H11 
2.80                    s                    -                  H4 
2.19-2.21           m                   -                 H9e 





















Correspondingly, the 13C-NMR spectra for the analogues containing saturated heterocyclic 
rings (41 – 43) in place of the left-hand side phenyl ring had reduced signals in the aromatic 
region with a corresponding appearance of aliphatic signals. Figure 2.18 shows the 13C-NMR 
spectrum for the representative analogue 43. In addition to the aliphatic signal at δ = 43.62 ppm 
which corresponds to the methylsulfinyl carbon C7, another aliphatic-region signal was 
observed at δ = 35.15 ppm which was unambiguously assigned to the methylsulfonyl carbon 
C15. Furthermore, the five aliphatic carbons of the installed piperidine ring (C12, C13 and 
C14) resonated at δ = 48.00, 30.82 and 44.76 ppm respectively. The five relatively weaker 
unassigned signals were attributed to the five quaternary carbons.     
 
Figure 2.18: 13C-NMR spectrum of 43 at 101 MHz in DMSO-d6. 
 
All the target compounds in this category were also characterized using HPLC-MS. A quasi-
molecular ion, [M + H]+, at m/z = 434.1 (calculated exact mass = 433.1242) was evident for 





















































Figure 2.19: HPLC Chromatogram and APCI+ mass spectrum of 43. 
 
2.3.2.6 O-Tosylation: Step (i), Scheme 2.2 
Towards the synthesis of the amine precursor 5d (Scheme 2.2), intermediate 5b was 
synthesized.50 However, this tosylated intermediate could not undergo ionization on HPLC-
MS and, therefore, evidence for its successful formation was based on 1H-NMR (Figure 2.20). 
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Exact mass: 433.1242 
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Two singlets in the aliphatic region at δ = 2.48 and 5.20 ppm, which integrated for three and 
two protons correspond to H3 and H4 respectively. Coupling with fluorine and proton H6 gave 
a triplet (J = 8.75 Hz) at δ = 7.22 ppm associated with proton H5. Protons H1 and H2 resonated 
as sharp doublets at δ = 7.38 (J = 7.97 Hz) and 7.84 ppm (J = 8.37 Hz) respectively. Further 
downfield, a multiplet integrating for two protons was observed corresponding to the aromatic 
protons H6 and H7. 
 
Figure 2.20: 1H-NMR spectrum of 5b at 300 MHz in CDCl3. 
 
2.3.2.7 Nucleophilic Substitution: Step (ii), Scheme 2.2 
The tosylated intermediate 5b was further subjected to nucleophilic substitution with 
diethylamine to afford the aminated intermediate 5c. Successful substitution of the tosylate 
group with diethylamine was accompanied by appearance of a 6-proton triplet signal (δ = 1.10 
ppm, J = 7.13 Hz); a 4-proton quartet signal (δ = 2.62 ppm, J = 7.12 Hz) and a 2-proton singlet 
signal (δ = 3.71 ppm) in the aliphatic region (Figure 2.21). This splitting pattern was similar to 
previous splitting patterns observed for analogues and intermediates containing the basic side 
chain. Additionally, a concomitant disappearance of the tosylate aromatic protons was also 
observed. At δ = 8.14 ppm, a doublet of doublet of doublets (J = 8.97, 4.40, and 2.97 Hz) was 
 
δ/ppm        Multiplicity      J/Hz              H 
8.29-8.16          m                    -             H6, H7 
7.84                   d                  8.37              H2 
7.38                   d                  7.97              H1 
7.22                   t                   8.75              H5 
5.20                   s                     -                 H4 















observed and attributed to proton H5. Such a splitting pattern was rationalized on the basis of 
the existence of three unequal couplings. In this respect, proton H5 experiences coupling to 
H4, H6 and the fluorine atom. The doublet of doublets (J = 6.24 and 2.92 Hz) observed at δ = 
8.48 ppm was associated with H4 which experiences two long range couplings to H5 and the 
fluorine atom. Consistent with the observation in the spectrum for 5b, the proton adjacent to 
the fluorine atom, H6, resonated as a triplet (J = 8.93 Hz). 
 
Figure 2.21: 1H-NMR spectrum of 5c at 300 MHz in CDCl3. 
 
2.3.2.8 Reduction of the Nitro Group: Step (iii), Scheme 2.2 
The SnCl2/HCl-mediated reduction of the nitro to the amino afforded the aniline starting 
material 5d. With the reduction of the nitro group, a significant upfield shift of aromatic signals 
in the 1H-NMR spectrum was observed (Figure 2.22) with protons H4 and H6 resonating at 
approximately the same chemical shift (δ = 6.86 – 6.78 ppm) as a multiplet. A doublet of 
doublet of doublets was still observed for proton H5 albeit at a lower chemical shift (δ = 6.53 
ppm, J = 8.65, 4.10, and 3.00 Hz). The preceding subsection has already discussed the magnetic 
interactions resulting in such a splitting pattern. The aliphatic signals also retained a similar 
splitting pattern as observed and noted in the preceding subsection. More corroborating 
 
δ/ppm        Multiplicity      J/Hz                H 
8.48                  dd             6.24, 2.92           H4 
8.14                 ddd        8.97, 4.40, 2.97      H5 
7.17                    t                   8.93               H6 
3.71                    s                     -                   H3 
2.62                    q                  7.12                H2 













evidence for successful nitro reduction was obtained from HPLC-MS measurements which 
showed a quasi-molecular ion [M + H]+ for 5d (m/z = 197.1, calculated exact mass = 196.1376). 
 
Figure 2.22: 1H-NMR spectrum of 5d at 300 MHz in CDCl3. 
 
2.3.2.9 N-Acetylation: Step (i), Scheme 2.3 
As mentioned earlier, an acetylation step on 4-aminophenol was necessary to prevent formation 
of polysubstituted products50 towards the synthesis of the phenolic starting material 5h. 
Successful acetylation was accompanied by the appearance of an upfield 1H-NMR singlet 
signal at δ = 2.10 ppm integrating for 3 protons (H1) of the acetyl methyl group (Figure 2.23). 
Protons H2 and H3 resonated as two doublets each integrating for 2 protons at δ = 7.31 and 









δ/ppm        Multiplicity      J/Hz                 H 
6.86-6.78           m                   -                 H4, H6 
6.53                  ddd       8.65, 4.10, 3.00        H5 
3.58                    s                    -                     H3 
2.59                    q                  7.13                 H2 
1.09                    t                   7.14                 H1 
 5d 





Figure 2.23: 1H-NMR spectrum of 5f at 300 MHz in CD3OD. 
 
Additionally, a characteristic [M + H]+ m/z value was also observed on HPLC-MS for this 
acetylated intermediate (m/z = 152.1, calculated exact mass = 151.0633). 
 
2.3.2.10 Mannich Reaction: Step (ii), Scheme 2.3 
The deactivation of the amino group was then followed by aminomethylation via a Mannich 
reaction on the benzene ring to give intermediate 5g. The characteristic 1H-NMR signals 
corresponding to the newly-incorporated Mannich base-like side chain were observed. 
However, the spectrum also showed that this intermediate was still contaminated with 
diethylamine and was subsequently used in the next step without further purification. The 
spectrum is, therefore, not shown albeit the 1H-NMR data is reported in the experimental 
section of this thesis. Moreover, a corresponding quasi-molecular ion [M + H]+ was detected 
on HPLC-MS (m/z = 237.2, calculated exact mass = 236.1525) which further confirmed 





 H2O in CD3OD 
H3 H2 
δ/ppm        Multiplicity      J/Hz              H 
7.31                    d                 9.05              H2 
6.74                    d                 9.05              H3 
2.10                    s                    -                 H1 
 
5f 




2.3.2.11 Acid-catalysed Deacetylation: Step (iii), Scheme 2.3 
Acid-catalysed hydrolysis of the amide bond in intermediate 5g furnished the free aniline 
compound 5h. Evidence for successful deacetylation was drawn from 1H-NMR which showed 
the corresponding disappearance of the acetyl hydrogens (Figure 2.24). A well resolved pattern 
of multiplicity was observed for all the protons, both aromatic and aliphatic. A doublet (J = 
8.43 Hz) at δ = 6.67 ppm and integrating for 1 proton was unambiguously associated with H3 
which experiences short range coupling to H2. As expected, proton H2 also exhibits a 
reciprocal short-range coupling to H3 as evidenced from one of its coupling constant values (J 
= 8.44 Hz, δ = 6.56 ppm). Proton H2 further experiences a long-range coupling to H1 which 
was characterized by a second coupling constant relatively smaller in magnitude (J = 2.77 Hz). 
Additionally, proton H1, only experiencing long-range coupling to H2, appears as a doublet at 
δ = 6.41 ppm (J = 2.73 Hz). The aliphatic protons H4, H5 and H6 gave the same splitting 
pattern as that observed in previous analogues/intermediates possessing a basic side chain. 
When subjected to mass spectroscopy, 5h also exhibited a quasi-molecular ion [M + H]+ (m/z 
= 195.2, calculated exact mass = 194.1419). 
 
Figure 2.24: 1H-NMR spectrum of 5h at 300 MHz in CDCl3. 
 
 
δ/ppm        Multiplicity      J/Hz              H 
6.67                    d                 8.43              H3 
6.56                   dd            8.44, 2.77         H2 
6.41                    d                 2.73              H1 
3.70                    s                    -                 H4 
2.64                    q                 7.18              H5 












2.3.2.12 Suzuki-Miyaura Cross-coupling: Step (i), Scheme 2.4A 
A one pot Suzuki-Miyaura cross coupling reaction in scheme 2.4A led to formation of 
diarylated imidazopyridazines 25 and 50. The characterization of these two analogues has been 
represented by compounds obtained in scheme 2.1 step (iv). 
 
2.3.2.13 Suzuki-Miyaura Cross-coupling: Step (ii), Scheme 2.4B 
A Suzuki-Miyaura cross coupling reaction on the pyridazine-chlorinated intermediate 2a gave 
the mono-phenylated intermediate 6a which was characterized by 1H-NMR (Figure 2.25). 
 
Figure 2.25: 1H-NMR spectrum of 6a at 400 MHz in CDCl3. 
 
The two imidazo protons H1 (δ = 8.10 ppm, doublet) and H9 (δ = 7.89 ppm, doublet) exhibited 
weak coupling, J = 1.31 and 1.40 Hz respectively. Such a magnitude of coupling constants for 
imidazo protons H1 and H9 was consistent with literature precedence.51 Although quite unusual 
for this class of compounds, proton H7, resonating as a 1-proton triplet of doublets signal at δ 
= 8.36 ppm, experienced long-range coupling (J5 = 0.58 Hz) with H5 in addition to its coupling 
(J4 = 1.78 Hz) to protons H4 and H6. Proton H4, in like manner, resonated as a doublet of 
triplets with short-range coupling (J3 = 7.72 Hz) to H5 as well as equal long-range coupling (J4 
= 1.74 Hz) to protons H6 and H7 accounting for this splitting pattern. Another well resolved 
 
δ/ppm        Multiplicity        J/Hz          H 
8.36                    td             1.78, 0.58      H7 
8.25                     d                  9.62          H2 
8.15                    dt             7.72, 1.74      H4 
8.10                     d                  1.31          H1 
7.89                     d                  1.40          H9 
7.78                    dt              7.80, 1.46     H6 
7.74                    td              7.59, 0.58     H5 
7.69                     d                   9.54         H3 















doublet of triplets signal integrating for one proton at δ = 7.78 ppm was observed which 
corresponds to proton H6. Once again, short range coupling (J3 = 7.80 Hz) to H5 and equal 
long-range coupling (J4 = 1.46 Hz) to H4 and H7 explains this multiplicity pattern. Proton H5 
resonated as a triplet of doublets at δ = 7.74 ppm, which was accounted for by short range 
coupling to H4 and H6 (J3 = 7.59 Hz) as well as a much weaker long-range coupling to H7 (J5 
= 0.58 Hz). For protons H3 and H2, a similar splitting pattern and corresponding coupling 
constants to those observed in previous intermediates and target compounds were observed. 
Mass spectroscopy further confirmed the successful formation of this intermediate with a 
quasi-molecular ion observed at m/z [M + H]+ = 258.1 (calculated exact mass = 257.0623), 
under ESI+ mode. 
 
2.3.2.14 Electrophilic Aromatic Bromination: Step (iii), Scheme 2.4B 
For the mechanism of this reaction, refer to subsection 2.3.2.2. Electrophilic aromatic 
bromination of the intermediate 6a to give the brominated intermediate 6b was accompanied 
by the disappearance of the 1H-NMR signal corresponding to the substituted proton H9 (Figure 
2.26). However, the 1H-NMR signals for this key intermediate were not as resolved as those of 
its precursor 6a. Successful hydrogen-bromine substitution was also evident from the mass 
spectrum which showed two m/z [M + H]+ peaks (336.0 and 338.0, calculated exact mass = 
334.9728) of virtually equal percentage abundance. Such a pattern of mass spectral peaks is 
typical of bromine-containing molecules owing to the fact that the isotopic abundances of the 
two stable isotopes of bromine (79Br and 81Br) is nearly 1 : 1.52   





Figure 2.26: 1H-NMR spectrum of 6b at 300 MHz in CDCl3. 
 
2.3.2.15 Buchwald-Hartwig Amination: Step (v), Scheme 2.4B 
The analogues 46 - 49 (Table 2.2) were realized through an amination reaction on the imidazo 
ring portion. For the reaction mechanism, refer to subsection 2.3.2.5. An important diagnostic 
feature in all the 1H-NMR spectra of all the four analogues was the appearance of a signal 
relatively downfield at δ ~ 9.0 ppm corresponding to the NH proton. To represent these 
imidazo-aminated analogues, the characterization of 49 is discussed. The 1H-NMR spectrum 
of this derivative is shown in figure 2.27. In this target compound, the NH proton (H2) was 
observed as a sharp singlet at δ = 8.83 ppm. Other notable signals associated with the 
incorporated aniline moiety include two doublets at δ = 7.53 and 7.03 ppm corresponding to 
protons H3 and H4 respectively. The two signals, integrating for two protons each, exhibited 
approximately equal coupling constants, J = 8.56 and 8.44 Hz for H3 and H4 respectively. Also 
notable is the aliphatic singlet signal at δ = 2.69 ppm integrating for three protons, which was 
attributed to H5 protons. 
 
 
δ/ppm        Multiplicity        J/Hz          H 
8.44-8.35            m                    -         H2, H7 
8.29-8.23            m                    -             H4 
7.93                     s                     -             H1 
7.90-7.73            m                    -      H3, H5, H6 















Figure 2.27: 1H-NMR spectrum of 49 at 400 MHz in DMSO-d6. 
 
Introduction of the para-substituted aniline group was accompanied by the appearance of 
corresponding 13C-NMR signals (Figure 2.28). An extra aliphatic signal corresponding to the 
sulfinylmethyl carbon C7 was observed at δ = 43.75 ppm. As expected, C7 resonated almost 
at the same chemical shift as the other sulfinylmethyl carbon C17 (δ = 43.63 ppm). Other 
diagnostic signals appeared at δ = 125.84 and 114.92 ppm with equal intensities corresponding 
to the aromatic carbons C4 and C5, respectively. Other carbon atoms connected to hydrogens 
such as C1, C9, C10, C13 – C15 and C18 were also unambiguously assigned while all the 
seven unassigned signals were attributed to the seven quaternary carbons. Additionally, 
analogue 49, like other isomeric analogues such as 37 (Figure 2.16), 38 (Table 2.1) and 48 
(Table 2.2) exhibited a protonated molecular ion [M + H]+ at m/z = 411.1 (calculated exact 
mass = 410.0871). 
 
δ/ppm        Multiplicity      J/Hz            H 
8.83                   s                     -               H2 
8.29                   d                  1.79           H11 
8.25                   d                  9.56            H6 
8.20                   d                  7.80            H8 
7.87-7.81          m                     -        H1, H7, H10 
7.75                    t                  7.75            H9 
7.53                   d                  8.56            H3 
7.03                   d                  8.44            H4 
2.81                   s                      -             H12 
2.69                   s                      -              H5 
 
H6 

















Figure 2.28: 13C-NMR spectrum of 49 at 101 MHz in DMSO-d6. 
 
2.3.2.16 Suzuki-Miyaura Cross-coupling: Steps (i) and (ii), Scheme 2.5 
The successful synthesis of intermediate 7a, a precursor to the silicon-containing analogues, 
was confirmed by HPLC-MS analysis, which showed a corresponding quasi-molecular ion [M 
+ H]+ peak (m/z = 274.0, calculated exact mass = 273.0305). Further confirmation was provided 
by 1H-NMR, which revealed a well resolved multiplicity of aromatic-region signals 
corresponding to the seven aromatic protons (Figure 2.29). As envisaged, the 1H-NMR 
spectrum showed four doublet signals with the symmetrical phenyl protons (H3 and H2) 
accounting for two doublets integrating for two protons each (δ = 8.26 and 8.09 ppm, 
respectively) and exhibiting approximately equal coupling constants (J ~ 8.6 Hz). In a similar 
fashion, protons H4 and H5 resonated as 1-proton doublets at δ = 7.48 and 8.34 ppm, 





















Figure 2.29: 1H-NMR spectrum of 7a at 300 MHz in DMSO-d6. 
 
The second Suzuki-Miyaura cross-coupling step in scheme 2.5 to give corresponding 
carboxylic acid intermediates was accompanied by appearance of extra aromatic protons. This 
confirmed successful incorporation of an aromatic functionality. For derivative 7d, whose 1H-
NMR spectrum will be used as a representative (Figure 2.30), the relatively shielded methyl 
group of the methylsulfonyl substituent resonated upfield (δ = 3.35 ppm), albeit partially 
overlapping with the water signal. Although some aromatic protons resonated as clusters of 
multiplets, some well-resolved multiplicities are noteworthy. Proton H9 resonated downfield 
(δ = 8.67 ppm) as a 1-proton triplet, experiencing long-range coupling to protons H6 and H8, 
as evidenced by the small magnitude of the coupling constant observed (J = 1.66 Hz). On the 
contrary, the more close-range (J3) coupling to protons H6 and H8 that proton H7 experiences 
gave rise to a triplet at δ = 7.91 ppm with a comparatively large coupling constant (J = 7.87 
Hz). 
 
δ/ppm        Multiplicity        J/Hz          H 
8.45                     s                    -              H1 
8.34                     d                  9.48          H5 
8.26                     d                  8.60          H3 
8.09                     d                  8.61          H2 












Figure 2.30: 1H-NMR spectrum of 7d at 400 MHz in DMSO-d6. 
 
These carboxylic acid precursors (7b-d; scheme 2.5) also exhibited characteristic m/z values 
corresponding to their protonated molecular ions [M + H]+ on HPLC-MS (7b: m/z = 378.1, 
calculated exact mass = 377.0834; 7c: m/z = 384.0, calculated exact mass = 383.0882 and 7d: 
m/z = 394.1, calculated exact mass = 393.0783). 
 
2.3.2.17 Amide Bond Formation: Step (iii), Scheme 2.5 
The formation of the amide bond to give the silicon-containing compounds (55 - 57; scheme 
2.5) proceeds via the known textbook mechanism detailed in scheme 2.10 below.39,53–55 The 
deprotonated carboxylic acid attacks the carbodiimide carbon of EDCI to give the O-
acylisourea mixed ester where the carbonyl carbon is rendered more electrophilic and, 
therefore, more prone to nucleophilic attack. The desired amide bond and a urea by-product 
are then formed by the reaction of the amine with the activated O-acylisourea mixed ester 
intermediate. The reaction is thought to be driven by the formation of a stable urea by-
product.39 However, a commonly encountered undesirable side reaction often occurs. The 
unstable O-acylisourea mixed ester could rearrange via an acetyl transfer to the stable N-
acylurea, a reaction that significantly compromises the yield of an amide bond-formation 
 
δ/ppm        Multiplicity        J/Hz          H 
8.67                     t                  1.66           H9 
8.56-8.51            m                    -             H8 
8.49                     s                     -             H1 
8.46-8.39            m                    -          H3, H4 
8.17-8.10            m                    -          H2, H6 
8.08                     d                  9.55          H5 
7.91                     t                   7.87          H7 
















reaction.39 The addition of DMAP substantially circumvents this side reaction by reacting with 
the O-acylisourea mixed ester at a relatively faster rate compared to the rearrangement. This 
faster reaction gives the DMAP intermediate still reactive enough to react with the amine. 
 
Scheme 2.10: Mechanism of amide bond formation.39,53–55  
 
Compounds 55-57 all contain the highly shielded trimethylsilyl protons. The acquired 1H-NMR 
spectra for these compounds were all consistent with this molecular feature. In this regard, the 
highly shielded nine trimethylsilyl protons resonated upfield at around δ = 0.18 ppm as a sharp 
singlet. Save for analogue 55, the methylene protons common to all compounds gave rise to a 
2-proton doublet signal at around δ = 3.00 ppm. A representative 1H-NMR for analogue 57 is 
shown in figure 2.31 below. Interestingly, the NH proton H4 coupling to H5 was reasonably 














DMAP prevents this side 
reaction  





Figure 2.31: 1H-NMR spectrum of 57 at 300 MHz in CDCl3. 
 
When subjected to molecular weight characterization by HPLC-MS, all the silicon containing 
analogues exhibited [M + H]+ m/z values corresponding to their protonated molecules (55: m/z 
= 463.1, calculated exact mass = 462.1546; 56: m/z = 469.2, calculated exact mass = 468.1593 
and 57: m/z = 479.1, calculated exact mass = 478.1495). As a representative example, the 













δ/ppm        Multiplicity      J/Hz             H 
8.56                    t                  1.56             H9 
8.35                   d                  8.23            H12 
8.26-8.15          m                    -          H1, H3, H7 
8.10                   d                  8.30             H10 
7.92                   d                  8.51              H2 
7.79                    t                  7.84             H11 
7.62                   d                  9.50              H8 
6.18                    t                  5.53              H4 
3.16                    s                    -                 H13 
3.03                    d                 5.78               H5 
0.18                    s                    -                  H6 
 
H6 






 H8 H11 
H2 
H10 



































Figure 2.32: HPLC Chromatogram and APCI+ mass spectrum of 57. 
 
2.4 Chemistry: Aminopyrazine Analogues 
2.4.1 Synthesis of Aminopyrazine Analogues 
2.4.1.1 Synthesis of Analogues 24 and 59 – 62 
Compounds 24 and 59 – 62 were synthesized according to scheme 2.11. Two consecutive 




Exact mass: 478.1495 
Molecular weight: 478.64  
 
 
HPLC Chromatogram at λ = 280 nm 
[M + H]+: 479.1 
APCI+ Mass Spectrum 




and 59 in 61 and 21% yields respectively. Reduction of the alkene double bond in presence of 
ammonium formate (NH4HCO2), hydrogen gas and palladium catalyst
57 gave the piperidine-
substituted compound 60 in good yield (68%). N-boc-deprotection mediated by HCl58 followed 
by a mesylation59 step afforded compound 62 in 66 % yield.   
 
Scheme 2.11: Synthetic approach to aminopyrazine compounds 24 and 59 – 62. 
Reagents and reaction conditions: (i) 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester, 
Pd(PPh3)2Cl2, 1 M aq K2CO3, 1,4-dioxane, 110 ⁰C, 20 h; (ii) appropriate boronic acid or boronic acid 
pinacol ester, Pd(PPh3)2Cl2, 1 M aq K2CO3, 1,4-dioxane, 100 ⁰C (24), 110 ⁰C (59), 3 h (24), 13 h (59); 
(iii) NH4HCO2, Pd/C, H2 (balloon), methanol, rt (24 ⁰C), 2.5 h; (iv) 4 M HCl in 1,4-dioxane, rt (24 ⁰C), 
30 min; (v) methanesulfonyl chloride, triethylamine, dichloromethane, 0 ⁰C – rt (23 ⁰C), 1 h.  
 
2.4.1.2 Synthesis of Analogues 63 – 66 and 69 
The installation of a piperidyl group on position 3 of the aminopyrazine scaffold was achieved 
following a synthetic protocol shown in scheme 2.12 which was similar to that described in 























Scheme 2.12: Synthetic approach to aminopyrazine compounds 63 – 66 and 69. 
Reagents and reaction conditions: (i) appropriate boronic acid or boronic acid pinacol ester, 
Pd(PPh3)2Cl2, 1 M aq K2CO3, 1,4-dioxane, 110 ⁰C, 2 h; (ii) NH4HCO2, Pd/C, H2 (balloon), methanol, rt 
(24 ⁰C), 1 h; (iii) 4 M HCl in 1,4-dioxane, rt (24 ⁰C), 1 h; (iv) methanesulfonyl chloride, triethylamine, 
dichloromethane, 0 ⁰C – rt (24 ⁰C), 1 h. 
 
2.4.1.3 Synthesis of Analogues 70 – 72 
In this category of compounds, partial and full saturation at positions 3 and 5 of the 
aminopyrazine scaffold were simultaneously introduced using a synthetic approach in scheme 
2.13. In the first step, a one-pot Suzuki-Miyaura cross-coupling reaction56 at both reaction sites 
in the presence of 2.2 equivalents of the boronic acid pinacol ester afforded compound 70 with 
tetrahydropyridine motifs in 68 % yield. Analogue 71, with fully saturated piperidine rings, 
was then realized via reduction of the double bond in presence of NH4HCO2, hydrogen gas and 
carbon-supported palladium catalyst.57 An HCl-promoted boc-deprotection step58 followed by 
N-methylsulfonylation59 at both piperidine nitrogens afforded 72 in very low yield (23 %). 
 

















Scheme 2.13: Synthetic approach to aminopyrazine compounds 70 – 72. 
Reagents and reaction conditions: (i) N-boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester 
(excess, 2.2 eq), Pd(PPh3)2Cl2, 1 M aq K2CO3, 1,4-dioxane, 110 ⁰C, 4 h; (ii) NH4HCO2, Pd/C, H2 
(balloon), methanol, rt (20 ⁰C), 4 h; (iii) 4 M HCl in 1,4-dioxane, rt (23 ⁰C), 1.5 h; (iv) methanesulfonyl 
chloride, triethylamine, dichloromethane, 0 ⁰C – rt (21.5 ⁰C), 12 h. 
 
2.4.1.4 Synthesis of Analogues 67 and 68 
Analogues 67 and 68 were synthesized according to synthetic scheme 2.14. Although the 
nucleophilic aromatic substitution in the first step was intended to deliver the N-boc-protected 
piperazine intermediate (1-boc-piperazine was used in the reaction), in situ boc-deprotection 
occurred resulting in the formation of the free piperazine-substituted compound 67. Since the 
reaction was carried out at 170 °C, such an in situ removal of the boc group is unsurprising and 
is in conformity with literature reports.60,61 The obtained free amine was then mesylated59 in 
the presence of methanesulfonyl chloride and triethylamine to deliver compound 68 in 74% 
yield. 
 
Scheme 2.14: Synthetic approach to aminopyrazine compounds 67 and 68. 
Reagents and reaction conditions: (i) 1-boc-piperazine, triethylamine, 170 ⁰C, sealed tube, 4 h; (ii) 
methanesulfonyl chloride, triethylamine, dichloromethane, 0 ⁰C – rt (20 ⁰C), 30 min. 
 




















2.4.2 Proposed Mechanistic Details and Characterization 
2.4.2.1 Suzuki-Miyaura Cross-coupling: Step (i), Scheme 2.11 
The bromo-intermediate 7g, obtained in this step, was confirmed by both 1H-NMR and HPLC-
MS. The 1H-NMR for 7g was solved as shown in figure 2.33. The most deshielded proton H3 
resonated as a singlet relatively downfield at δ = 9.16 ppm. As anticipated, J3 coupling between 
protons H4 (δ = 8.30 ppm) and H5 (δ = 7.85 ppm) resulted in two doublets with approximately 
equal coupling constants (J ~ 8 Hz). A singlet at δ = 8.20 ppm was attributed to H1 while a 
broad singlet integrating for two protons at δ = 4.84 ppm was assigned to the two amino 
hydrogens (H2). 
Under negative ionization mode, the mass spectrum of intermediate 7g exhibited two peaks at 
m/z = 317.0 ([M – H]-, calculated exact mass = 317.9728) and 319.9 of virtually equal 
percentage abundance. As earlier mentioned in subsection 2.3.2.14, this observation is 
characteristic of bromo-containing compounds - bromine has two stable isotopes whose natural 
abundance is nearly equal.52      
 
Figure 2.33: 1H-NMR spectrum of 7g at 300 MHz in CDCl3. 
 
 
δ/ppm        Multiplicity      J/Hz             H 
9.16                    s                    -               H3 
8.30                    d                 7.76            H4 
8.20                    s                    -               H1 
7.85                    d                 8.19            H5 















2.4.2.2 Suzuki-Miyaura Cross-coupling: Step (ii), Scheme 2.11 
Although step (ii) in scheme 2.11 resulted in compounds 24 and 59, the NMR and mass spectral 
interpretation of 24 has been omitted because this has already been dealt with in literature.56 
The 1H-NMR for compound 59 is captured in figure 2.34 below. For the aromatic region 
signals, the splitting pattern remained somewhat the same as that for the preceding intermediate 
7g. However, it is worth noting that unlike proton H5 in 7g, which resonated as a clear doublet, 
proton H10 resonated as a doublet of doublets. The larger coupling constant (J = 8.14 Hz) was 
associated with the J3 coupling to H9 while the smaller J value (0.79 Hz) resulted from long-
range coupling to H8. On the other hand, despite having a typical doublet of doublets 
appearance, the multiplicity for the H9 signal was not well resolved and this was consequently 
recognized as a multiplet. The reaction was further accompanied by the appearance of extra 
signals corresponding to the introduced boc-protected tetrahydropyridyl moiety. In this regard, 
the vinylic proton H7 resonated as a broad singlet at δ = 6.57 ppm, which is within the range 
of chemical shifts (δ = 5.5–7.5 ppm) expected for conjugated vinylic systems.62 However, the 
expected splitting pattern (triplet) of H7 was not observed. Nevertheless, the broad nature of 
the observed singlet could suggest that this, in fact, was a triplet, which was not just well 
resolved. This observation was also noted for H3, which resonated as a broad singlet with a 
triplet-like appearance when closely examined. On the other hand, protons H6 resonated as a 
doublet (δ = 4.15 ppm, J = 3.13 Hz) suggesting coupling to H7 while protons H4 resonated as 
a 2-proton triplet signal (δ = 3.67 ppm, J = 5.67 Hz) suggesting coupling to H3. The most 
shielded nine hydrogens of the boc group (H5) resonated as an intense singlet signal (δ = 1.51 
ppm) integrating for 9 protons.       





Figure 2.34: 1H-NMR spectrum of 59 at 400 MHz in CDCl3. 
 
Under the APCI+/ESI+ mode, the molecular ion or its protonated/adduct version could not be 
observed on HPLC-MS for compound 59. The mass spectrum for this compound was, 
therefore, acquired in APCI- mode. At a retention time tr = 2.919 min, a quasi-molecular ion 
peak was observed at m/z = 420.1 (calculated exact mass = 421.1726) corresponding to the 
deprotonated (M – H) molecule of 59.  
 
2.4.2.3 Reduction of the Alkene Double Bond: Step (iii), Scheme 2.11 
Hydrogen transfer reaction mechanisms are poorly understood. Particularly, the ammonium-
formate-mediated reduction is believed to occur via a mechanism shown in scheme 2.15.63–65 
The formation of CO2, a very stable molecule, is the driving force behind the ammonium 
formate-mediated transfer hydrogenation reduction.64 In the first step, the chemisorption of the 
formate ion onto the palladium metal catalyst surface promotes its decomposition to CO2 and 
a hydride ion. The hydride ion then attacks the double bond resulting in the abstraction of an 
ammonium ion proton by the π bond electrons. It is also likely that the hydride ion abstracts an 














δ/ppm        Multiplicity      J/Hz             H 
9.19                    d                1.96              H8 
8.36-8.31           m                  -                 H9 
8.16                    s                   -                 H2 
7.86                   dd          8.14, 0.79         H10 
6.57                  br s                 -                 H7 
5.25                  br s                 -                 H1 
4.15                    d                3.13              H6 
3.67                    t                 5.67              H4 
2.63                  br s                 -                 H3 
1.51                    s                   -                 H5 
 59 




In this case, the addition of hydrogen across the double bond occurs via the well-known syn 
addition catalysed by the metal surface.66 
 
Scheme 2.15: Proposed reaction mechanism for formate-mediated alkene double bond reduction.63–65  
 
Following this reduction step, analogue 60 was obtained and confirmed by 1H-NMR (Figure 
2.35). The most striking diagnostic feature confirming successful reduction was the 
disappearance of the vinylic proton (H7) signal which was observed in the 1H-NMR spectrum 
of compound 59 (Figure 2.34). The reduction to a fully saturated piperidine ring was 
accompanied by the appearance of aliphatic signals associated with equatorial (e) and axial (a) 
protons of the piperidine chair conformation. Being relatively more deshielded, the equatorial 
protons H4e resonated as a multiplet at δ = 4.26 ppm while the more shielded axial protons 
H4a resonated at the same chemical shift as that of the tertiary hydrogen H6 (δ = 2.86 ppm).49 
Protons H3 signals were also resolved into H3e and H3a signals resonating as multiplets at δ = 
1.93 and 1.76 ppm respectively, each integrating for two protons. 
In situ H2 could 
be generated 





Figure 2.35: 1H-NMR spectrum of 60 at 400 MHz in CDCl3. 
 
As expected, successful reduction was also confirmed by the corresponding appearance of a 
pseudo-molecular ion peak (m/z [M – H]- = 422.1, calculated exact mass = 423.1882) in 
negative ionization mode which differed from that of the alkene intermediate by two m/z units. 
 
2.4.2.4 N-Boc-deprotection: Step (iv), Scheme 2.11 
The boc-deprotection step leading to formation of compound 61 occurs according to the 
reaction mechanism shown in scheme 2.16.67 The carbamate oxygen is first protonated by the 
acid, in this case, HCl. Carbamic acid is then generated following the loss of a tert-butyl 
carbocation. Loss of CO2 through a decarboxylation step gives the free amine which undergoes 
protonation in excess acid to give the corresponding salt. Treatment of the salt with a base, in 
this case NaOH, liberates the free amine compound 61. Following deprotonation, the generated 
carbocation forms isobutylene gas which, together with the generated CO2 escape from the 
reaction mixture. It is also likely that the formed tert-butyl carbocation can either be quenched 















δ/ppm        Multiplicity      J/Hz             H 
9.19-915            m                   -                H7 
8.32                    d                 8.02             H8 
7.95                    s                    -                H2 
7.85                    d                 8.01             H9 
5.12                  br s                  -                H1 
4.38-4.17           m                    -               H4e 
2.96-2.78           m                    -           H4a, H6 
2.00-1.87           m                    -               H3e 
1.84-1.68           m                    -               H3a 
1.49                    s                     -                H5 
 





Scheme 2.16: General reaction mechanism for acid-mediated boc-deprotection reaction.67  
 
The N-boc-deprotection step to afford analogue 61 was accompanied by the disappearance of 
the upfield signal of the tert-butyl group (Figure 2.36). As anticipated, since the spectrum was 
acquired in deuterated methanol, the exchangeable amino hydrogens (NH2 and NH) were not 
observed. Strikingly, the multiplicity patterns for this analogue were also somewhat different 
from its precursors. Proton H6 resonated at δ = 9.10 ppm as a doublet (J = 2.10 Hz) arising 
from J4 coupling to H7. A doublet of doublets of triplets (J = 8.20, 2.11 & 0.73 Hz) integrating 
for one proton was observed for proton H7. This was attributed to J3 coupling to H8, a long-
range (J4) coupling to H6 and potentially a space coupling to two neighbouring protons, in this 
case amino protons (NH2). Proton H1 resonated as a doublet with weak coupling (J
4 = 0.41 Hz, 
δ = 7.96 ppm) to H2. At δ = 7.93 ppm, a 1-proton doublet of doublets signal was observed 
which was unambiguously assigned to H8 experiencing both short-range coupling (J3 = 8.20 
Hz) to H7 and long-range coupling (J5 = 0.86 Hz) to H6. For the aliphatic signals, the most 
deshielded protons H4 resonated relatively downfield compared to the more shielded H3 
protons. Additionally, a clear resolution between equatorial and axial protons was evident. The 
most deshielded equatorial protons H4e resonated as a 2-proton multiplet signal at δ = 3.17 
ppm while the more shielded axial protons H4a resonated as a triplet of doublets (J = 12.43, 
2.85 Hz, δ = 2.77 ppm). Axial protons in cyclohexane and piperidine rings are known to 
experience almost equal coupling to an equatorial proton at the same carbon (Ja-e, geminal) and 
an axial proton at an adjacent carbon (Ja-a, vicinal).68 The triplet pattern could be arising from 
these interactions. A weak coupling to the vicinal equatorial proton H3e, which also has 
literature precedence,68 further splits the triplet into triplet of doublets. Furthermore, a multiplet 
signal integrating for two protons at δ = 1.91 ppm was attributed to H3e protons while protons 
Isobutylene gas 
free amine 61 




H3a accounted for a doublet of triplets of doublets at 1.80 ppm. This H3a splitting pattern arises 
from coupling to an axial proton H2 (Ja-a = 13.32 Hz), equal coupling to H3e and H4a (Ja-e = 
Ja-a = 12.01 Hz) and a weak coupling to a vicinal equatorial proton H4e (Ja-e = 4.02 Hz). The 
splitting pattern of H3a was also informative of the stereochemistry of proton H2 and the bulky 
pyrazinyl group about the tertiary piperidine carbon. Since vicinal axial-axial couplings are 
known to be stronger than vicinal axial-equatorial couplings,68 a large coupling constant (J = 
13.32 Hz) observed between H3a and H2 indicates the H2 proton is axial while the bulky 
pyrazinyl group is equatorial.                 
 
Figure 2.36: 1H-NMR spectrum of 61 at 400 MHz in CD3OD. 
 
Upon N-boc-deprotection, a mass loss of 100 m/z units corresponding to the mass of the 
removed boc group was observed on the mass spectrum of compound 61. Under negative 
ionization mode, this corresponded to a pseudo-molecular ion M – H (m/z = 321.8, calculated 








H2 H4a H3e 
H3a 
δ/ppm        Multiplicity      J/Hz                H 
9.10                     d                2.10                H6 
8.44                   ddt      8.20, 2.11, 0.73       H7 
7.96                     d                0.41                H1 
7.93                    dd           8.20, 0.86           H8 
3.22-3.13            m                   -                  H4e 
2.85                     tt           11.80, 3.86          H2 
2.77                     td          12.43, 2.85          H4a 
1.96-1.88             m                   -                 H3e 
1.80                    dtd    13.32, 12.01, 4.02    H3a 
 
 Stable isomer 
(observed): 
Large J value 










2.4.2.5 N-Mesylation: Step (v), Scheme 2.11 
Mechanistic studies69 employing kinetic isotope effects on the hydrolysis of methanesulfonyl 
chloride (i.e., nucleophilic substitution of the Cl for OH in MeSO2Cl) have revealed that, in 
basic media, the reaction occurs via the formation of a sulfene intermediate (scheme 2.17). 
Although the piperidine nitrogen is capable of directly attacking the electrophilic sulfur centre, 
the abstraction of the acidic alpha (α) proton proceeds much faster to form the sulfene 
intermediate. However, for the tosylation reaction (see scheme 2.2), which involves 
toluenesulfonyl chloride with no acidic α hydrogens, the nucleophile directly attacks the sulfur 
in an SN2 fashion. In the second step, the piperidine nitrogen then adds to the sulfene sulfur, 
which is then followed by proton transfer steps to give the N-mesylated compound. 
 
Scheme 2.17: General reaction mechanism for N-mesylation.69  
 
Successful N-mesylation was confirmed by the appearance of a sharp 1H-NMR methyl signal 
which co-resonated with protons H3 and H5a at δ = 2.84 ppm (Figure 2.37). Other aliphatic 
protons in the piperidine ring resonated as multiplets with the most shielded H4 protons 
resonating upfield. The aromatic region still retained a similar pattern of signals as that 









Figure 2.37: 1H-NMR spectrum of 62 at 600 MHz in CDCl3. 
 
The target compound 62 was also further confirmed by 13C-NMR (Figure 2.38) with well-
resolved aliphatic carbon signals. The introduced methylsulfonyl carbon C6 resonated at δ = 
35.21 ppm with nearly equal intensity to the C3 (δ = 40.10 ppm) signal. Similarly, the two 
piperidinyl carbons, C4 (δ = 30.93 ppm) and C5 (δ = 46.00 ppm) resonated as equal intensity 
peaks and were approximately twice as intense as C3 and C6 signals. The aromatic carbons 
also resonated as well-resolved signals and were unambiguously assigned. However, almost 








H3, H5a, H6 
H4e H4a 
δ/ppm        Multiplicity      J/Hz                 H 
9.16                     d                1.83                H7 
8.34-8.30            m                  -                   H8 
7.94                     s                   -                   H2 
7.87                     d                8.07                H9 
5.61                   br s                 -                   H1 
4.01-3.93            m                   -                  H5e 
2.95-2.74            m                   -           H3, H5a, H6 
2.14-2.04            m                   -                  H4e 
2.02-1.92            m                   -                  H4a 
 





Figure 2.38: 13C-NMR spectrum of 62 at 151 MHz in CDCl3. 
 
Compound 62 was further characterized by HPLC-MS and exhibited a retention time of 2.517 
min with a pseudo-molecular ion (m/z [M + H]+ = 402.1, calculated exact mass = 401.1133) 

























































Figure 2.39: HPLC Chromatogram and APCI+ mass spectrum of 62. 
 
2.4.2.6 Suzuki-Miyaura Cross-coupling: Step (i), Scheme 2.12 
Successful Suzuki-Miyaura coupling to deliver compound 63 was confirmed by 1H-NMR 
(Figure 2.40). A singlet integrating for one proton observed at the most downfield chemical 
shift (δ = 8.36 ppm) was attributed to H2. The well resolved doublets at δ = 8.10 and 8.01 ppm, 




Exact mass: 401.1133 




HPLC Chromatogram at λ = 280 nm 
[M + H]+: 402.1 
APCI+ Mass Spectrum 




unambiguously assigned to H3 and H4 respectively. Although protons H6 (δ = 6.39 ppm) and 
H9 (δ = 2.73 ppm) were theoretically expected to resonate as triplets, this was not the case. 
Both resonated as broad singlets indicating they could, in fact, be triplets which are not just 
well resolved. Typical of amino protons, these (H1) resonated at δ = 5.63 ppm as a broad 
singlet. On the other hand, protons H7 (δ = 4.17 ppm, J = 3.34 Hz) and H8 (δ = 3.71 ppm, J = 
5.65 Hz) resonated as a doublet and triplet respectively, which confirmed the count of their 
vicinal neighbours. Furthermore, sharp signals at δ = 3.08 and 1.51 ppm were attributed to the 
methyl protons H5 and H10 respectively. 
 
Figure 2.40: 1H-NMR spectrum of 63 at 600 MHz in CDCl3. 
 
Compound 63 was further subjected to HPLC-MS characterization, which revealed a 
deprotonated molecular ion (m/z [M - H]- = 429.1, calculated exact mass = 430.1675) in the 
negative APCI mode and a retention time of 2.703 min. 
The reduction of the alkene double bond in 63 delivered 64 which, as revealed by 1H-NMR 
was still contaminated with trace amounts of the former. Compound 64 was used without 
further purification in the boc-deprotection step. The 1H-NMR spectrum of 64 is, therefore, not 










H10 δ/ppm        Multiplicity      J/Hz                H 
8.36                     s                   -                   H2 
8.10                     d                8.50                H3 
8.01                     d                8.49                H4 
6.39                   br s                 -                   H6 
5.63                   br s                 -                   H1 
4.17                     d                3.34                H7 
3.71                     t                 5.65                H8 
3.08                     s                    -                  H5 
2.73                   br s                  -                  H9 
1.51                     s                    -                 H10 
 




For compound 69, the introduction of the 4-carboxyphenyl ring was confirmed by the 
corresponding appearance of two 2-proton doublet signals at δ = 8.26 ppm (J = 8.80 Hz) and δ 
= 7.98 ppm (J = 8.74 Hz) in the 1H-NMR spectrum (Figure 2.41). Respectively, these signals 
were assigned to H6 and H7, which were differentiated from those of H3 and H4 based on 
differences in coupling constants. 
On HPLC-MS, compound 69 eluted at tr = 2.496 min and exhibited a pseudo-molecular ion 
(m/z [M + H]+ = 370.1, calculated exact mass = 369.0783) under APCI+ mode.       
 
Figure 2.41: 1H-NMR spectrum of 69 at 400 MHz in DMSO-d6. 
 
2.4.2.7 N-Boc-deprotection: Step (iii), Scheme 2.12 
The N-boc-deprotection reaction, whose mechanism has already been described (see 
subsection 2.4.2.4), was accompanied by the disappearance of the signal corresponding to the 
boc tert-butyl group (Figure 2.42). Save for the equatorial protons H7e, which resonated as a 
doublet (J = 12.23 Hz) at δ = 3.09 ppm, all the other piperidine protons resonated as multiplets. 
In this case, the doublet signal corresponding to H7e arises from geminal coupling to H7a while 
vicinal coupling to H6a and H6e was not detected at this resolution.     
 69 
δ/ppm        Multiplicity      J/Hz                H 
8.74                     s                   -                   H2 
8.26                     d                8.80                H6 
8.09                     d                8.52                H3 
7.98                     d                8.74                H7 
7.93                     d                8.51                H4 
6.66                     s                   -                   H1 
3.24                     s                   -                   H5 
 
H2 
H3 H6 H4 H7 
H1 
H5 





Figure 2.42: 1H-NMR spectrum of 65 at 400 MHz in DMSO-d6. 
 
As anticipated, the polar compound 65 eluted relatively quicker on the reversed phase column 
conditions of the HPLC (tr = 0.249 min). A corresponding pseudo-molecular ion (m/z [M + H]
+ 
= 332.8, calculated exact mass = 332.1307) was observed under APCI+ mode.  
 
2.4.2.8 N-Mesylation: Step (iv), Scheme 2.12 
The N-mesylation step (see mechanism in subsection 2.4.2.5) was accompanied by the 
appearance of an additional methyl signal in 1H-NMR spectrum (not shown) as observed in the 
synthetic target 62 described in subsection 2.4.2.5. The molecular mass of compound 66 was 
also confirmed by HPLC-MS which showed a pseudo-molecular ion peak of m/z [M + H]+ = 
410.7 (calculated exact mass = 410.1082) at tr = 2.434 min. 
 
2.4.2.9 Suzuki-Miyaura Cross-coupling: Step (i), Scheme 2.13 
The one-pot Suzuki-Miyaura cross coupling reaction in step (i) of scheme 2.13 led to 
introduction of partially saturated substituents at both positions 3 and 5 of the 2-aminopyrazine 
core-scaffold. Consistent with this transformation, the 1H-NMR spectrum of the resulting 
compound 70 (Figure 2.43) only exhibited one aromatic singlet signal at δ = 7.73 ppm 
 65 
δ/ppm        Multiplicity      J/Hz                H 
8.52                     s                   -                   H2 
8.20                     d                8.66                H3 
7.94                     d                8.63                H4 
6.63                     s                   -                   H1 
3.21                     s                   -                   H5 
3.09                     d               12.23              H7e 
3.03-2.93            m                  -                   H8 
2.78-2.66            m                  -                  H7a 

















corresponding to H2. The spectrum revealed that protons at the same positions of the two 
tetrahydropyridyl rings were nearly magnetically equivalent as shown by small differences in 
their chemical shifts. While H12 resonated as a broad singlet at a distinct chemical shift (δ = 
6.59 ppm), the corresponding proton H7 on the tetrahydropyridyl ring at position 5 co-
resonated with H1 as a 3-proton multiplet signal at δ = 6.39 ppm. Protons H11 (δ = 4.19 ppm, 
J = 3.06 Hz) and H6 (δ = 4.15 ppm, J = 3.50 Hz) resonated as doublets with weak coupling to 
their neighbours H12 and H7 respectively. The two triplet signals at δ = 3.70 and 3.67 ppm (J 
= 5.55 Hz) were attributed to H9 and H4 respectively. On the other hand, protons H8 and H3 
resonated as broad singlets as previously observed. Furthermore, the boc tert-butyl groups 
(H10 and H5) resonated upfield of all the other protons overlapping with a water peak in 
CDCl3. 
HPLC-MS showed a pseudo-molecular ion m/z [M + H]+ = 458.2 (calculated exact mass = 
457.2689) at tr = 3.01 min further confirming that compound 70 was successfully synthesized. 
 
Figure 2.43: 1H-NMR spectrum of 70 at 400 MHz in CDCl3. 
 
 
δ/ppm        Multiplicity      J/Hz                H 
7.73                     s                   -                   H2 
6.59                   br s                 -                  H12 
6.50-6.32            m                  -                H1, H7 
4.19                     d                3.06               H11 
4.15                     d                3.50                H6 
3.70                     t                 5.55                H9 
3.67                     t                 5.55                H4 
2.72-2.62            m                  -                   H8 
2.57-2.48            m                  -                   H3 
1.53                     s                   -                  H10 

















2.4.2.10 Reduction of the Alkene Double Bond: Step (ii), Scheme 2.13 
The reduction of the alkene double bond (see mechanism in subsection 2.4.2.3) in compound 
70 gave compound 71 (1H-NMR spectrum shown in figure 2.44). This reduction step led to the 
corresponding disappearance of the vinylic proton signals and a concomitant appearance of 
more upfield multiplet signals between δ = 1.93 and 1.58 ppm indicating the double bond was 
successfully reduced. 
Additionally, although the pseudo-molecular ion corresponding to a mass increase of four m/z 
units could not be observed, two fragment ions, one corresponding to loss of one boc group 
(m/z [M – boc + H]+ = 362.2, calculated exact mass = 461.3002) and another corresponding to 
loss of both boc groups (m/z [M – 2boc + H]+ = 262.2, calculated exact mass = 461.3002) were 
observed. 
The boc-deprotection step afforded a very polar compound 7i (Scheme 2.13) which presented 
challenges during purification. This compound was confirmed by ultra-pressure liquid 
chromatography mass spectrometry (UPLC-MS) (m/z [M + H]+ = 262.1, calculated exact mass 
= 261.1953). It was subsequently mesylated without further purification.         
 
Figure 2.44: 1H-NMR spectrum of 71 at 400 MHz in CDCl3. 
 
 71 
δ/ppm        Multiplicity      J/Hz                H 
7.47                     s                   -                   H2 
6.55                   br s                 -                   H1 
4.34-4.10            m                   -              H4e, H9e 
3.04-2.89            m                   -               H7, H9a 
2.88-2.69            m                   -               H5, H4a 
1.93-1.75            m                   -          H3e, H8a, H8e 
1.73-1.58            m                   -                   H3a 
















2.4.2.11 N-Mesylation: Step (iv), Scheme 2.13 
The boc-deprotection step and subsequent N-mesylation (see mechanism in subsection 2.4.2.5) 
to give compound 72 was accompanied by a disappearance of the upfield tert-butyl hydrogen 
signals of the boc groups and a  corresponding appearance of relatively deshielded sulfone-
bonded methyl signals in the 1H-NMR spectrum (Figure 2.45). However, these co-resonated 
with other piperidyl protons as a multiplet at δ = 2.88 ppm. On HPLC-MS, the pseudo-
molecular ion corresponding to this compound was not observed.  
 
Figure 2.45: 1H-NMR spectrum of 72 at 300 MHz in CDCl3. 
 
2.4.2.12 Nucleophilic Aromatic Substitution: Step (i), Scheme 2.14 
The reaction mechanism for the nucleophilic aromatic substitution (SNAr) proceeds most likely 
via an addition-elimination pathway (Scheme 2.18).70 Nucleophilic attack of the nucleophile, 
in this case, 1-boc-piperazine on the brominated carbon generates an anion intermediate. 
Aromatization to eliminate the bromide anion followed by deprotonation gives the boc-
protected compound. Under the influence of high temperature (170 °C), the boc-protecting 
group decomposes giving the free amine compound 67, CO2 and a tert-butyl carbocation. It is 
also likely that this thermolysis could also occur directly on the 1-boc-piperazine before it 
 72 
δ/ppm        Multiplicity      J/Hz                      H 
8.31                     s                   -                         H1 
4.06-3.94            m                  -                    H3e, H8e 
3.22-3.08            m                  -                         H6 
3.04-2.75            m                  -         H4, H5, H9, H3a, H8a 




















attacks the bromo-containing starting material. The generated tert-butyl carbocation has the 
same fate as that described in scheme 2.16.    
 
Scheme 2.18: Reaction mechanism for nucleophilic aromatic substitution (SNAr).
70  
 
The introduction of the piperazine moiety was confirmed by the appearance of two multiplet 
4-proton signals at δ = 3.09 and 2.90 ppm corresponding to H6 and H7 respectively (Figure 
2.46). It is also noteworthy that the peak for protons H5 significantly overlapped with a water 
peak in DMSO-d6.  
Additionally, compound 67 eluted relatively earlier under the reversed phase conditions on 
HPLC-MS (tr = 0.170 min) with its pseudo-molecular ion (m/z [M + H]
+ = 334.1, calculated 
exact mass = 333.1259) being observed in APCI+ mode. 
 
 67 
δ/ppm        Multiplicity      J/Hz                H 
8.33                     s                   -                   H2 
8.17                     d                8.57                H3 
7.92                     d                8.58                H4 
6.27                     s                   -                   H1 
3.21                     s                   -                   H5 
3.11-3.06            m                  -                   H6 
2.93-2.87            m                  -                   H7 
 













Figure 2.46: 1H-NMR spectrum of 67 at 400 MHz in DMSO-d6. 
 
2.4.2.13 N-Mesylation: Step (ii), Scheme 2.14 
The mesylation reaction occurs via a mechanism outlined in scheme 2.17. The 1H-NMR 
spectrum for the obtained compound (68) is shown in figure 2.47. Correspondingly, an 
additional sharp 3-proton signal at δ = 2.94 ppm was observed confirming successful 
mesylation. The signal for protons H7 was obscured by a water peak at δ = 3.37 ppm.  
 
Figure 2.47: 1H-NMR spectrum of 68 at 400 MHz in DMSO-d6. 
 
The 13C-NMR spectrum accounted for all carbons in the expected structure of compound 68 
(Figure 2.48). Expectedly, the five quaternary carbons resonated as five relatively weak signals 
downfield of all other carbons. The two sharp and intense signals in the aromatic region (δ = 
127.84 and 125.67 ppm) were respectively attributed to C4 and C3 of the phenyl ring. 
Similarly, the two sharp and equally intense peaks in the aliphatic region at δ = 47.65 and 45.50 
ppm were assigned to the two piperazinyl carbons C7 and C6 respectively. The introduced 
methylsulfonyl carbon C8 resonated at the most upfield chemical shift δ = 34.76 ppm followed 
by C5 at δ = 44.20 ppm. The aromatic carbon (C2) was the most deshielded of the aromatic 
 68 
δ/ppm        Multiplicity      J/Hz                H 
8.39                     s                   -                   H2 
8.19                     d                8.62                H3 
7.94                     d                8.62                H4 
6.45                     s                   -                   H1 
3.40-3.34            m                  -                   H6 
3.29-3.26            m                  -                   H7 
3.22                     s                   -                   H5 













hydrogen-bearing carbons. This is also true for 1H-NMR spectra of the precursors to compound 
68 where proton H2 consistently resonates downfield of protons H3 and H4.      
 
Figure 2.48: 13C-NMR spectrum of 68 at 101 MHz in DMSO-d6. 
 
A pseudo-molecular ion (m/z [M + H]+ = 412.1, calculated exact mass = 411.1035) at a 
retention time of 2.447 min was observed when 68 was subjected to HPLC-MS analysis under 























































Figure 2.49: HPLC Chromatogram and APCI+ mass spectrum of 68. 
 
2.5 Concluding Remarks 
In this chapter, the rationale behind the design of the synthesized target compounds have been 
described. The imidazopyridazine and aminopyrazine target compounds were obtained in 8 – 
80 % and 21 – 86% yields respectively. The target compounds were characterized by, among 
other techniques, NMR, HPLC-MS and UPLC-MS. HPLC-MS also ensured the target 
 
 68 
Exact mass: 411.1035 




HPLC Chromatogram at λ = 280 nm 
[M + H]+: 412.1 
APCI+ Mass Spectrum 




compounds were of acceptable purity (≥ 95%) for solubility and biological evaluation which 
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RESULTS AND DISCUSSION: BIOLOGICAL AND SOLUBILITY DATA 
 
3.1 Chapter Overview 
In this chapter, the biological and solubility results of the synthesized target compounds are 
discussed. The chapter commences with a discussion of the in vitro asexual blood stage 
antiplasmodial activity and solubility of all synthesized imidazopyridazine analogues. The in 
vitro gametocytocidal and liver stage antiplasmodial activity of selected imidazopyridazine 
compounds is then discussed followed by a discussion of cytotoxicity and hERG inhibition 
results. Metabolic stability studies on selected imidazopyridazine compounds are then covered 
before a discussion of the in vitro asexual blood stage antiplasmodial activity and solubility 
evaluation of the aminopyrazines. The chapter closes with a subsection dedicated to target-
based rationalization of in vitro antiplasmodial SAR using a homology model of Plasmodium 
falciparum phosphatidylinositol 4-kinase, PfPI4K. 
   
3.2 Imidazopyridazines 
3.2.1 In Vitro Asexual Blood Stage Antiplasmodial Activity and Solubility Evaluation 
The synthesized target compounds were subjected to HPLC-MS purity check experiments to 
ensure acceptable purity (≥ 95%) before in vitro asexual blood stage antiplasmodial and 
solubility evaluation. Primarily, all the target compounds were evaluated against the drug-
sensitive strain of P. falciparum (NF54). After this primary screen, compounds possessing 
significant potency (IC50 < 1 μΜ) were further tested against the chloroquine- and 
pyrimethamine-resistant strain of P. falciparum (K1). A modified [3H]-hypoxanthine uptake 
assay1 was used to evaluate parasite viability in presence of test compounds, which was 
calculated as percentage of recorded radioactivity relative to the untreated parasites. The 
experimental chapter of this thesis describes this method in detail. The IC50 values on the NF54 
strain are used in the descriptions of all SAR explorations. 
Solubility evaluation of all synthesized analogues was performed in parallel. A miniaturized 
shake flask method2 was used to measure the solubility of all imidazopyridazine compounds. 
Briefly, this involved preparation of calibration standards (10 – 220 μΜ in DMSO) for each 
compound whose absorbance values were measured using an HPLC-DAD (diode array 
detector) to plot the calibration curves as absorbance versus concentration. The absorbance 
values of duplicate aqueous samples were used to read off solubility from the calibration curve. 
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This method is given in detail in the experimental chapter of this thesis. A summary of in vitro 
antiplasmodial (IC50) and solubility values for all the synthesized target compounds is shown 
in tables 3.1 – 3.3. 
 
3.2.1.1 SAR and Solubility of Pyridazine-Substituted Analogues 
In the initial phase of SAR exploration, saturated ring systems, subtle modifications and water-
solubilizing groups at position 6 were introduced while keeping a 4-methylsulfinylphenyl 
group at position 3 of the imidazopyridazine core-scaffold constant (Table 3.1). Relative to the 
previously reported3 lead compound 19 (IC50 = 0.0034 μM), all analogues in this series 
exhibited lower antiplasmodial potency (IC50 = 0.14 – 2.7 μM). The antiplasmodial activity 
results for analogues tested on both the NF54 and K1 parasites show that they are equipotent 
across these two parasite strains suggesting the absence of cross resistance and potentially a 
novel mechanism of action for this class of analogues. This pan-activity was also observed for 
all the other imidazopyridazine analogues explored in this project and those previously reported 
in literature.4 
Table 3.1: In vitro antiplasmodial activity against P. falciparum (NF54 
and K1) and solubility of pyridazine-substituted analogues 
 
Code R5 
P. f IC50, μM
b,c Solubility, μM,  
pH 6.5d NF54 K1 
25 
 
0.67 0.50 200 
27 
 
0.97 0.82 5 
28 
 
1.9 eND 180 
29 
 
1.7 eND 195 
30 
 
0.14 0.11 200 
44 
 
1.6 eND 200 
45 
 
0.92 0.77 195 
36 
 
0.27 0.24 20 
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Table 3.1: In vitro antiplasmodial activity against P. falciparum (NF54 
and K1) and solubility of pyridazine-substituted analogues 
 
Code R5 
P. f IC50, μM
b,c Solubility, μM,  
pH 6.5d NF54 K1 
37 
 
0.82 0.85 190 
38 
 
0.55 0.49 195 
39 
 
0.42 0.24 < 5 
40 
 
0.47 0.44 25 
41 
 
0.52 0.49 10 
42 
 
2.7 eND 200 
43 
 
0.50 0.44 70 
bMean from n values of ≥ 2 independent experiments with multidrug resistant (K1) and sensitive (NF54) strains 
of P. falciparum. The majority of the individual values differed less than 2-fold (maximum 2-fold). 
cArtesunate [IC50 = 2.2 ng/mL (NF54), 0.93 ng/mL (K1)] and chloroquine [IC50 = 4.3 ng/mL (NF54), 83 ng/mL 
(K1)] were used as reference drugs. 
dDetermined using a miniaturized shake flask method.2 
eND, not determined. 
  
As demonstrated by analogues 25 (IC50 = 0.67 μM) and 27 (IC50 = 0.97 μM), para substitution 
with either a sulfone or sulfoxide group at the phenyl ring on position 6 of the 
imidazopyridazine core was detrimental to potency. As expected, compared to the sulfone-
substituted analogue 27 which exhibited poor aqueous solubility (5 μM), the sulfoxide 
derivative 25 was highly soluble (200 μM). This can be explained when one considers the 
energetics of interactions between these two groups (sulfone and sulfoxide) and water. 
Examination of interactions of the sulfoxide with water shows that these are energetically 
favoured compared to those of the sulfone. For this reason, despite having more hydrogen 
bonding sites and a larger dipole moment, sulfones have limited solubility in water compared 
to their sulfoxide counterparts. It is known that hydrogen bonding also involves the partial 
interaction of non-bonding electrons with the antibonding sigma orbitals (σ*) of the H2O 
molecules.5 In this regard, sulfoxides have higher energy orbitals than sulfones, which results 
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in the greatest stabilization and net drop in energy upon interaction with water than is the case 
with sulfones. 
Compound 30 exhibited the highest potency (IC50 = 0.14 μM) amongst analogues substituted 
with a fluoro group and a bulky basic side chain (28, 29 and 30, Table 3.1) highlighting the 
importance to potency of the para-fluoro and meta-diethylaminomethyl substitution pattern. 
Also notable is the fact that, of all the analogues in this series, compound 30 was the most 
potent. On the other hand, the solubility of such basic amine-substituted analogues was 
significantly improved (180 – 200 μM).  
In the case of aminated imidazopyridazines, antiplasmodial potency was generally 
compromised albeit most of them still retained sub-micromolar potency. A particular example 
in this class is compound 36 (IC50 = 0.27 μM) which was more active than its reduced version 
37 (IC50 = 0.82 μM) by a 3-fold margin. On the contrary, compounds 38 (IC50 = 0.55 μM) and 
39 (IC50 = 0.42 μM) which are the para-substituted forms were equipotent. Additionally, in the 
quest to improve solubility, analogues 41 – 43 (Table 3.1) with saturated heterocyclic rings at 
position 6, which were envisaged to discourage the solubility-suppressing effect of π – π 
stacking, were designed.6 As reflected in compounds 43 (IC50 = 0.50 μM) and 42 (IC50 = 2.7 
μM), the sulfone group in 43 was found to be crucial to the retention of sub-micromolar potency 
– compound 42 devoid of this group was 5-fold less potent. When evaluated for solubility, the 
NH-linked compounds generally had improved solubility with sulfoxide analogues, as 
expected, exhibiting superior solubility compared to the sulfones. 
 
3.2.1.2 SAR and Solubility of Imidazo-Substituted Analogues 
In the next phase of SAR studies, various substitutions at position 3 of the core-scaffold were 
explored while keeping a meta-substituted group, the 3-methylsulfinylphenyl, at position 6 of 
the core-scaffold fixed. The choice of a meta-substituted group at position 6 was motivated by 
previous studies3 which found this substitution pattern optimal for potency. Table 3.2 
summarizes all antiplasmodial and solubility results for this series of analogues. While one 
analogue (35) with promising potency against both the NF54 (IC50 = 0.15 μM) and K1 (IC50 = 
0.087 μM) strains was identified, analogues in this series displayed the lowest antiplasmodial 
activity (IC50 = 0.99 – 7.6 μM) compared to other SAR explorations. Consequently, this portion 
of SAR was not explored further. However, these analogues exhibited moderate to high 
solubility (35 – 200 μM) which resulted from the introduced water-solubilizing groups. The 
observed difference in solubility between the ortho-fluorinated analogue 32 (200 μM) and the 
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meta-fluorinated regioisomer 33 (35 μM) could be attributed to the increase in dihedral angle 
which accompanies ortho substitution of biaryl systems. Such an increase in dihedral angle 
disrupts π – π stacking which increases solubility.6 As noted previously, compared to the 
sulfone-substituted aminated analogues 47 (40 μM) and 46 (60 μM) which were only 
moderately soluble, sulfoxide-substituted aminated compounds 48 (150 μM) and 49 (165 μM) 
were highly soluble. 
Table 3.2: In vitro antiplasmodial activity against P. falciparum 
(NF54 and K1) and solubility of imidazo-substituted analogues 
 
Code R6 
P. f IC50, μM
b,c Solubility, μM,  
pH 6.5d NF54 K1 
32 
 
3.2 eND 200 
33 
 
1.1 eND 35 
34 
 
0.99 0.56 200 
35 
 
0.15 0.087 200 
46 
 
3.6 eND 60 
47 
 
7.6 eND 40 
48 
 
4.7 eND 150 
49 
 
3.8 eND 165 
bMean from n values of ≥ 2 independent experiments with multidrug resistant (K1) and sensitive (NF54) strains 
of P. falciparum. The majority of the individual values differed less than 2-fold (maximum 2-fold). 
cArtesunate [IC50 = 2.2 ng/mL (NF54), 0.93 ng/mL (K1)] and chloroquine [IC50 = 4.3 ng/mL (NF54), 83 ng/mL 
(K1)] were used as reference drugs. 
dDetermined using a miniaturized shake flask method.2 
eND, not determined. 
 
3.2.1.3 SAR and Solubility of Discreetly-Modified Analogues 
Different drug discovery programmes have successfully detuned hERG activity by making 
subtle changes to drug molecules,7 a strategy which was also exploited in this thesis work as 
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shown in analogues 26, 50 – 54 (Table 3.3), 25, 27 (Table 3.1) and 35 (Table 3.2). Under this 
category of molecules, sulfones were swapped with sulfoxide groups in addition to the 
peripheral positional changes of these two groups on the two phenyl rings. Such changes were 
also inspired by the need to preserve antiplasmodial potency since more drastic modifications 
made in other portions of SAR drastically compromised potency. Also included in this series, 
for comparison purposes, was compound 31 (Table 3.3) a sulfone version of analogue 29 
(Table 3.1). Interestingly, a highly potent compound 50 (IC50 = 0.031 μM) which is a positional 
isomer of the previously reported3 lead compound 19 was identified suggesting a para-to-meta 
positional change of the right-hand side sulfone is tolerated although solubility (< 5 μM) 
remained unresolved. However, this positional change is accompanied by a 9-fold decrease in 
potency compared to the lead compound 19 (IC50 = 0.0034 μM). As shown in analogues 51 
(IC50 = 0.40 μM) and 52 (IC50 = 0.26 μM), para substitution on the left-hand side phenyl ring, 
regardless of the nature of the substituent, while keeping a sulfone at the meta position on the 
right-hand side phenyl ring was detrimental to potency. Similarly, antiplasmodial potency was 
also compromised when the sulfoxide was fixed at the meta position on the right-hand side 
phenyl ring while a sulfone or sulfoxide group was installed at the para position of the left-
hand side phenyl ring (see analogues 53, IC50 = 1.7 μM and 54, IC50 = 0.87 μM). It is also 
noteworthy that the sulfone-substituted analogue 53 was 2-fold less potent compared to the 
sulfoxide version 54. When compared to its previously reported4 regioisomer, compound 26 
was 7-fold less potent, which further confirms how unfavourable para substitution on the left-
hand side phenyl ring is. Furthermore, all analogues bearing at least one sulfone group had sub-
optimal solubility (< 5 – 10 μM) except 31 whose impressive solubility (200 μM) could be 
ascribed to its water-solubilizing basic side chain. On the other hand, and as anticipated, 
analogue 54 possessing sulfoxide groups on both phenyl rings was highly soluble (200 μM). 
Table 3.3: In vitro antiplasmodial activity against P. falciparum (NF54 
and K1) and solubility for discreetly-modified analogues 
Code Structure 
P. f IC50, μM
b,c Solubility, μM,  
pH 6.5d NF54 K1 
26 
 
0.28 0.21 10 
31 
 
0.82 eND 200 
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Table 3.3: In vitro antiplasmodial activity against P. falciparum (NF54 
and K1) and solubility for discreetly-modified analogues 
Code Structure 
P. f IC50, μM
b,c Solubility, μM,  
pH 6.5d NF54 K1 
19 
 
0.0034 0.0023 10 
50 
 
0.031 0.025 < 5 
51 
 
0.40 0.31 < 5 
52 
 
0.26 0.19 < 5 
53 
 
1.7 eND < 5 
54 
 
0.87 0.87 200 
56 
 
0.95 1.4 < 5 
55 
 
0.16 0.38 < 5 
57 
 
0.14 0.11 < 5 
bMean from n values of ≥ 2 independent experiments with multidrug resistant (K1) and sensitive (NF54) strains 
of P. falciparum. The majority of the individual values differed less than 2-fold (maximum 2-fold). 
cArtesunate [IC50 = 2.2 ng/mL (NF54), 0.93 ng/mL (K1)] and chloroquine [IC50 = 4.3 ng/mL (NF54), 83 ng/mL 
(K1)] were used as reference drugs. 
dDetermined using a miniaturized shake flask method.2 
eND, not determined. 
 
Finally, three other silicon-containing compounds (55 – 57, Table 3.3) were also designed and 
synthesized purely on the principle of introducing novelty. Two of these silylamide derivatives 
were found to possess marked potency – 55 (IC50 = 0.16 μM) and 57 (IC50 = 0.14 μM). The 
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two analogues were equipotent, suggesting that variation between the sulfone (57) and 
sulfoxide (55) at the meta position of the left-hand side phenyl ring does not affect potency. 
Replacement with a trifluoromethyl group at the same position, however, resulted in a marked 
decrease in potency (56, IC50 = 0.95 μM). Furthermore, the three analogues exhibited poor 
solubility (< 5 μM), presumably due to the introduced lipophilic trimethylsilyl group. 
 
3.2.2 In Vitro Gametocytocidal and Liver Stage Activity 
As outlined in subsection 1.7.1.1 of chapter 1, to achieve the goals of the malaria eradication 
agenda, new TPPs for new antimalarial medicines have been spelled out by the malaria 
community. Amongst these is the need to deliver antimalarial drugs which target multiple 
stages of parasite development.8,9 In line with this requirement, the transmission blocking 
potential of a selected number of analogues was assessed by evaluating their in vitro 
gametocytocidal activity employing both early and late stage gametocyte assays. Two 
transgenic luciferase reporter cell lines of the NF54 strain of P. falciparum, NF54-PfS16-GFP-
Luc and NF54-Mal8p1.16-GFP-Luc were used to assess the early and late stage 
gametocytocidal activity respectively. Briefly, this assay involved the exposure of parasites to 
test compounds for 48 hours. Luciferase activity was then determined by adding luciferin 
substrate to the parasite lysate and measuring the resulting bioluminescence.10 Furthermore, an 
ATP assay was used to independently evaluate late stage gametocytocidal activity.10 For this 
assay, the parasites were exposed to test samples for 24 hours after which ATP was added to 
measure its uptake. The full details of the methodology for both the luciferase and ATP assays 
are given in the experimental chapter of this thesis.  
Initially, 13 selected compounds (19, 26, 35, 38 - 41, 45, 50, 51, 54, 56 and 57 (see structures 
in tables 3.1 – 3.3) were screened for their percentage inhibition against both the early stage (> 
90% stage II/III) and late stage (> 90% stage IV/V) gametocytes at two concentrations (1 and 
5 μM) (Figure 3.1A). Compounds which displayed good activity (> 70% inhibition at 5 μM 
and > 50% inhibition at 1 μM) in this primary dual point screen were prioritized for full dose-
response IC50 determination (n = 3 independent experiments). On the other hand, those with 
moderate activity (> 70% inhibition at 5 μM and < 50% inhibition at 1 μM; < 70% inhibition 
at 5 μM and > 50% inhibition at 1 μM; 50 - 70% inhibition at 5 μM and < 50% inhibition at 1 
μM) underwent a single IC50 determination (n = 1 experiment). An exception was compound 
26 whose ATP-based full dose-response IC50 was determined despite not meeting this selection 
criteria. 




















Figure 3.1: Gametocytocidal activity of selected compounds: 
(A) % Inhibition of gametocytes at 1 μM; (B) % Inhibition of gametocytes at 5 μM; (C) 
Gametocytocidal activity measured as IC50 values (values with error bars represent measurements from 
three independent biological replicates while those without error bars represent a single experiment); 
Methylene blue [IC50 = 200 nM (luciferase, early gametocytes), 140 nM (luciferase, late gametocytes), 
900 nM (ATP, late gametocytes)] and dihydroartemisinin [IC50 = 43 nM (luciferase, early gametocytes), 
11 nM (luciferase, late gametocytes), 15.0 μM (ATP, late gametocytes)] were used as reference drugs. 
 
The lead compound 19 (68 – 81% and 76 – 89% inhibition at 1 and 5 μΜ respectively) and its 
regioisomer 50 (56 – 79% and 82 – 91% inhibition at 1 and 5 μΜ respectively) exhibited good 
activity in the primary dual point screen assays across both the luciferase and ATP assays 
(Figures 3.1A and B). Also notable is compound 57 which exhibited good activity (55% 
inhibition at 1 μΜ) albeit only on the ATP platform. When evaluated under dose-response 
mode (Figure 3.1C), compounds 19 (IC50 = 0.062 – 0.30 μM) and 50 (IC50 = 0.098 – 0.78 μM) 
exhibited submicromolar potency across the two assay platforms. It is also worth noting that, 
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specific activity for the late stage gametocytes as shown by the ≥ 2-fold difference between 
early and late stage gametocytocidal IC50 values. 
Parasitic development in the liver precedes the blood stage parasite life cycle.11 Blocking the 
establishment of the asymptomatic liver stage infection has potential to offer prophylaxis 
against both the liver stage and symptomatic blood stage infection. New antimalarials need to 
have such liver stage activity which is another important TPP expected to accelerate malaria 
eradication.8,9 In this regard, seven compounds (19, 26, 39, 41, 50, 54 and 56) were evaluated 
against the liver stage sporozoites of P. berghei parasites using the Huh7 human liver cell line. 
The tested compounds were chosen in such a way as to represent each SAR explored. In each 
SAR, only compounds exhibiting submicromolar (IC50 < 1 μM) in vitro asexual blood stage 
antiplasmodial potency and selectivity indices (SI) > 100 over the Chinese Hamster Ovarian 
(CHO) mammalian cell line (see SI values in table 3.4) were tested. The choice of compounds 
for this assay was also influenced by availability of material at the time. Luminescence intensity 
in Huh7 cells infected with a firefly luciferase-expressing P. berghei parasite strain, PbGFP-
Luccon, was used as a measure of inhibition of liver stage infection.
12 Briefly, this assay 
involved the treatment of the Huh7 cells with appropriate concentrations of each compound 
followed by infection with sporozoites freshly harvested from the salivary glands of infected 
female Anopheles stephensi mosquitoes. Luminescence measurement using a luciferase assay 
system kit was used to determine parasite load 48 hours post-infection. This was achieved by 
lysing the Huh7 cells followed by addition of luciferase substrate to the resulting lysate to 
detect luciferase activity. The full details of this procedure are given in the experimental chapter 
of this thesis. 
In a similar approach to that employed for gametocytocidal activity, compounds were subjected 
to a primary luciferase four-point assay at concentrations of 0.01, 0.1, 1.0 and 10 μM. 
Compounds for full IC50 determination were selected based on activity in this primary screen 
and the absence of toxicity on the hepatocytes. Consequently, compounds 19, 50 and 54 which 
met these criteria were progressed for full IC50 determination. The lead compound 19 was 
highly potent displaying single digit nanomolar activity (IC50 = 0.0020 μM). Its new 
regioisomer, compound 50, was also highly potent with double digit nanomolar range potency 
(IC50 = 0.045 μM). On the other hand, an IC50 value for 54 could not be determined because 
this compound did not display dose-dependent activity.    
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3.2.3 In Vitro Mammalian Cytotoxicity and hERG Inhibition 
In vitro cytotoxicity against the mammalian CHO cell line was determined for compounds 
exhibiting submicromolar (IC50 < 1 μM) in vitro asexual blood stage antiplasmodial potency. 
The corresponding cytotoxic IC50 value was divided by the antiplasmodial (P. f NF54) IC50 
value to get selectivity index values. The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay13 which measures cellular growth and survival 
calorimetrically was used to assess the cytotoxicity of the compounds. Tetrazolium salt 
formation was used to measure growth and chemosensitivity with emetine being used as a 
reference drug. Triplicate serial dilutions of 6 concentrations were used to generate dose-
response curves, which enabled the determination of IC50 values. A detailed description of the 
method has been given in the experimental chapter. 
Similarly, analogues with submicromolar in vitro asexual blood stage antiplasmodial activity 
were generally progressed to hERG inhibition studies. On the other hand, only representative 
compounds were tested for hERG inhibition for compounds representing discreet peripheral 
changes (e.g., 25 - 27, 35, 50 – 52 and 54) despite possessing submicromolar antiplasmodial 
activity. The hERG inhibition assay was performed by Metrion Biosciences Ltd of the United 
Kingdom (UK) using the CHO cell line stably expressing the hERG channel on a QPatch 
gigaseal automated patch clamp platform. Samples were screened in triplicate in dose-response 
mode at four concentrations to enable IC50 determination. For compounds which could not 
exhibit > 40% hERG inhibition at the highest tested concentration (10 μM), extrapolated IC50 
values are reported. Thus, all IC50 values above 10 μM are extrapolated and are not to be 
considered accurate but approximate indicators of hERG activity. Verapamil was used as a 
reference positive control. Details of the procedure including cell preparation, recording 
solutions and voltage pulses used to elicit currents are given in the experimental chapter of this 
thesis. 
Encouragingly, most analogues demonstrated a clean cytotoxicity profile with selectivity 
indices in the range 72 - > 874 (Table 3.4). However, the basic side chain-containing analogues 
(30, 31, 34 and 45) possessed marked cytotoxicity with lower selectivity (SI = 10 – 30). 
Table 3.4 also summarizes the hERG evaluation results for selected analogues. Compound 19 
exhibited hERG potency (IC50 = 3.6 μM) which is in conformity with previous findings.
3 
Compounds 50 (IC50 = 2.4 μM) and 51 (IC50 = 4.0 μM) which are regioisomers of 19 also still 
retained hERG potency. However, hERG activity was detuned by almost 4-fold when sulfones 
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in compound 50 were replaced with sulfoxides as shown in compound 35 (IC50 = 8.5 μM). 
Moreover, hERG activity was further significantly lowered following a meta-to-para 
positional change of the left-hand side sulfoxide in 35 (see 54, IC50 = 21 μM). As shown in 
analogue 26 (IC50 = 18 μM), hERG activity was reduced by 5-fold compared to the lead 
compound 19 upon para sulfoxide substitution on the left hand-side phenyl ring. Strikingly, 
compounds 30 (IC50 = 0.59 μM), 31 (IC50 = 5.2 μM) and 45 (IC50 = 7.8 μM) possessing basic 
side chains were relatively potent on the hERG channel. Indeed, a basic nitrogen is a known 
pharmacophore for hERG binding since it can potentially get protonated at physiological pH 
consequently promoting cation – π interactions between the protonated nitrogen and the π 
electron cloud of suitably positioned aromatic amino acid residues in the channel.7 The 
observed hERG activity for these basic analogues is, therefore, unsurprising. For the aniline-
substituted compounds 36 – 39, hERG activity seems enhanced with meta sulfonylation (see 
36, IC50 = 2.4 μM). Interestingly, as demonstrated in analogue 37 (IC50 = 18 μM), replacing a 
sulfone in 36 with a sulfoxide detunes hERG activity by 8-fold. A further decrease in hERG 
potency was noted in compound 38 (IC50 = 32 μM) a para-substituted regioisomer of 37. 
Additionally, an 11-fold reduction in hERG activity was observed following a meta-to-para 
positional change (36 to 39). Furthermore, analogues 41 and 43, with saturated rings replacing 
aromatic groups, were designed with the hypothesis that such a saturation strategy would 
minimize hERG binding by discouraging π – π interactions between phenyl rings in molecules 
and those embedded in the cavity of the hERG channel.7 Consistent with this reasoning, 
significantly weaker hERG inhibition was observed for the two compounds (41, IC50 = 29 μM 
and 43, IC50 = 26 μM). 




CHO cells hERG IC50, 
μM (SD)g 




> 234 > 69,000 3.6 (0.62) 
50 
 
12 (0.89) 377 2.4 (0.46) 
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CHO cells hERG IC50, 
μM (SD)g 




31 (0.2) 206 8.5 (0.8) 
51 
 
180 (5.2) 457 4 (0.83) 
52 
 
19 (1.5) 72 eND 
54 
 
110 (21) 122 21 (2.8) 
25 
 
> 253 > 376 eND 
27 
 
> 243 > 249 eND 
26 
 
> 243 > 874 18 (5.6) 
30 
 
4.1 (0.96) 30 0.59 (0.02) 
45 
 
9.4 (3.0) 10 7.8 (1.2) 
36 
 
120 (0.4) 449 2.4 (0.21) 
37 
 
eND eND 18 (8.5) 
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CHO cells hERG IC50, 
μM (SD)g 




> 244 > 442 32 (1.5) 
39 
 
> 234 > 553 26 (6.3) 
40 
 
280 (18) 592 7.8 (0.76) 
43 
 
> 231 > 464 26 (1.8) 
41 
 
> 247 > 471 29 (3.6) 
31 
 
9.4 (2.1) 11 5.2 (0.44) 
34 
 
12 (2.7) 12 eND 
eND, not determined. 
fMean from n = 3 independent experiments; SD, standard deviation; Emetine was used as a reference drug (IC50 
= 0.033 ± 0.006 μM). 
gMean from n = 3 independent experiments; Verapamil was used as a positive control (IC50 = 0.56 ± 0.096 μM). 
hSI = selectivity index = IC50 (CHO)/IC50 (P. f NF54). 
 
3.2.4 Metabolic Stability of Selected Analogues 
The design of molecules that will, not only exert the desired therapeutic effect, but also exhibit 
sustained action is one of the primary concerns of medicinal chemists. Metabolic stability, a 
subset of ADME (absorption, distribution, metabolism and excretion) studies, can influence 
pharmacokinetic parameters such as bioavailability and half-life which in turn influence the 
drug’s duration of action.14 Although various tissues such as the intestinal wall, lung, kidneys, 
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skin and blood are potential sites for the metabolism of drugs and xenobiotics, the liver is 
considered the main site of drug metabolism.15 Therefore, a fast and cost-effective way to 
determine the metabolic stability of drug candidates is to expose them to hepatocytes or liver 
microsomes. In this regard, selected compounds (35, 38 and 41) exhibiting submicromolar in 
vitro asexual blood stage antiplasmodial potency (IC50 < 1 μM), reasonable solubility (> 50 
μM) and selectivity over hERG (IC50 > 8 μM) and the CHO cell line (SI > 100) were evaluated 
for metabolic stability in human (H), rat (R) and mouse (M) liver microsomal preparations 
(Table 3.5).16 As an exception, compound 41 was nominated for metabolic testing to represent 
analogues with saturated heterocyclic ring systems despite possessing suboptimal solubility 
(10 μM). Compounds not tested despite meeting these criteria were not available at the time of 
testing. Compounds were incubated in the presence of human, rat and mouse liver microsomes 
and the percentage (%) of compound remaining after 30 minutes was determined. 
Compound 35 was metabolically unstable in liver microsomes of all the three species with a 
high hepatic extraction ratio (EH) of about 0.7. This rapid in vitro metabolism is most likely 
mainly an oxidation of the sulfoxide groups to sulfones. In an earlier report, Le Manach et al.,4 
observed a rapid in vivo biotransformation of sulfoxide-substituted imidazopyridazine 
analogues into corresponding sulfones. Consistent with these initial findings, compound 35 
was designed to act as a solubility-enhancing prodrug of the very potent sulfone (50, Table 
3.4). This rapid metabolism was, therefore, anticipated. On the other hand, the aniline 
derivative 38 retained excellent metabolic stability (97.6 – 100% remaining) across the three 
species with a projected half-life (t1/2) of > 150 min and EH values of < 0.42. Additionally, 
compound 41 was highly stable in human (100% remaining) and mouse (94.7% remaining) 
liver microsomes while exhibiting slightly less metabolic stability in rat microsomes (89.5% 
remaining). Overall, metabolic stability was consistent across the three species for compounds 
38 and 41 while 35 was more metabolically stable in human liver microsomes than in the rat 
and mouse ones potentially suggesting a species difference in its metabolism. 










Hi/Rj/Mk Hi/Rj/Mk Hi/Rj/Mk 
35 
 
54/37/37.1 33.7/22.3/21 0.74/0.72/0.73 
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Hi/Rj/Mk Hi/Rj/Mk Hi/Rj/Mk 
38 
 
99.9/100/97.6 >150/>150/>150 <0.42/<0.30/<0.33 
41 
 
100/89.5/94.7 >150/120.1/>150 <0.42/0.32/<0.33 
iH, human; jR, rat; kM, mouse. 
 
3.3 Aminopyrazines: In Vitro Asexual Blood Stage Antiplasmodial Activity and Solubility 
The aminopyrazine compounds were tested for in vitro asexual blood stage antiplasmodial 
activity against both the NF54 and K1 strains of P. falciparum using the same assay as the one 
used for the imidazopyridazines (see brief description in subsection 3.2.1). The SAR for this 
class of analogues is also discussed with respect to IC50 values on the NF54 strain.  
Unlike imidazopyridazines whose solubility was determined using a miniaturized shake flask 
method2 employing an HPLC-DAD to measure absorbance, the solubility of aminopyrazine 
analogues was determined using a turbidimetric (kinetic) solubility assay.17 This involved 
preparing solutions of test compounds in a solvent in which they are freely soluble, in this case 
DMSO. Aliquots of these solutions were then added to a buffered (pH = 7.4) aqueous media to 
give nominal serial dilutions. The concentration value above which the test compound causes 
turbidity by precipitating from solution is taken to be its approximate solubility. A UV-Visible 
spectrometer was used to detect turbidity by measuring the absorbance of the suspension at a 
wavelength the test compound is not expected to absorb electromagnetic radiation (620 nm in 
this case). This method is simple, cost-effective, fast, requires small amounts of sample and is 
suitable for high throughput screening of a large number of compounds although it has limited 
accuracy compared to the alternative HPLC-based method. The antiplasmodial and solubility 
results are summarized in table 3.6. 
Compared to the previously reported lead compound 24 (IC50 = 0.0081 μM), all the new 
analogues generally exhibited drastically reduced potency (IC50 = 1.2 - > 10 μM). An exception 
was 62 which still retained submicromolar potency (IC50 = 0.51 μM). Additionally, there are 
still interesting structure activity relationships worth discussing. The benzoic acid derivative 
CHAPTER 3: RESULTS AND DISCUSSION: BIOLOGICAL AND SOLUBILITY DATA 
166 
 
(69) was inactive (IC50 = 3.8 μM), suggesting the trifluoromethylpyridyl group is critical to 
potency. Reduction of the alkene double bond in 59 (IC50 = 1.2 μM) results in nearly 7-fold 
reduction in potency (see 60, IC50 = 8.4 μM). Strikingly, the N-mesylated analogue 62 was over 
20-fold more potent (IC50 = 0.51 μM) than its free amine version 61 (IC50 > 10 μM). On the 
other hand, in analogues were the trifluoromethylpyridyl group was replaced, double bond 
reduction (63 to 64) results in over 2-fold increase in antiplasmodial activity while N-boc-
deprotection (64 to 65) was detrimental to potency. 
Table 3.6: In vitro antiplasmodial activity against P. falciparum (NF54 and K1) 
and solubility for aminopyrazine analogues 
Code Structure 
P. f IC50, μM
b,c Solubility, μM,  








3.8 3.7 > 200 
59 
 
1.2 0.85 80 
60 
 
8.4 7.4 40 
61 
 
> 10 8.7 160 
62 
 
0.51 0.47 160 
63 
 
9.8 8.4 80 
64 
 
4.5 4.0 160 
65 
 
> 10 > 10 > 200 
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Table 3.6: In vitro antiplasmodial activity against P. falciparum (NF54 and K1) 
and solubility for aminopyrazine analogues 
Code Structure 
P. f IC50, μM
b,c Solubility, μM,  
pH 7.4 l NF54 K1 
66 
 
> 6.0 eND 40 
70 
 
3.1 1.6 160 
71 
 
5.5 2.0 80 
72 
 
> 6.0 eND > 200 
67 
 
> 6.0 eND > 200 
68 
 
> 6.0 eND 160 
bMean from n values of ≥ 2 independent experiments with multidrug resistant (K1) and sensitive (NF54) strains 
of P. falciparum. The majority of the individual values differed less than 2-fold (maximum 2-fold). 
cArtesunate [IC50 = 2.2 ng/mL (NF54), 0.93 ng/mL (K1)] and chloroquine [IC50 = 4.3 ng/mL (NF54), 83 ng/mL 
(K1)] were used as reference drugs. 
eND, not determined. 
lDetermined using kinetic (turbidimetric) solubility assay.17 
 
Although the modifications made compromised antiplasmodial activity, such changes 
substantially improved solubility compared to the lead 24 (10 μM). As anticipated, the benzoic 
acid derivative 69 was highly soluble (> 200 μM) most likely due to its water-solubilizing 
carboxylic acid group. As initially hypothesized, the replacement of the aromatic rings with 
partially and fully saturated heterocyclic rings substantially improved solubility (40 - > 200 
μM). Expectedly, the free amines 61 (160 μM) and 65 (> 200 μM) were more soluble than their 
corresponding boc-protected intermediates 60 (40 μM) and 64 (160 μM) respectively. 
Furthermore, mesylated analogues were generally more soluble than the boc-protected forms 
(cf. 60 vs 62 and 71 vs 72). 
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3.4 Retrospective Target-based Rationalization of In Vitro Antiplasmodial Results 
3.4.1 Aminopyrazines 
Employing genomic and chemoproteomic approaches, the PfPI4K has been identified as the 
antiplasmodial target of the aminopyridine clinical candidate MMV390048 (Figure 1.10, 
chapter 1).18,19 More recently, PI4K has also been confirmed as a target of the structurally 
analogous second generation aminopyrazine preclinical candidate UCT943 (Figure 1.10, 
chapter 1) with improved solubility and antiplasmodial potency.20 Therefore, in an attempt to 
explain the drastic reduction in antiplasmodial activity observed for new aminopyrazine 
analogues described in this thesis, their binding to a homology model of PfPI4K built against 
a crystal structure of a human PI4KIIIβ (PDB ID: 4D0L) as a template, was retrospectively 
assessed.21 This homology model has been used to model interactions of PfPI4K inhibitors in 
the absence of a crystal structure.22  
Briefly, the compound SMILES (Simplified Molecular Input Line Entry Specification) were 
imported into Maestro 11.6 of the Schrodinger 2018-2 (Schrodinger LLC, New York) suite of 
molecular modelling software. Protonation states and tautomers around the sulfoxide moieties 
were generated using the Schrodinger LigPrep protocol. Compounds were then docked against 
a PfPI4K homology model prepared by Dr Joe Eyermann of the University of Cape Town Drug 
Discovery and Development Centre, H3D.22 The docking grid was generated centred on the 
ATP binding site using the default grid size with no van der Waal scaling. Hydrogen bonding 
constraints to the backbone amide and carbonyl of Val 1357 (V1357) were added to the grid. 
The compounds were then docked against this grid using the XP precision with both hydrogen 
bonding constraints for the aminopyrazines and just the V1357 amide donor constraint for the 
imidazopyridazines. Docked poses were all visually inspected before a minimization and MM-
GBSA calculation of the binding energy using Prime. All residues within an 8 Å radius from 
the ligand were minimized using the VSGB implicit solvent model and the OPLSe forcefield 
followed before approximating the binding energy using the MM-GBSA protocol. 
Docking studies showed that the lead compound 24 (Table 3.6) sits deep in the ATP binding 
pocket occupying the catalytic site, hinge region and the ribose binding pocket (Figure 3.2A). 
Two putative hydrogen bond interactions were noted – one between the pyrazinyl nitrogen at 
position 1 and the back-bone NH of the hinge residue V1357 and another between the 2-amino 
group and the carbonyl group of the same hinge residue. This is consistent with previous 
parasite-based SAR findings which have shown the 2-amino group and the nitrogen at position 
1 essential for activity.23 The two oxygens of the sulfone group, which extend into the catalytic 
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site, are also known to interact with the catalytic residue Lys 1308 (K1308) by making a 
hydrogen bond contact. However, the exact pose of the residue K1308 may be a bit inaccurate 
due to rigid docking. Fluorine atoms are known to be part-time hydrogen bond acceptors.24,25 
In this regard, it is also shown that the fluorine atoms of the trifluoromethyl group, which 
extend into the ribose pocket, can interact with the residues K1369 and Ser 1365 (S1365) by 
accepting hydrogen bonds from these two residues. Indeed, these residues and the 
trifluoromethyl group are within hydrogen bonding distance of 3.0 Å. This is also in agreement 
with prior parasite-based SAR findings, which have demonstrated the importance of the 
trifluoromethyl group to activity.26 The phenyl ring of the phenyl alanine residue Phe 827 
(F827) could also potentially interact with the pyridyl and phenyl rings of compound 24 
through π – π stacking. A two-dimensional model illustrating these possible interactions is 










Figure 3.2: Homology model of PfPI4K with 24 (A) [(B) a two-dimensional model illustrating possible 
interactions of 24] and representative new analogues 65 (C) and 64 (D) in the ATP binding pocket. 
 
The substitution of some of these molecular features could explain the drastic fall in potency 
observed in the new analogues. For analogues 65 and 67 (Table 3.6), with a basic secondary 
amino group on the left-hand side of the aminopyrazine core, the piperidine and piperazine 
motifs extend into the ribose binding site (65, Figure 3.2C). In this pose, the protonated forms 
of these two analogues are unlikely to interact favourably with the positively charged proximal 
lysine residues (K1369 and K825). The removal of the trifluoromethyl group also removes a 
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The presence of the boc-protecting group on the left-hand side of the aminopyrazine core 
(analogues 63, 64, 70 and 71, Table 3.6) extends this lipophilic group into the solvent wall, 
which may create an entropic penalty (64, Figure 3.2D). The introduced boc-protecting group 
may also not interact favourably with the polar hydrogen bond donor residues K1369 and 
S1365. The replacement of the 4-methylsulfonylphenyl group at position 5 with partially or 
fully saturated boc-protected heterocyclic groups, most likely, has the same effect – disrupting 
hydrogen bonding interactions with the catalytic lysine residue K1308.  
Additionally, compound 61 (Table 3.6), like 65 and 67, is most likely protonated and will, 
therefore, not interact favourably with the positively charged lysine residue K1308. 
Interestingly, when compound 61 (IC50 > 10 μM) was mesylated to give analogue 62 (IC50 = 
0.51 μM, Table 3.6), an over 20-fold increase in parasite potency was observed. The sharp 
increase in potency could be attributed to potential hydrogen bonding interactions between the 
sulfone oxygens and the lysine residue K1308 much like those observed in the case of the lead 
compound 24 (Figure 3.2A and B). It is also possible that the presence of a partially or fully 
saturated heterocyclic ring system at least on the left-hand side of the core in the new analogues 
disrupts π – π stacking interactions with the nearby phenyl alanine residue F827. Furthermore, 
it is important to note that the in vitro antiplasmodial activity for the new aminopyrazine 
analogues could be affected by other factors such as sub-optimal physicochemical profiles 
which may limit their access to the site of action in the parasite. 
 
3.4.2 Imidazopyridazines 
As with the aminopyrazine series, PfPI4K has also been shown to be the target of 
imidazopyridazines.27,28 Using a PfPI4K homology model, the imidazopyridazines were also 
shown to bind to the ATP binding pocket. Docking experiments were also performed on the 
imidazopyridazine series to generate a structure-based hypothesis to help explain the in vitro 
antiplasmodial SAR. 
Docking experiments show the imidazopyridazine series to sit deep in the ATP binding pocket. 
For the lead compound 19 (Table 3.4), three putative interactions were noted (Figure 3.3A). 
The sulfone oxygens on the pyridazine-attached phenyl ring form an interaction by accepting 
a hydrogen bond from an OH of the ribose pocket residue S1362. In the hinge region, the 
imidazole nitrogen at position 1 accepts a hydrogen bond from an NH proton of a valine residue 
V1357. This interaction is typical of most kinase inhibitors and was observed for both the 
aminopyrazine and imidazopyridazine analogues. The sulfone oxygens at the para position of 
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the imidazo-attached phenyl ring facilitate a third hydrogen bonding interaction to the catalytic 
lysine residue K1308. The possible interactions are also further clarified in a two-dimensional 
model in figure 3.3B. 
When the sulfone on the imidazo-attached phenyl ring is moved to a meta position resulting in 
analogue 50 (Table 3.4), this hydrogen bonding interaction is lost (Figure 3.3C). This result is 
in agreement with the in vitro antiplasmodial SAR which has revealed a 9-fold reduction in 
potency of 50 (IC50 = 0.031 μM) compared to 19 (IC50 = 0.0034 μM). However, like 19, 
compound 50 still interacts with a hinge residue V1357 via the imidazole nitrogen at position 
1. Additionally, this analogue also shows a hydrogen bonding interaction between a sulfone 
oxygen on the pyridazine-attached phenyl ring and the OH group of the residue S1365 in the 
ribose pocket. A much weaker interaction between the other sulfone oxygen and an NH 











Figure 3.3: Homology model of PfPI4K with 19 (A) [(B) a two-dimensional model illustrating possible 
interactions of 19] and representative new analogues 50 (C) and 25 (D) in the ATP binding pocket. 
 
Like the lead compound 19, analogue 25 (Table 3.4), also para substituted on the imidazole-
attached phenyl ring has a key hydrogen bonding interaction with a catalytic residue K1308 
(Figure 3.3D). Para substitution at this phenyl ring, therefore, appears important for binding to 
the catalytic site (cf. 50). In addition to hinge region binding, two additional hydrogen bonding 
interactions between the two sulfoxide groups and the residues K1369 and D1430 (Asp 1430) 
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Also, quiet striking was the result obtained from the docking experiments of compound 47 
(Table 3.2, figure not shown). The binding of this analogue was disrupted, and Glide was 
unable to find a plausible pose for this analogue. Of all the analogues synthesised in the 
imidazopyridazine series, this compound had the poorest in vitro antiplasmodial potency (IC50 
= 7.6 μM). Consistent with this observation, compound 47 could not sit in the binding site in a 
pose the imidazopyridazine analogues are known to assume (see figures 3.3A – D). Compound 
47 is, therefore, a poor binder consistent with the in vitro antiplasmodial data. 
 
3.5 Conclusion 
In conclusion, the antiplasmodial SAR of imidazopyridazine and aminopyrazine analogues was 
expanded. Various imidazopyridazine analogues with good antiplasmodial activity against the 
asexual (IC50 = 0.031 – 0.99 μM) and sexual (IC50 = 0.062 – 0.78 μM) blood stages as well as 
liver stage (IC50 = 0.045 μM) parasites were identified. Moreover, analogues with improved 
solubility (60 - 200 μM), good selectivity over the mammalian CHO cell line (SI = 72 - > 874) 
and a substantially improved hERG inhibition profile (IC50 = 7.8 – 32 μM) were also identified. 
Additionally, two out of the three imidazopyridazine compounds evaluated for metabolic 
stability in this series were stable across human, rat and mouse liver microsomes (% remaining 
after 30 minutes = 89.5 – 100). For the aminopyrazines, although the chemical modifications 
made drastically compromised antiplasmodial potency, a drastic improvement in solubility (40 
- > 200 μM) was observed. One analogue in this series still retained submicromolar 
antiplasmodial activity (IC50 = 0.51 μM). Furthermore, some aspects of the SAR findings for 
both series were rationalized using a homology model of PfPI4K. In the next chapter, factors 















(1)  Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. Quantitative Assessment 
of Antimalarial Activity in Vitro by a Semiautomated Microdilution Technique. 
Antimicrob. Agents Chemother. 1979, 16, 710–718. 
(2)  Hill, A. P.; Young, R. J. Getting Physical in Drug Discovery: A Contemporary 
Perspective on Solubility and Hydrophobicity. Drug Discov. Today. 2010, 15, 648–655. 
(3)  Le Manach, C.; Gonzàlez Cabrera, D.; Douelle, F.; Nchinda, A. T.; Younis, Y.; Taylor, 
D.; Wiesner, L.; White, K. L.; Ryan, E.; March, C.; Duffy, S.; Avery, V. M.; Waterson, 
D.; Witty, M. J.; Wittlin, S.; Charman, S. A.; Street, L. J.; Chibale, K. Medicinal 
Chemistry Optimization of Antiplasmodial Imidazopyridazine Hits from High 
Throughput Screening of a SoftFocus Kinase Library: Part 1. J. Med. Chem. 2014, 57, 
2789–2798. 
(4)  Le Manach, C.; Paquet, T.; Gonzàlez Cabrera, D.; Younis, Y.; Taylor, D.; Wiesner, L.; 
Lawrence, N.; Schwager, S.; Waterson, D.; Witty, M. J.; Wittlin, S.; Street, L. J.; 
Chibale, K. Medicinal Chemistry Optimization of Antiplasmodial Imidazopyridazine 
Hits from High Throughput Screening of a SoftFocus Kinase Library: Part 2. J. Med. 
Chem. 2014, 57, 8839–8848. 
(5)  Kingsbury, C. A. Why are the Nitro and Sulfone Groups Poor Hydrogen Bonders? 
https://digitalcommons.unl.edu/cgi/viewcontent.cgi?referer=https://www.google.co.za/
&httpsredir=1&article=1080&context=chemfacpub. Accessed: 2018-07-18. (Archived 
by WebCite® at http://www.webcitation.org/7107YWmgd). 
(6)  Ishikawa, M.; Hashimoto, Y. Improvement in Aqueous Solubility in Small Molecule 
Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry. J. Med. 
Chem. 2011, 54, 1539–1554. 
(7)  Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal Chemistry of hERG 
Optimizations: Highlights and Hang-Ups. J. Med. Chem. 2006, 49, 5029–5046. 
(8)  Burrows, J. N.; Hooft van Huijsduijnen, R.; Möhrle, J. J.; Oeuvray, C.; Wells, T. N. 
Designing the next Generation of Medicines for Malaria Control and Eradication. Malar. 
J. 2013, 12, 187. 
(9)  Wells, T. N. C.; van Huijsduijnen, R. H.; Van Voorhis, W. C. Malaria Medicines: A 
Glass Half Full? Nat. Rev. Drug Discov. 2015, 14, 424–442. 
(10)  Reader, J.; Botha, M.; Theron, A.; Lauterbach, S. B.; Rossouw, C.; Engelbrecht, D.; 
Wepener, M.; Smit, A.; Leroy, D.; Mancama, D.; Coetzer, T. L.; Birkholtz, L.-M. 
Nowhere to Hide: Interrogating Different Metabolic Parameters of Plasmodium 
CHAPTER 3: RESULTS AND DISCUSSION: BIOLOGICAL AND SOLUBILITY DATA 
174 
 
Falciparum Gametocytes in a Transmission Blocking Drug Discovery Pipeline towards 
Malaria Elimination. Malar. J. 2015, 14, 213. 
(11)  About Malaria: Biology. https://www.cdc.gov/malaria/about/biology/index.html. 
Accessed: 2018-03-28. (Archived by WebCite® at 
http://www.webcitation.org/6yFgts13H). 
(12)  Ploemen, I. H. J.; Prudêncio, M.; Douradinha, B. G.; Ramesar, J.; Fonager, J.; van 
Gemert, G.-J.; Luty, A. J. F.; Hermsen, C. C.; Sauerwein, R. W.; Baptista, F. G.; Mota, 
M. M.; Waters, A. P.; Que, I.; Lowik, C. W. G. M.; Khan, S. M.; Janse, C. J.; Franke-
Fayard, B. M. D. Visualisation and Quantitative Analysis of the Rodent Malaria Liver 
Stage by Real Time Imaging. PLoS ONE. 2009, 4, e7881. 
(13)  Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application 
to Proliferation and Cytotoxicity Assays. J. Immunol. Methods. 1983, 65, 55–63. 
(14)  Thompson, T. N. Early ADME in Support of Drug Discovery: The Role of Metabolic 
Stability Studies. Curr. Drug Metab. 2000, 1, 215–241. 
(15)  Schonborn, J. L.; Gwinnutt, C. The Role of the Liver in Drug Metabolism: Anaesthesia 
Tutorial of the Week 179. https://www.aagbi.org/sites/default/files/179-The-role-of-
the-liver-in-drug-metabolism.pdf. Accessed: 2018-08-08. (Archived by WebCite® at 
http://www.webcitation.org/71WEKBHJj). 
(16)  Obach, R. S. Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic 
Microsomal Intrinsic Clearance Data: An Examination of in Vitro Half-Life Approach 
and Nonspecific Binding to Microsomes. Drug Metab. Dispos. 1999, 27, 1350–1359. 
(17)  Bevan, C. D.; Lloyd, R. S. A High-Throughput Screening Method for the Determination 
of Aqueous Drug Solubility Using Laser Nephelometry in Microtiter Plates. Anal. 
Chem. 2000, 72, 1781–1787. 
(18)  Ghidelli-Disse, S.; Lafuente-Monasterio, M.; Waterson, D.; Witty, M.; Younis, Y.; 
Paquet, T.; Street, L. J.; Chibale, K.; Gamo-Benito, F.; Bantscheff, M.; Drewes, G. 
Identification of Plasmodium PI4 Kinase as Target of MMV390048 by 
Chemoproteomics. Malar. J. 2014, 13, 38. 
(19)  Paquet, T.; Le Manach, C.; Cabrera, D. G.; Younis, Y.; Henrich, P. P.; Abraham, T. S.; 
Lee, M. C. S.; Basak, R.; Ghidelli-Disse, S.; Lafuente-Monasterio, M. J.; Bantscheff, 
M.; Ruecker, A.; Blagborough, A. M.; Zakutansky, S. E.; Zeeman, A.-M.; White, K. L.; 
Shackleford, D. M.; Mannila, J.; Morizzi, J.; Scheurer, C.; Angulo-Barturen, I.; 
Martínez, M. S.; Ferrer, S.; Sanz, L. M.; Gamo, F. J.; Reader, J.; Botha, M.; Dechering, 
K. J.; Sauerwein, R. W.; Tungtaeng, A.; Vanachayangkul, P.; Lim, C. S.; Burrows, J.; 
CHAPTER 3: RESULTS AND DISCUSSION: BIOLOGICAL AND SOLUBILITY DATA 
175 
 
Witty, M. J.; Marsh, K. C.; Bodenreider, C.; Rochford, R.; Solapure, S. M.; Jiménez-
Díaz, M. B.; Wittlin, S.; Charman, S. A.; Donini, C.; Campo, B.; Birkholtz, L.-M.; 
Hanson, K. K.; Drewes, G.; Kocken, C. H. M.; Delves, M. J.; Leroy, D.; Fidock, D. A.; 
Waterson, D.; Street, L. J.; Chibale, K. Antimalarial Efficacy of MMV390048, an 
Inhibitor of Plasmodium Phosphatidylinositol 4-Kinase. Sci. Transl. Med. 2017, 9, 
eaad9735. 
(20)  Brunschwig, C.; Lawrence, N.; Taylor, D.; Abay, E.; Njoroge, M.; Basarab, G. S.; Le 
Manach, C.; Paquet, T.; Cabrera, D. G.; Nchinda, A. T.; de Kock, C.; Wiesner, L.; Denti, 
P.; Waterson, D.; Blasco, B.; Leroy, D.; Witty, M. J.; Donini, C.; Duffy, J.; Wittlin, S.; 
White, K. L.; Charman, S. A.; Jiménez-Díaz, M. B.; Angulo-Barturen, I.; Herreros, E.; 
Gamo, F. J.; Rochford, R.; Mancama, D.; Coetzer, T. L.; van der Watt, M. E.; Reader, 
J.; Birkholtz, L.-M.; Marsh, K. C.; Solapure, S. M.; Burke, J. E.; McPhail, J. A.; 
Vanaerschot, M.; Fidock, D. A.; Fish, P. V.; Siegl, P.; Smith, D. A.; Wirjanata, G.; 
Noviyanti, R.; Price, R. N.; Marfurt, J.; Silue, K. D.; Street, L. J.; Chibale, K. UCT943, 
a Next-Generation Plasmodium Falciparum PI4K Inhibitor Preclinical Candidate for the 
Treatment of Malaria. Antimicrob. Agents Chemother. 2018, 62, e00012-18. 
(21)  Burke, J. E.; Inglis, A. J.; Perisic, O.; Masson, G. R.; McLaughlin, S. H.; Rutaganira, F.; 
Shokat, K. M.; Williams, R. L. Structures of PI4KIII Complexes Show Simultaneous 
Recruitment of Rab11 and Its Effectors. Science. 2014, 344, 1035–1038. 
(22)  Kandepedu, N.; Gonzàlez Cabrera, D.; Eedubilli, S.; Taylor, D.; Brunschwig, C.; 
Gibhard, L.; Njoroge, M.; Lawrence, N.; Paquet, T.; Eyermann, C. J.; Spangenberg, T.; 
Basarab, G. S.; Street, L. J.; Chibale, K. Identification, Characterization, and 
Optimization of 2,8-Disubstituted-1,5-Naphthyridines as Novel Plasmodium 
Falciparum Phosphatidylinositol-4-Kinase Inhibitors with in Vivo Efficacy in a 
Humanized Mouse Model of Malaria. J. Med. Chem. 2018, 61, 5692–5703. 
(23)  Younis, Y.; Douelle, F.; González Cabrera, D.; Le Manach, C.; Nchinda, A. T.; Paquet, 
T.; Street, L. J.; White, K. L.; Zabiulla, K. M.; Joseph, J. T.; Bashyam, S.; Waterson, D.; 
Witty, M. J.; Wittlin, S.; Charman, S. A.; Chibale, K. Structure–Activity-Relationship 
Studies around the 2-Amino Group and Pyridine Core of Antimalarial 3,5-
Diarylaminopyridines Lead to a Novel Series of Pyrazine Analogues with Oral in Vivo 
Activity. J. Med. Chem. 2013, 56, 8860–8871. 
(24)  Howard, J. A. K.; Hoy, V. J.; O’Hagan, D.; Smith, G. T. How Good Is Fluorine as a 
Hydrogen Bond Acceptor? Tetrahedron. 1996, 52, 12613–12622. 
(25)  Dalvit, C.; Invernizzi, C.; Vulpetti, A. Fluorine as a Hydrogen-Bond Acceptor: 
CHAPTER 3: RESULTS AND DISCUSSION: BIOLOGICAL AND SOLUBILITY DATA 
176 
 
Experimental Evidence and Computational Calculations. Chem. - A Eur. J. 2014, 20, 
11058–11068. 
(26)  Younis, Y.; Douelle, F.; Feng, T.-S.; Cabrera, D. G.; Le Manach, C.; Nchinda, A. T.; 
Duffy, S.; White, K. L.; Shackleford, D. M.; Morizzi, J.; Mannila, J.; Katneni, K.; 
Bhamidipati, R.; Zabiulla, K. M.; Joseph, J. T.; Bashyam, S.; Waterson, D.; Witty, M. 
J.; Hardick, D.; Wittlin, S.; Avery, V.; Charman, S. A.; Chibale, K. 3,5-Diaryl-2-
Aminopyridines as a Novel Class of Orally Active Antimalarials Demonstrating Single 
Dose Cure in Mice and Clinical Candidate Potential. J. Med. Chem. 2012, 55, 3479–
3487. 
(27)  McNamara, C. W.; Lee, M. C. S.; Lim, C. S.; Lim, S. H.; Roland, J.; Nagle, A.; Simon, 
O.; Yeung, B. K. S.; Chatterjee, A. K.; McCormack, S. L.; Manary, M. J.; Zeeman, A.-
M.; Dechering, K. J.; Kumar, T. R. S.; Henrich, P. P.; Gagaring, K.; Ibanez, M.; Kato, 
N.; Kuhen, K. L.; Fischli, C.; Rottmann, M.; Plouffe, D. M.; Bursulaya, B.; Meister, S.; 
Rameh, L.; Trappe, J.; Haasen, D.; Timmerman, M.; Sauerwein, R. W.; Suwanarusk, 
R.; Russell, B.; Renia, L.; Nosten, F.; Tully, D. C.; Kocken, C. H. M.; Glynne, R. J.; 
Bodenreider, C.; Fidock, D. A.; Diagana, T. T.; Winzeler, E. A. Targeting Plasmodium 
PI(4)K to Eliminate Malaria. Nature. 2013, 504, 248–253. 
(28)  Zou, B.; Nagle, A.; Chatterjee, A. K.; Leong, S. Y.; Tan, L. J.; Sim, W. L. S.; Mishra, 
P.; Guntapalli, P.; Tully, D. C.; Lakshminarayana, S. B.; Lim, C. S.; Tan, Y. C.; Abas, 
S. N.; Bodenreider, C.; Kuhen, K. L.; Gagaring, K.; Borboa, R.; Chang, J.; Li, C.; 
Hollenbeck, T.; Tuntland, T.; Zeeman, A.-M.; Kocken, C. H. M.; McNamara, C.; Kato, 
N.; Winzeler, E. A.; Yeung, B. K. S.; Diagana, T. T.; Smith, P. W.; Roland, J. Lead 
Optimization of Imidazopyrazines: A New Class of Antimalarial with Activity on 
Plasmodium Liver Stages. ACS Med. Chem. Lett. 2014, 5, 947–950. 
 





PHYSICOCHEMICAL EVALUATION AND STRUCTURE-PROPERTY 
RELATIONSHIPS 
 
4.1 Chapter Overview 
In this chapter, physicochemical evaluation and the investigation of factors influencing 
solubility of new analogues described in this thesis are reported. The chapter first highlights 
the importance of physicochemical parameters on drug-likeness followed by physicochemical 
characterization with brief descriptions of the in silico and in vitro methods employed. This is 
then followed by an assessment of the drug-likeness compliance of the compounds with 
emphasis on Lipinski’s Rule of Five (Ro5). The chapter concludes with a section on the 
investigation of factors influencing solubility for both series of analogues.  
 
4.2 Impact of Physicochemical Properties on Drug-likeness 
Pharmacokinetic, pharmacodynamic and drug safety profiles can be influenced by 
physicochemical and molecular properties. Between the years 2000 and 2010, drug discovery 
suffered a nosedive with increasingly less drug candidates making it to the clinic despite huge 
financial investments.1 Poor oral bioavailability was identified as a potential cause of attrition 
and it soon became clear that this issue could be circumvented by identifying molecular 
features in drug molecules that are responsible for poor absorption. In order to assist the 
medicinal chemist to triage potential drug candidates, different sets of simple rules which 
define boundaries of fundamental properties considered acceptable for a compound to become 
a successful drug (drug-likeness) have been devised.2 Chris Lipinski is arguably the most 
influential pioneer in this field. By examining structural features of compounds that entered 
phase II clinical studies, Lipinski and co-workers were able to correlate computed 
physicochemical properties of these molecules to their aqueous solubility, permeability and 
oral bioavailability.3,4 Consequently, Lipinski and co-workers3,4 were able to put forward some 
guidelines on properties of molecules that are likely to exhibit poor permeability and 
absorption. These guidelines, famously known as Lipinski’s Ro5, state that a compound is 
likely to exhibit poor passive permeability or absorption if it has the following features: 1) > 5 
hydrogen bond donors (HBD); 2) > 10 hydrogen bond acceptors (HBA); 3) molecular weight 
(MW) > 500 g/mol and 4) cLog P > 5. 




Since Lipinski proposed the Ro5, variants of these guidelines have been put forward. In this 
regard, Veber et al.,5 correlated molecular flexibility to permeability and established that for 
good permeability, the number of rotatable bonds in a drug candidate should not exceed 10. 
Veber et al.,5 also established that the topological polar surface area (TPSA) values above 140 
Å2 are detrimental to permeability. Other extensions of the Ro5 relevant to fragment-based 
drug discovery such as the Rule of Three (Ro3) have been proposed.6 In this thesis, some of 
these structural properties were characterized for the synthesized compounds towards assessing 
their Ro5 compliance. How parameters such as cLog P, TPSA, melting point and HPLC 
retention time affect the solubility of the compounds was further assessed. 
 
4.3 Physicochemical Characterization 
4.3.1 Brief Description of Methods 
Some physicochemical parameters (MW, cLog P, TPSA, HBDs and HBAs) were calculated 
while others (HPLC retention time, melting point and solubility) were experimentally 
determined. The MW, TPSA, HBD and HBA values were calculated using StarDrop™ 64 
while the cLog P values were calculated using ChemDraw Professional 16.0. The full details 
of methodologies for experimentally determined parameters are given in chapter 6 of this 
thesis. Calculated parameters such as MW, cLog P and TPSA were plotted on frequency 
distribution histograms to assess their compliance to Lipinski’s Ro5. On the other hand, 
assessment of Ro5 compliance with respect to number of HBDs and HBAs was done by simple 
inspection of the values directly from the tables summarising all physicochemical parameters 
since there was not much variability in these parameters for both series of analogues. 
Factors influencing solubility were then investigated by plotting solubility as a function of 
different physicochemical parameters, which included HPLC retention time, cLog P, TPSA, 
and melting point. For analogues whose solubility values were uncertain, such as < 5 and > 
200 μM, definite values of 0 and 200 μM respectively were used in the plots. Microsoft excel 
version 2016 was used in plotting both the frequency distributions and correlations. 
 
4.3.2 Results and Discussion 
The calculated and experimentally determined physicochemical parameters are summarized in 
tables 4.1 – 4.4




Table 4.1: Physicochemical properties of pyridazine-substituted imidazopyridazine analogues 
 
Code R5 
Calculated physicochemical properties  Experimental physicochemical properties 
MW,m g/mol cLog Pn TPSA,m Å2 HBDm HBAm  tr,
o min m.p.,p °C Solubility,q μM 
25 
 
395.50 1.59 64.33 0 5 
 
2.563 181.4 200 
27 
 
411.49 1.54 81.40 0 6 
 
2.609 261.3 5 
28 
 
436.55 4.21 50.50 0 5 
 
2.467 110.7 180 
29 
 
436.55 4.21 50.50 0 5 
 
2.428 163.5 195 
30 
 
436.55 4.21 50.50 0 5 
 
2.462 122.4 200 
44 
 
451.56 4.22 62.53 1 6 
 
2.549 119.0 200 
45 
 
449.57 3.36 82.76 2 7 
 
2.401 eND 195 
36 
 
426.51 1.71 93.43 1 7 
 
2.635 eND 20 
37 
 
410.51 1.72 76.36 1 6 
 
2.636 eND 190 
38 
 
410.51 1.73 76.36 1 6 
 
2.579 eND 195 
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Table 4.1: Physicochemical properties of pyridazine-substituted imidazopyridazine analogues 
 
Code R5 
Calculated physicochemical properties  Experimental physicochemical properties 
MW,m g/mol cLog Pn TPSA,m Å2 HBDm HBAm  tr,
o min m.p.,p °C Solubility,q μM 
39 
 
426.51 1.71 93.43 1 7 
 
2.650 298.0 < 5 
40 
 
350.40 1.25 85.07 1 7 
 
2.617 eND 25 
41 
 
404.50 0.69 93.43 1 7 
 
2.434 273.8 10 
42 
 
369.49 1.41 62.53 1 6 
 
0.230 eND 200 
43 
 
433.55 0.61 96.67 1 8 
 
2.488 eND 70 
eND, not determined. 
mMW, molecular weight; TPSA, topological polar surface area; HBD, hydrogen bond donors; HBA, hydrogen bond acceptors: Calculated using StarDrop™ 64.   
ncLog P, calculated log P: Calculated using ChemDraw Professional 16.0. 
otr, retention time: Measured using HPLC-MS (method described in chapter 6). 
pm.p., melting point (values are averages between the upper and lower limit values of the melting range): Measured using a Stuart automatic melting point machine SMP40. 
qDetermined using a miniaturized shake flask method at pH 6.5 (method described in chapter 6).            
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Table 4.2: Physicochemical properties of imidazo-substituted imidazopyridazine analogues 
 
Code R6 
Calculated physicochemical properties  Experimental physicochemical properties 
MW,m g/mol cLog Pn TPSA,m Å2 HBDm HBAm  tr,
o min m.p.,p °C Solubility,q μM 
32 
 
436.55 4.12 50.50 0 5 
 
2.505 162.6 200 
33 
 
436.55 4.12 50.50 0 5 
 
2.416 eND 35 
34 
 
436.55 4.12 50.50 0 5 
 
2.492 eND 200 
35 
 
395.50 1.59 64.33 0 5 
 
2.525 eND 200 
46 
 
426.51 1.84 93.43 1 7 
 
2.534 106.1 60 
47 
 
426.51 1.84 93.43 1 7 
 
2.555 151.2 40 
48 
 
410.51 1.88 76.36 1 6 
 
2.476 111.8 150 
49 
 
410.51 1.88 76.36 1 6 
 
2.450 162.6 165 
eND, not determined. 
mMW, molecular weight; TPSA, topological polar surface area; HBD, hydrogen bond donors; HBA, hydrogen bond acceptors: Calculated using StarDrop™ 64.   
ncLog P, calculated log P: Calculated using ChemDraw Professional 16.0. 
otr, retention time: Measured using HPLC-MS (method described in chapter 6). 
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pm.p., melting point (values are averages between the upper and lower limit values of the melting range): Measured using a Stuart automatic melting point machine SMP40. 
qDetermined using a miniaturized shake flask method at pH 6.5 (method described in chapter 6).            
 
Table 4.3: Physicochemical properties of discreetly-modified imidazopyridazine analogues 
Code Structure 
Calculated physicochemical properties  Experimental physicochemical properties 
MW,m g/mol cLog Pn TPSA,m Å2 HBDm HBAm  tr,
o min m.p.,p °C Solubility,q μM 
26 
 
411.49 1.53 81.40 0 6 
 
2.518 237.8 10 
31 
 
452.55 4.16 67.57 0 6 
 
2.555 183.0 200 
19 
 
427.49 1.48 98.47 0 7 
 
2.526 245.6 10 
50 
 
427.49 1.48 98.47 0 7 
 
2.586 229.8 < 5 
51 
 
427.49 1.48 98.47 0 7 
 
2.588 265.0 < 5 
52 
 
411.49 1.53 81.40 0 6 
 
2.619 219.8 < 5 
53 
 
411.49 1.54 81.40 0 6 
 
2.578 219.8 < 5 
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Table 4.3: Physicochemical properties of discreetly-modified imidazopyridazine analogues 
Code Structure 
Calculated physicochemical properties  Experimental physicochemical properties 
MW,m g/mol cLog Pn TPSA,m Å2 HBDm HBAm  tr,
o min m.p.,p °C Solubility,q μM 
54 
 
395.50 1.59 64.33 0 5 
 
2.602 175.1 200 
56 
 
468.56 6.83 59.29 1 5 
 
3.190 174.2 < 5 
55 
 
462.64 4.36 76.36 1 6 
 
2.820 131.4 < 5 
57 
 
478.64 4.31 93.43 1 7 
 
2.903 210.4 < 5 
mMW, molecular weight; TPSA, topological polar surface area; HBD, hydrogen bond donors; HBA, hydrogen bond acceptors: Calculated using StarDrop™ 64.   
ncLog P, calculated log P: Calculated using ChemDraw Professional 16.0. 
otr, retention time: Measured using HPLC-MS (method described in chapter 6). 
pm.p., melting point (values are averages between the upper and lower limit values of the melting range): Measured using a Stuart automatic melting point machine SMP40. 
qDetermined using a miniaturized shake flask method at pH 6.5 (method described in chapter 6). 
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Table 4.4: Physicochemical properties of aminopyrazine analogues 
Code Structure 
Calculated physicochemical properties  Experimental physicochemical properties 
MW,m g/mol cLog Pn TPSA,m Å2 HBDm HBAm  tr,
o min m.p.,p °C Solubility,r μM 
24 
 
394.37 1.97 98.83 1 6 
 
2.631 213.5 10 
69 
 
369.40 2.19 123.2 2 7 
 
2.496 272.5 > 200 
59 
 
421.42 3.42 94.23 1 7 
 
2.919 194.0 80 
60 
 
423.44 3.53 94.23 1 7 
 
2.824 152.5 40 
61 
 
323.32 1.60 76.72 2 5 
 
0.566 128.0 160 
62 
 
401.41 1.24 102.1 1 7 
 
2.517 194.5 160 
63 
 
430.52 2.30 115.5 1 8 
 
2.703 176.0 80 
64 
 
432.54 2.10 115.5 1 8 
 
2.806 181.5 160 
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Table 4.4: Physicochemical properties of aminopyrazine analogues 
Code Structure 
Calculated physicochemical properties  Experimental physicochemical properties 
MW,m g/mol cLog Pn TPSA,m Å2 HBDm HBAm  tr,
o min m.p.,p °C Solubility,r μM 
65 
 
332.42 0.17 97.97 2 6 
 
0.249 126.5 > 200 
66 
 
410.51 - 0.19 123.3 1 8 
 
2.434 eND 40 
70 
 
457.58 3.74 110.9 1 9 
 
3.007 91.0 160 
71 
 
461.61 3.64 110.9 1 9 
 
2.940 70.5 80 
72 
 
417.54 - 0.93 126.6 1 9 
 
2.417 96.5 > 200 
67 
 
333.41 0.45 101.2 2 7 
 
0.170 159.5 > 200 
68 
 
411.50 0.46 126.6 1 9 
 
2.447 240.5 160 
eND, not determined. 
mMW, molecular weight; TPSA, topological polar surface area; HBD, hydrogen bond donors; HBA, hydrogen bond acceptors: Calculated using StarDrop™ 64.   
ncLog P, calculated log P: Calculated using ChemDraw Professional 16.0. 
otr, retention time: Measured using HPLC-MS (method described in chapter 6). 
pm.p., melting point (values are averages between the upper and lower limit values of the melting range): Measured using a Reichert-Jung Thermovar hot stage microscope. 
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Table 4.5: Comparison of calculated physicochemical properties to drug-like guidelines 
Compound class MW, g/mol cLog P TPSA, Å2 HBD HBA 
Imidazopyridazines 350.40 – 478.64 0.61 – 6.83 50.50 – 98.47 0 - 2 5 - 8 
Aminopyrazines 323.32 – 461.61 - 0.93 – 3.74 76.72 – 126.6 1 - 2 5 - 9 
Targeted criterias < 500 < 5 < 140 < 5 < 10 
sTargeted criteria defined according to Lipinski’s Ro5 (MW, cLog P, HBD and HBA)3,4 and Veber’s 
rule on TPSA.5 
 
4.3.2.1 Assessment of Lipinski’s Ro5 Compliance for Imidazopyridazines 
For imidazopyridazines, four out of the five calculated molecular features were Ro5 compliant. 
These included MW (350.40 – 478.64 g/mol), TPSA (50.50 – 98.47 Å2), HBDs (0 – 2) and 
HBAs (5 – 8) (Table 4.5). Except for one analogue (56, cLog P = 6.83, table 4.3), all the others 
possessed cLog P values below 5 which was in conformity to the Ro5. The frequency 
distribution for molecular weight (Figure 4.1A) shows most analogues in this class have 
molecular weights in the range 411 – 440 g/mol. On the other hand, the majority analogues 
have cLog P in the range 1.1 – 2 (Figure 4.1B) while the TPSA values are distributed over a 









































































(A) Molecular weight; (B) Calculated Log P and (C) Topological polar surface area. 
 
4.3.2.2 Assessment of Lipinski’s Ro5 Compliance for Aminopyrazines 
All the aminopyrazine analogues were Ro5 compliant across all the five physicochemical 
parameters: MW = 323.32 – 461.61 g/mol; cLog P = - 0.93 – 3.74; TPSA = 76.72 – 126.6 Å2; 
HBDs = 1 – 2 and HBAs = 5 – 9 (Table 4.5). The frequency distribution plot showed majority 
of analogues have molecular weights in the range 391 – 465 g/mol (Figure 4.2A). Furthermore, 
except for one analogue with a TPSA value in the range 70 – 80 Å2, all the other analogues 
have TPSA values in the range 91 – 130 Å2 (Figure 4.2B). Unlike the imidazopyridazines, the 
cLog P values of aminopyrazines varied over a narrow range and, therefore, just like HBD and 










Figure 4.2: Frequency distribution of physicochemical parameters for aminopyrazine analogues:  
(A) Molecular weight; (B) Topological polar surface area. 
 
4.3.2.3 Investigation of Factors Influencing Solubility of Imidazopyridazines 
Figures 4.3 captures the correlation plots between solubility and different factors envisaged to 
potentially influence solubility. For this class of analogues, melting point seems to influence 
solubility the most (Figure 4.3A). Although the correlation is weak (R2 = 0.3905), the observed 
negative trendline is consistent with the hypothesis and literature precedence.7,8 In this regard, 
a high melting point is an indicator of efficient crystal packing and hence high crystal packing 
energy. This, in turn, discourages the dissolution of a solute in an aqueous medium. However, 
the weak correlation observed could suggest that there are other factors influencing solubility. 
Additionally, the strength of the correlation could also be affected by a number of data points 
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reported as < 5 μM were arbitrarily assigned a definite value of 0 μM, an estimation which 


















Figure 4.3: Correlations between solubility and different physicochemical parameters for 
imidazopyridazine analogues:  
(A) Solubility versus melting point; (B) Solubility versus HPLC retention time; (C) Solubility versus 
calculated log P and (D) Solubility versus topological polar surface area. 
tFor the purpose of plotting the correlations, all compounds with uncertain solubility values, i.e., < 5 
μM, as shown in tables 4.1 – 4.3, were arbitrarily assigned a definite solubility value of 0 μM.  
 
A negative correlation between solubility and HPLC retention time (Figure 4.3B) was 
observed. Although this correlation was also weak (R2 = 0.1086), the decrease in solubility 
with increase in retention time was anticipated. In this case, the HPLC retention time is used 
as a surrogate measure of the compound’s ability to interact with the aqueous media of the 
reversed phase HPLC column. Therefore, this is also a more realistic measure of a compound’s 
polarity. In reversed phase HPLC, the mobile phase is more polar than the stationary phase of 
the column9 with each gradient run starting with a high percentage of the aqueous media which 
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Also noted was limited diversity of retention times for the analysed analogues with most 
analogues possessing values between 2.4 and 2.9 min. Within this region, some analogues 
possess high solubility while others are poorly soluble. Additionally, as already mentioned, 
factors such as uncertain solubility values which needed arbitrary assignment of definite values 
to be plotted could have affected the strength of the correlation. 
An unexpected weak (R2 = 0.0415) positive correlation was observed between solubility and 
cLog P (Figure 4.3C). One major factor that significantly influenced this correlation was the 
data corresponding to a subset of analogues containing sulfoxides, sulfones and basic side 
chains. As stated earlier in subsection 3.2.1.1 of chapter 3, despite having a higher cLog P and 
lower hydrogen bonding sites than sulfones, sulfoxides are more water-soluble due to their 
energetically favourable hydrogen bonding interactions with water molecules.10 Additionally, 
save for compound 33, all the other analogues containing a basic side chain were expectedly 
highly soluble (see tables 4.1 – 4.3) although the cLog P values were relatively high due to the 
presence of the lipophilic ethyl groups. Therefore, the highly soluble sulfoxide- and amino-
substituted derivatives with high cLog P values significantly skewed the trendline to a positive 
correlation. Indeed, a more realistic indicator of a molecule’s capacity to interact with polar 
media such as water, the reversed phase HPLC retention time, shows a negative correlation 
with solubility (Figure 4.3B). 
When solubility was plotted as a function of TPSA, an even much stronger (R2 = 0.4457) 
unexpected negative correlation was observed (Figure 4.3D). Once again, the highly soluble 
analogues containing sulfoxides and basic side chains yet possessing lower calculated TPSA 
compared to sulfones significantly influenced the trendline. 
 
4.3.2.4 Investigation of Factors Influencing Solubility of Aminopyrazines 
For the aminopyrazine analogues, captured in table 4.4, retention time was found to be a major 
factor influencing solubility compared to cLog P, TPSA and melting point. In this regard, the 
correlation between solubility and retention time (Figure 4.4A) was found to be much stronger 
(R2 = 0.2449) than the corresponding solubility-cLog, -TPSA and -melting point correlations 
(R2 = 0.0016 – 0.1645, Figures 4.4B – D). However, in absolute terms, the solubility-retention 
time correlation is weak suggesting there are other factors driving the solubility of this class of 
analogues. For this series, solubility was determined by a turbidimetric assay as briefly 
described in subsection 3.3 of the preceding chapter. In this method, serial dilutions of the test 





compound such as 0, 5.0, 10.0, 20.0, 40.0, 80.0, 160.0 and 200 μM in buffered aqueous media 
were incubated for 2 hours at 37 °C to mimic body temperature. The absorbance values of the 
test concentrations were then recorded using a UV-Visible spectrometer at a wavelength the 
test compound is not expected to absorb (620 nm in this case). Any absorbance values recorded 
were thus attributed to the turbidity caused by precipitation of the test compound at a certain 
concentration above which the compound crushes out from solution. Thus, the solubility values 
obtained from this method are limited to the aforementioned serial dilution concentrations. This 
makes it difficult to certainly determine solubility values for compounds which crush out of 
solution at concentrations other than those used in the assay set-up. Indeed, as can be noted 
from the correlation plots in figure 4.4, solubility values for all compounds are limited to these 
definite concentrations used in the assay. Therefore, due to the uncertainty of the solubility 
values determined from such an assay, the strength of the correlations obtained may have been 
affected. Moreover, for analogues possessing solubility values > 200 μM, a definite value of 
200 μM was arbitrarily assigned for the purpose of plotting the graphs which could have further 
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Figure 4.4: Correlations between solubility and different physicochemical parameters for 
aminopyrazine analogues:  
(A) Solubility versus HPLC retention time; (B) Solubility versus calculated log P; (C) Solubility versus 
topological polar surface area and (D) Solubility versus melting point. 
uFor the purpose of plotting the correlations, all compounds with uncertain solubility values, i.e., > 200 
μM, as shown in table 4.4, were taken to possess a definite solubility value of 200 μM. 
 
Unlike the imidazopyridazine derivatives which exhibited a positive solubility – cLog P 
correlation, the aminopyrazines showed the expected negative correlation between these two 
parameters (Figure 4.4B). This is consistent with the fact that in this series, there was no 
combination of sulfoxide-, sulfone- and diethylaminomethyl-substituted analogues which 
could have influenced the trendline in the same manner as observed in the imidazopyridazine 
class. Furthermore, although the correlation was very weak (R2 = 0.0237, Figure 4.4C), the 
expected positive trendline was obtained between solubility and TPSA for the aminopyrazine 
compounds while the opposite is true for the imidazopyridazines. On the other hand, there was 
no observed meaningful correlation (R2 = 0.0016) between solubility and melting point (Figure 
4.4D). 
    
4.4 Conclusions 
In conclusion, physicochemical profiling revealed that all imidazopyridazine and 
aminopyrazine analogues were Ro5 compliant except for compound 33 which has a cLog P > 
5. Evaluation of factors influencing solubility for imidazopyridazine analogues showed that 
melting point influenced solubility to a greater extent than HPLC retention time, cLog P and 
TPSA. For the aminopyrazine series, the HPLC retention time was found to be the most 
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SUMMARY, CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK 
 
5.1 Summary and Conclusions 
5.1.1 Imidazopyridazines 
The target compounds were synthesized by diverse protocols centred around metal-mediated 
coupling reactions and were obtained in poor to very good yields (8 – 80%). The compounds 
were then characterized by TLC, HPLC-MS, 1H-NMR, 13C-NMR and melting point.  
Initial SAR studies1–3 on this class of compounds identified lead compounds such as 19, among 
others which, despite exhibiting good in vitro antiplasmodial activity (NF54 IC50 = 0.0034 μM; 
K1 IC50 = 0.0023 μM) and in vivo antimalarial efficacy (98% at 4 × 50 mg/kg, po), was plagued 
by poor solubility (10 μΜ at pH 6.5) and a hERG inhibition liability (IC50 = 3.6 μM). In an 
effort to address these liabilities, further expansion of the SAR for this class of analogues is 
reported. In this regard, the SAR was pursued in such a way as to introduce molecular features 
to improve solubility and counter hERG inhibition while preserving antiplasmodial potency. 
The newly synthesized analogues represented drastic as well as more subtle and discreet 
modifications around the imidazopyridazine core-scaffold. 
Although all the newly synthesized analogues were not as potent as the lead 19, the reported 
SAR further provides a guide for future SAR studies. Moreover, the introduced modifications 
resulted in the identification of analogues with drastically improved solubility and reduced 
hERG inhibition. The SAR and SSR (structure solubility relationship) summary is shown in 
figure 5.1 with only representative analogues shown for each class of modifications. The P.f 
NF54 IC50 values shown in this figure refer to activity at the asexual blood stage of parasite 
development. Derivatization at the pyridazine-attached phenyl ring (SAR1 and 3) identified 
analogue 30 with potent antiplasmodial activity (IC50 = 0.14 μM) and high solubility (200 μM) 
but was still beset by a serious hERG inhibition liability (IC50 = 0.59 μM). Other analogues 
containing the basic side chain were also found to be generally highly soluble (180 – 200 μM) 
but two analogues tested on hERG were found to be relatively potent on this channel. However, 
hERG activity was successfully detuned to a large extent by introducing saturation at this 
position as exemplified by compounds 41 (IC50 = 29 μM) and 43 (IC50 = 26 μM) in figure 5.1. 
Other subtle changes, which included switching sulfones with sulfoxides as well as positional 
changes of these groups, also diminished hERG activity (see analogues 36 - 39 in table 3.4, 
chapter 3). Additionally, the solubilities of sulfoxide-substituted analogues were significantly 




higher than those of the corresponding sulfones (cf. 25 vs 27 and 38 vs 39, figure 5.1). This 
observation was also true for all the other sulfone and sulfoxide derivatives from other portions 
of SAR.    
 
Figure 5.1: SAR and SSR summary of imidazopyridazine analogues. 
eND, not determined; vRHS, right hand side; wLHS, left hand side. 
Other discreet modifications 
Key: 
Compound code 
P. f, NF54 IC50 (μM) 
hERG IC50 (μM) 













































































• p-F and m-diethylaminomethyl 
substitution important for 
antiplasmodial potency. 
• Analogues with basic side 
chains potent on hERG. 
• Sulfoxides more soluble than 
sulfones. 
• Diethylaminomethyl-
substituted analogues highly 
soluble. 
• Saturation improves solubility 
(42 & 43) and detunes hERG 
activity (41 & 43).   
• Antiplasmodial activity 
retained for m-SOMe-
substituted analogue (35). 
Relative to 19, hERG activity 
detuned. 
• Modifications on this portion 
generally detrimental to 
antiplasmodial potency. 
• Sulfoxides more soluble than 
sulfones; diethylaminomethyl-
substituted analogues highly 
soluble.  
SAR5 & 6 
• Highly potent analogue 50, an isomer of 19 identified – m-SO2Me substitution on RHS
v phenyl 
tolerated. 
• For silyl amides, CF3 on LHS
w phenyl ring detrimental to antiplasmodial potency (cf. 57 & 56). 
• Sulfones are more potent inhibitors of hERG than sulfoxides. 
• Sulfoxides are more soluble than sulfones. 
• Silyl amide analogues poorly soluble.  




Generally, exploration of SAR2 and 4 (Figure 5.1) led to analogues with the lowest 
antiplasmodial potency (IC50 = 0.99 – 7.6 μM). However, compound 35 which still retained 
strong submicromolar potency (IC50 = 0.15 μM) was identified. This compound is also a 
potential prodrug of a highly potent sulfone analogue 50 (IC50 = 0.031 μM) (SAR5 and 6) 
which has poor solubility (< 5 μM). Compared to 50, analogue 35 has a nearly 4-fold reduced 
hERG potency. Nevertheless, hERG inhibition upon the anticipated biotransformation in vivo 
is still a concern. Consistent with this observation, the sulfoxide 54 was also found to have 
weak hERG activity (IC50 = 21 μM) while its sulfone version 51 was more active on hERG 
(IC50 = 4.0 μM). Furthermore, a silicon-containing analogue 57 with relatively potent 
antiplasmodial activity (IC50 = 0.14 μM) was also identified. This analogue and its sulfoxide 
counterpart 55 (IC50 = 0.16 μM, table 3.3, chapter 3) had equipotent antiplasmodial activity 
while a trifluoromethylated version 56 was nearly 7-fold less potent highlighting the 
importance of a polar electron withdrawing substituent on the phenyl ring. However, all silyl 
amides retained poor solubility (< 5 μM). 
Selected analogues with good to excellent gametocytocidal (IC50 = 0.031 – 0.99 μM) and liver 
stage (IC50 = 0.045 μM) activities on plasmodium parasites were identified (see subsection 
3.2.2 of chapter 3). These data suggest the analogues have potential for transmission blocking 
and chemoprotection, a very important TPP for the malaria eradication agenda. Furthermore, 
docking studies on a PfPI4K homology model correlated well with parasite-based SAR.   
Additionally, most analogues evaluated for cytotoxicity had a wide safety margin with 
selectivity indices over the CHO mammalian cell line in the range 72 - > 874 (Table 3.4, chapter 
3). However, all analogues possessing a basic side chain were relatively more cytotoxic (SI = 
10 – 30). 
Two out of the three analogues evaluated for metabolic stability were stable across liver 
microsomal preparations from three species – human, rat and mouse (Table 3.5, chapter 3). 
The poor metabolic stability for the sulfoxide analogue 35 was anticipated – this compound, in 
the presence of microsomes, could be undergoing rapid oxidation to the corresponding sulfone 
derivative 50. Nevertheless, metabolite identification studies are needed to confirm this 
hypothesis. 
Physicochemical profiling showed the new imidazopyridazine analogues were Ro5 compliant 
with only one violating this guideline with respect to cLog P (Table 4.5, chapter 4). 




Additionally, melting point was found to be the most influential factor of solubility for this 
class of analogues (Figure 4.3A).    
 
5.1.2 Aminopyrazines 
The aminopyrazine analogues were realized in low to very good yields (21 – 86%) via metal-
mediated coupling, reduction, deprotection, nucleophilic aromatic substitution and mesylation 
reactions. The target compounds were characterized by the same techniques as those used for 
the imidazopyridazines. 
In an effort to identify aminopyrazine analogues with better physicochemical properties, 
further SAR explorations not covered in previous reports4,5 have been presented and discussed. 
The obtained data suggest that the introduction of partial or full saturation at positions 3 and 5 
of the aminopyrazine core-scaffold is highly detrimental to antiplasmodial potency – most 
analogues were poorly active (IC50 = 1.2 - > 10 μM) compared to the lead 24 (IC50 = 0.0081 
μM) (Table 3.6, chapter 3). An exception in this series was compound 62 (possessing an N-
methylsulfonylpiperidinyl group) which retained submicromolar potency (IC50 = 0.51 μM). 
The methylsulfonyl group in this molecule was critical to antiplasmodial potency – the removal 
of this group, as shown in analogue 61 (IC50 > 10 μM), eliminates potency. Furthermore, using 
a homology model of PfPI4K, parasite-based SAR were rationalized. Such docking studies 
showed the introduced molecular features disrupted key binding interactions of the lead 
molecule 24. The most active analogue 62 was shown to resemble the lead 24 regarding the 
interactions experienced by the methylsulfonyl group in the binding site.   
Although antiplasmodial potency was drastically affected by the introduced chemical 
modifications, the solubility of all analogues was improved by a 4 - > 20-fold margin compared 
to the lead compound 24 (Table 3.6, chapter 3). These data confirmed the hypothesis that 
introducing partial or full saturation should disrupt planarity and discourage π – π stacking, 
consequently resulting in improved solubility. Installation of a water-solubilizing carboxylic 
acid in compound 69 also drastically improved solubility. All the analogues in this class were 
Ro5 compliant (Table 4.5, chapter 4), and the solubility values showed the strongest correlation 
with HPLC retention time (Figure 4.4, chapter 4). 
To conclude, this PhD thesis has reported the synthesis, biological evaluation and 
physicochemical profiling of new imidazopyridazine and aminopyrazine analogues. The 
efforts to detune off-target activities and improve physicochemical properties for these two 




chemotypes is of paramount importance in drug discovery. Indeed, optimization of activity for 
a desired target during lead optimization is important. Nevertheless, translatability of such 
activity to the in vivo and clinical situations may not be achieved if the optimization of 
physicochemical parameters is neglected. 
 
5.2 Recommendations for Future Work 
Based on the results obtained in this study, a summary of proposed SAR (pSAR) for future 
studies is shown in figure 5.2. For imidazopyridazines, the introduction of an NH linker 
between the core-scaffold and aromatic as well as saturated heterocyclic ring systems was 
detrimental to antiplasmodial potency. In pSAR1 and 2, to potentially address the hERG 
inhibition and solubility issue, future SAR studies should focus on introducing saturated and 
aromatic groups with hydrogen bond acceptors and donors (sulfones, sulfoximines and 
tetrazolones) while avoiding NH linking. It is also recommended that the meta and para 
substitution patterns in pSAR1 and 2 respectively be preserved to avoid compromising activity 
as revealed by both parasite-based SAR and docking studies on the PfPI4K homology model. 
The same recommendation applies for pSAR3 explorations where both phenyl rings would be 
simultaneously replaced by two saturated piperidine rings. Generation of analogues with ortho-
fluoro or -methyl substitution in both pSAR1 and 2 will ensure molecular planarity is disrupted 
to possibly improve solubility while avoiding the disruption of key interactions in the binding 
site. The replacement of the imidazopyridazine core-scaffold with other fused ring 
heterocyclics which can potentially preserve binding to the hinge region of PfPI4K while 
possibly addressing the hERG and solubility issues is further recommended (pSAR4). 
Moreover, testing the analogues in a PfPI4K biochemical assay to guide the computational 
modelling and synthesis is another important aspect future studies should consider.  
For the aminopyrazines, it is recommended that the replacement of position 3 and 5 aromatic 
rings with saturated ring systems is avoided since such modifications led to a drastic reduction 
in antiplasmodial potency. Efforts to improve the solubility of this class should instead focus 
on more discreet modifications such as introduction of planarity-disrupting ortho substituents 
as well as water-solubilizing tetrazolone groups (pSAR5 and 6) (Figure 5.2).     
  





Figure 5.2: Recommendations for future SAR studies. 
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6.1.1 General Comments on Experimental Data 
All reagents and chemicals used in all reactions were purchased from various commercial 
sources and used without further purification. All the solvents used in the reactions were 
anhydrous save for ethanol which was absolute (99.9%). Reactions were monitored by a 
combination of analytical TLC, HPLC-MS and UPLC-MS. The TLC plates were sourced from 
Merck (TLC Silica gel 60 F254 aluminium-backed) and were developed in a 100 mL beaker 
covered with either a watch glass or aluminium foil. The plates were visualized under 
ultraviolet light (UV 254 and 366 nm). An Agilent HPLC-MS instrument with the following 
components was used for compound purity checks and reaction monitoring: Agilent 1260® 
Infinity Binary Pump, Agilent 1260® Infinity Diode Array Detector, Agilent 1290® Infinity 
Column Compartment, Agilent 1260® Infinity Autosampler, Agilent 6120® Quadrupole LC-
MS, and Peak Scientific® Genius 1050 Nitrogen Generator. An X-bridge® (C18, 2.5 µm, 3.0 
mm (ID) x 50 mm length) column maintained at 35 °C or 40 °C was used. The HPLC mobile 
phase compositions and run times for reaction monitoring for final compounds and 
intermediates varied during the entire period in which this PhD study was undertaken. 
Therefore, the retention times for all intermediates were not determined under the same 
conditions. However, the retention times used in the solubility – retention time correlation plots 
for all final compounds, as shown in chapter 4, were measured using the same conditions. 
These included a Kinetex Core (C18, 2.6 µm, 2.1 mm (ID) x 30 mm length) column maintained 
at 40 °C, a flow rate of 0.7 mL/min and an injection volume of 2 μL. The chromatographic 
mobile phase was composed of 10 mM aqueous ammonium acetate (NH4OAc) spiked with 
0.4% acetic acid while the organic phase was composed of 10 mM NH4Ac in 90% methanol in 
water spiked with 0.4% acetic acid. The gradient conditions are summarised in table 6.1 below. 
Table 6.1: HPLC gradient conditions used to measure retention times for final compounds 
Time (min) %Ax %By 
0.00 85 15 
0.30 85 15 
1.20 0.0 100 
4.50 0.0 100 
xA: 10 mM aqueous ammonium acetate (NH4OAc) spiked with 0.4% acetic acid. 
yB: 10 mM NH4Ac in 90% methanol in water spiked with 0.4% acetic acid. 
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The mass spectra were acquired using electrospray ionisation (ESI) and atmospheric pressure 
chemical ionization (APCI) either in the positive or negative ionisation mode. 
Biotage grade silica gel was employed for column chromatographic purifications on the 
Biotage Isolera One Flash Chromatography system. Additionally, Analtech Uniplate 
preparative TLC (prep-TLC) plates (silica gel GF, 20 × 20 cm, 2000 microns) were used for 
prep-TLC purifications. The mobile phase solvents were AR grade and were used without 
further distillation. 
1H-NMR and 13C-NMR spectra were acquired on either of the following instruments: Bruker 
AV 400 (1H 400.0, 13C 101 MHz), Varian Mercury 300 (1H 300.1 MHz) or Bruker Ascend™ 
600 (1H 600.0, 13C 151 MHz) spectrometers. The 13C-NMR spectra for compounds 30, 44, 57, 
66 and 72 were not acquired due to insufficient material to undertake such analyses. 
All final compounds were subjected to purity check experiments using HPLC-MS to ensure 
acceptable purity (≥ 95%). Melting points were measured using the Automatic Stuart Melting 
Point Apparatus SMP40 (imidazopyridazines) and a Reichert-Jung Thermovar hot stage 
microscope (aminopyrazines) and are uncorrected. 
 
6.1.2 Synthetic Methods for Imidazopyridazines 
6.1.2.1 Procedure for Synthesis of 6-chloroimidazo[1,2-b]pyridazine (2a)1 
Bromoacetaldehyde diethylacetal (12.0 mL, 78 mmol) was added to a 
suspension of 3-amino-6-chloropyridazine (5.00 g, 39 mmol) in absolute 
ethanol (99.9%) (78 mL) and deionized water (50 mL). A 48% aqueous 
solution of HBr (4.4 mL, 39 mmol) was added after which the suspension 
cleared. The reaction mixture was refluxed at 103 °C for 22 hours. The resulting brown solution 
was extracted with ethyl acetate (EtOAc) (100 mL × 3). The combined organic layers were 
concentrated in vacuo to obtain 2a as a brown solid which was used in the next step without 
further purification (HPLC-MS, ESI+/APCI+: m/z [M + H]+ = 154.0, calculated exact mass = 
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6.1.2.2 Procedure for Synthesis of 6-chloro-3-iodoimidazo[1,2-b]pyridazine (3a)1 
A reddish solution of 6-chloroimidazo[1,2-b]pyridazine (2a) (4.60 g, 30 
mmol) in 30 mL of N,N-dimethylformamide (DMF) was purged with 
nitrogen for 30 minutes. N-Iodosuccinimide (NIS) (7.41 g, 33 mmol) was 
then added followed by the addition of another 45 mL of DMF. The 
reaction mixture was then left to stir at room temperature (~ 21 °C) for 5 
days (initially a suspension, the reaction mixture cleared after 2 days of magnetic stirring). 
DMF was then removed under reduced pressure. The resulting brown residue was taken up in 
200 mL dichloromethane (DCM) and washed with deionized water (100 mL × 3), a saturated 
aqueous solution of a mixture of sodium metabisulfite (Na2S2O5) and sodium bisulfite 
(NaHSO3) (100 mL × 2). The organic layer was concentrated in vacuo to afford 3a as a brown 
solid (6.82 g, 81%); 1H-NMR δH (300 MHz; CDCl3) 7.92 (1H, d, J = 9.4 Hz, H2), 7.88 (1H, s, 
H1), 7.14 (1H, d, J = 9.4 Hz, H3); HPLC-MS, ESI
+/APCI+: m/z [M + H]+ = 279.8, calculated 
exact mass = 278.9060, tr = 3.0 min. 
 
6.1.2.3 General Procedure for Synthesis of Chloro-substituted Intermediates (4a – g) 
A suspension of 6-chloro-3-iodoimidazo[1,2-b]pyridazine (3a) (1.0 eq), an appropriate boronic 
acid or boronic acid pinacol ester (1.1 eq) and Pd(PPh3)2Cl2 (0.05 eq) in DMF (3 mL/mmol of 
3a) was purged with nitrogen for 20 minutes. A 1 M aqueous solution of K2CO3 (1.05 eq) was 
then added after which the reaction mixture was heated to 80 °C and left to magnetically stir at 
that temperature for 3.5 – 46 hours. The reaction mixture was diluted with DCM, washed with 
deionized water (8 ×), saturated aqueous solutions of NaHCO3 (3 ×), NH4Cl (3 ×) and NaCl (1 
×). For analogues 4e – g, containing the basic side chain, washing with aq NH4Cl was avoided. 
After drying the organic layer (MgSO4), the solvent was removed in vacuo and the resulting 
residue subjected to automated column chromatography on silica to give the chloro-substituted 
derivatives in 26 – 77% yield. 
 
 




Purified by flash chromatography (0 – 3% CH3OH/DCM). Yellow solid 
(0.587 g, 77%); 1H-NMR δH (300 MHz; CDCl3) 8.24 (2H, d, J = 8.2 Hz, 
H2), 8.18 (1H, s, H1), 8.11 (1H, d, J = 9.4 Hz, H5), 7.82 (2H, d, J = 8.0 
Hz, H3), 7.22 (1H, d, J = 8.8 Hz, H6), 2.81 (3H, s, H4); HPLC-MS, 
ESI+/APCI+: m/z [M + H]+ = 292.0, calculated exact mass = 291.0233, tr 
= 3.0 min. 
 
6-Chloro-3-(4-(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazine (4b) 
Purified by flash chromatography (0 – 2% CH3OH/DCM). Yellow solid 
(0.577 g, 65%); 1H-NMR δH (300 MHz; CDCl3) 8.30 (2H, d, J = 8.8 Hz, 
H3), 8.23 (1H, s, H1), 8.18 - 8.07 (4H, m, H2, H5, H6), 3.13 (3H, s, H4); 
HPLC-MS, ESI+/APCI+: m/z [M + H]+ = 308.0, calculated exact mass = 




Purified by flash chromatography (0 – 3% CH3OH/DCM). Yellow 
solid (0.1713 g, 66%); 1H-NMR δH (300 MHz; CDCl3) 8.32 (1H, s, 
H2), 8.28 – 8.20 (1H, m, H4), 8.19 (1H, s, H1), 8.05 (1H, d, J = 9.4 Hz, 
H7), 7.74 – 7.69 (2H, m, H3, H5), 7.18 (1H, d, J = 9.4 Hz, H8), 2.84 




Purified by flash chromatography (0 – 4% CH3OH/DCM). Yellow 
solid (0.1797 g, 66%); 1H-NMR δH (300 MHz; CDCl3) 8.63 (1H, s, 
H2), 8.41 (1H, d, J = 8.1 Hz, H6), 8.20 (1H, s, H1), 8.04 (1H, d, J = 
9.5 Hz, H7), 7.99 (1H, d, J = 8.9 Hz, H4), 7.76 (1H, t, J = 8.0 Hz, H5), 
7.19 (1H, d, J = 9.4 Hz, H8), 3.16 (3H, s, H3); HPLC-MS, APCI
+: 










Purified by flash chromatography (0 – 5% CH3OH/DCM), then prep-
TLC (developed in 6% CH3OH/DCM). Yellow oil (0.097 g, 26%); 
1H-NMR δH (300 MHz; CDCl3) 8.23 – 8.10 (2H, m, H1, H2), 8.00 
(1H, d, J = 9.4 Hz, H8), 7.40 – 7.30 (2H, m, H3, H4), 7.12 (1H, d, J = 
9.4 Hz, H9), 3.70 (2H, s, H5), 2.65 (4H, q, J = 7.1 Hz, H6), 1.13 (6H, 
t, J = 7.1 Hz, H7); HPLC-MS, ESI
+/APCI+: m/z [M + H]+ = 333.1, 
calculated exact mass = 332.1204, tr = 2.5 min. 
 
N-(4-(6-Chloroimidazo[1,2-b]pyridazin-3-yl)-2-fluorobenzyl)-N-ethylethanamine (4f) 
Purified by flash chromatography (0 – 3% CH3OH/DCM). Yellow 
crystalline solid (0.135 g, 37%); 1H-NMR δH (300 MHz; CDCl3) 
8.10 (1H, s, H1), 7.98 (1H, d, J = 9.4 Hz, H8), 7.89 – 7.77 (2H, m, 
H2, H7), 7.66 (1H, t, J = 7.9 Hz, H3), 7.12 (1H, d, J = 9.4 Hz, H9), 





Purified by flash chromatography (0 – 4% CH3OH/DCM). 
Yellow oil (0.182 g, 50%); 1H-NMR δH (300 MHz; CDCl3) 8.24 
(1H, s, H1), 8.09 (1H, s, H2), 7.98 (1H, d, J = 9.4 Hz, H8), 7.95 - 
7.91 (1H, m, H3), 7.26 – 7.16 (1H, m, H4), 7.10 (1H, d, J = 9.4 Hz, 
H9), 3.86 (2H, s, H5), 2.73 (4H, d, J = 6.5 Hz, H6), 1.21 (6H, t, J 
= 6.5 Hz, H7); HPLC-MS, ESI
+/APCI+: m/z [M + H]+ = 333.1, 
calculated exact mass = 332.1204, tr = 2.8 min. 
 
6.1.2.4 General Procedure for Synthesis of Diarylated Imidazopyridazines (19, 26 – 34, 
51 – 54 and 58) 
A suspension of the relevant chloro-substituted intermediate (4a – g) (1.0 eq), appropriate 
boronic acid or boronic acid pinacol ester (1.1 eq) and Pd(PPh3)2Cl2 (0.05 eq) in DMF (3 
mL/mmol of 4a – g) was purged with nitrogen for 20 minutes. A 1 M aqueous solution of 
K2CO3 (1.05 eq) was then added after which the reaction mixture was heated to 100 °C and 
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with DCM, washed with deionized water (8 ×), saturated aqueous solutions of NaHCO3 (3 ×), 
NH4Cl (3 ×) and NaCl (1 ×). For analogues 28 – 34, with basic side chains, washing with 
NH4Cl (aq) was avoided. The organic layer was dried (MgSO4 for 19 and 28 - 34; Na2SO4 for 
26, 27 and 51 – 54) after which the solvent was removed in vacuo and the resulting crude 
mixture subjected to further purification procedures. 
 
6-(4-(Methylsulfinyl)phenyl)-3-(4-(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazine (26) 
Purified by prep-TLC (developed in 4% CH3OH/DCM) and 
trituration in ethyl acetate. Yellow solid (0.0683 g, 57%), m.p. 
236.6 – 239.0 °C; Rf (CH3OH : CH2Cl2 4 : 96) 0.18; 1H-NMR 
δH (400 MHz; CDCl3) 8.41 (2H, d, J = 8.8 Hz, H2), 8.27 (1H, s, 
H1), 8.24 (1H, d, J = 9.5 Hz, H5), 8.19 (2H, d, J = 8.7 Hz, H7), 
8.13 (2H, d, J = 8.8 Hz, H3), 7.88 (2H, d, J = 8.7 Hz, H8), 7.70 
(1H, d, J = 9.5 Hz, H6), 3.15 (3H, s, H4), 2.84 (3H, s, H9); 
13C-NMR δC (101 MHz; CDCl3) 
151.23, 148.38, 140.09, 139.43, 137.92, 134.52, 133.74, 128.08 (3C), 127.97 (2C), 127.05 
(2C), 126.65, 124.49 (2C), 116.66, 44.58, 44.00; HPLC-MS, APCI+: m/z [M + H]+ = 412.0, 
calculated exact mass = 411.0711, purity: 98.8%, tr = 2.518 min. 
 
3-(4-(Methylsulfinyl)phenyl)-6-(4-(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazine (27) 
Purified by prep-TLC (developed in 4% CH3OH/DCM). Yellow 
solid (0.067 g, 60%), m.p. 260.0 – 262.5 °C; Rf (CH3OH : CH2Cl2 
4 : 96) 0.33; 1H-NMR δH (400 MHz; CDCl3) 8.34 (3H, m, H5, H7), 
8.23 (3H, m, H3, H6), 8.16 (2H, d, J = 8.0 Hz, H2), 7.85 (2H, d, J 
= 7.7 Hz, H8), 7.65 (1H, s, H1), 3.15 (3H, s, H9), 2.84 (3H, s, H4); 
13C-NMR δC (101 MHz; CDCl3) 150.25, 145.50, 142.06, 140.63, 
131.18, 128.31 (4C), 128.09 (3C), 127.49 (2C), 126.74, 124.15 (2C), 115.95, 44.50, 44.04; 
HPLC-MS, APCI+: m/z [M + H]+ = 412.0, calculated exact mass = 411.0711, purity: 97.5%, tr 









Purified by flash chromatography (0 – 4% CH3OH/DCM) and 
trituration in diethyl ether. Yellow solid (0.128 g, 59%), m.p. 
110.7 – 113.0 °C; Rf (CH3OH : CH2Cl2 6 : 94) 0.32; 
1H-NMR 
δH (300 MHz; CDCl3) 8.35 (2H, d, J = 8.3 Hz, H2), 8.20 (1H, 
s, H1), 8.11 (1H, d, J = 9.0 Hz, H5), 7.94 – 7.75 (3H, m, H3, 
H7), 7.62 (1H, d, J = 9.2 Hz, H6), 7.46 – 7.34 (2H, m, H8, H9), 
3.76 (2H, s, H10), 2.81 (3H, s, H4), 2.70 (4H, br s, H11), 1.17 (6H, t, J = 6.8 Hz, H12); 
13C-NMR 
δC (100.6 MHz; CDCl3) 162.1, 159.4, 148.8, 144.8, 134.1, 131.6, 130.5, 127.3 (4C), 125.8 
(2C), 124.0 (3C), 119.0, 117.4, 56.6, 46.9 (2C), 44.0, 11.2 (2C); HPLC-MS, ESI+/APCI+: m/z 




Purified by flash chromatography (0 – 4% CH3OH/DCM), 
trituration in diethyl ether. Yellow solid (0.112 g, 57%), m.p. 
162.0 – 165.0 °C; Rf (CH3OH : CH2Cl2 6 : 94) 0.23; 
1H-NMR 
δH (300 MHz; CDCl3) 8.35 (2H, d, J = 8.4 Hz, H2), 8.20 (1H, s, 
H1), 8.14 (1H, d, J = 9.4 Hz, H5), 7.98 – 7.78 (4H, m, H3, H7, 
H8), 7.74 (1H, d, J = 11.4 Hz, H9), 7.58 (1H, d, J = 9.4 Hz, H6), 
3.89 (2H, s, H10), 3.50 (4H, q, J = 7.0 Hz, H11), 2.83 (3H, s, H4), 1.23 (6H, t, J = 7.0 Hz, H12); 
13C-NMR δC (101 MHz; CDCl3) 162.9, 160.5, 145.0, 140.0, 134.4 (2C), 132.9, 131.4, 127.9, 
127.4 (2C), 126.5, 124.1 (2C), 122.9, 115.7 (2C), 114.0 (d, J = 24.4 Hz), 65.8 (2C), 46.8, 44.0, 
15.2 (2C); HPLC-MS, ESI+/APCI+: m/z [M + H]+ = 437.2, calculated exact mass = 436.1733, 









Purified by flash chromatography (0 – 4% CH3OH/DCM), 
trituration in diethyl ether. Yellow solid (0.243 g, 80%), m.p. 
122.4 – 124.5 °C; Rf (CH3OH : CH2Cl2 6 : 94) 0.33; 
1H-NMR δH 
(300 MHz; CDCl3) 8.37 (2H, d, J = 8.6 Hz, H2), 8.23 (1H, d, J = 
6.6 Hz, H9), 8.17 (1H, s, H1), 8.11 (1H, d, J = 9.5 Hz, H5), 7.98 
– 7.87 (1H, m, H7), 7.80 (2H, d, J = 8.6 Hz, H3), 7.63 (1H, d, J = 
9.4 Hz, H6), 7.25 – 7.15 (1H, m, H8), 3.78 (2H, s, H10), 2.81 (3H, s, H4), 2.67 (4H, q, J = 7.1 
Hz, H11), 1.14 (6H, t, J = 7.1 Hz, H12); HPLC-MS, ESI
+/APCI+: m/z [M + H]+ = 437.1, 




Purified by flash chromatography (0 – 1% CH3OH/DCM), 
trituration in methanol. Yellow solid (0.0627 g, 13%), m.p. 
183.0 – 186.0 °C; Rf (CH3OH : CH2Cl2 6 : 94) 0.28; 
1H-NMR 
δH (400 MHz; CDCl3) 8.41 (2H, d, J = 8.8 Hz, H3), 8.23 (1H, 
s, H1), 8.15 (1H, d, J = 9.5 Hz, H5), 8.12 (2H, d, J = 8.7 Hz, 
H2), 7.79 (2H, m, H7, H8), 7.71 (1H, d, J = 10.9 Hz, H9), 7.61 
(1H, d, J = 9.5 Hz, H6), 3.82 (2H, s, H10), 3.15 (3H, s, H4), 2.70 (4H, br d, J = 6.6 Hz, H11), 
1.17 (6H, t, J = 7.1 Hz, H12); 
13C-NMR δC (100.6 MHz; CDCl3) 162.9, 160.4, 150.9, 140.4, 
139.2, 134.9, 134.0, 132.4, 127.9 (4C), 126.9 (2C), 126.6, 122.7, 116.3, 113.8 (d, J = 24.7 Hz), 
49.6, 47.0 (2C), 44.6, 11.4 (2C); HPLC-MS, ESI+/APCI+: m/z [M + H]+ = 453.1, calculated 




Purified by prep-TLC (developed in 6% CH3OH/DCM). Yellow 
oil (0.0483 g, 38%); Rf (CH3OH : CH2Cl2 6 : 94) 0.26; 
1H-NMR 
δH (300 MHz; CDCl3) 8.51 (1H, t, J = 7.7 Hz, H11), 8.30 (1H, s, 
H13), 8.26 (1H, s, H1), 8.21 – 8.13 (2H, m, H2, H8), 7.82 – 7.71 
(3H, m, H3, H10, H12), 7.67 (1H, d, J = 9.5 Hz, H9), 7.61 (1H, d, J 
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H14), 1.44 (6H, t, J = 6.6 Hz, H7); 
13C-NMR δC (100.6; CDCl3) 160.8, 158.3, 150.6, 147.2, 
139.5, 137.1, 136.8, 130.2, 129.8, 129.6 (2C), 126.5 (3C), 125.0, 122.1, 118.2, 116.0, 55.5, 
46.2 (2C), 44.2, 9.0 (2C); HPLC-MS, ESI+/APCI+: m/z [M + H]+ = 437.2, calculated exact 




Purified by flash chromatography (0 – 4% CH3OH/DCM), prep-
TLC (silica, developed in 10% CH3OH/DCM). Yellow oil 
(0.0484 g, 27%); Rf (CH3OH : CH2Cl2 6 : 94) 0.15; 
1H-NMR δH 
(300 MHz; CDCl3) 8.30 (1H, s, H13), 8.25 – 8.09 (3H, m, H1, H8, 
H10), 8.01 (1H, d, J = 11.6 Hz, H4), 7.90 (1H, d, J = 8.0 Hz, H3), 
7.85 – 7.60 (4H, m, H2, H9, H11, H12), 3.81 (2H, s, H5), 2.84 (3H, 
s, H14), 2.70 (4H, br d, J = 7.1 Hz, H6), 1.17 (6H, t, J = 7.0 Hz, H7); 
13C-NMR δC (100.6 MHz; 
CDCl3) 162.7, 160.2, 150.6, 147.3, 139.9, 137.1, 134.3, 132.6, 130.3, 129.6, 127.3, 126.6, 
125.0 (2C), 122.5, 122.1, 115.6, 113.1 (d, J = 25.4 Hz), 49.3, 46.6 (2C), 44.1, 15.2 (2C); HPLC-





Purified by prep-TLC (developed in 6% CH3OH/DCM). 
Yellow oil (0.101 g, 42%); Rf (CH3OH : CH2Cl2 6 : 94) 0.21; 
1H-NMR δH (300 MHz; CDCl3) 8.39 – 8.29 (2H, m, H2, H10), 
8.25 (1H, dt, J = 7.4, 1.6 Hz, H12), 8.16 – 8.07 (2H, m, H1, H8), 
8.00 (1H, ddd, J = 8.4, 4.9, 2.4 Hz, H3), 7.80 – 7.66 (2H, m, H11, 
H13), 7.61 (1H, d, J = 9.5 Hz, H9), 7.25 – 7.15 (1H, m, H4), 3.80 
(2H, s, H5), 2.82 (3H, s, H14), 2.68 (4H, q, J = 7.1 Hz, H6), 1.12 (6H, t, J = 7.1 Hz, H7); 
13C-
NMR δC (100.6 MHz; CDCl3) 162.2, 159.8, 150.3, 147.1, 139.3, 137.3, 133.6, 130.1 (2C), 
129.6, 128.3, 127.2, 126.4, 124.8, 124.6, 122.1, 115.6 (d, J = 22.9 Hz), 115.0, 49.9, 47.0 (2C), 
44.1, 11.6 (2C); HPLC-MS, ESI+/APCI+: m/z [M + H]+ = 437.2, calculated exact mass = 








Purified by prep-TLC (developed in 4% CH3OH/DCM). 
Yellow solid (0.0223 g, 20%), m.p. 264.0 – 267.5 °C; Rf 
(CH3OH : CH2Cl2 4 : 96) 0.38; 
1H-NMR δH (400 MHz; 
DMSO-d6) 9.12 – 9.08 (1H, m, H2), 8.56 (1H, s, H1), 8.53 
(1H, d, J = 8.0 Hz, H3), 8.50 (2H, d, J = 8.4 Hz, H9), 8.45 
(1H, d, J = 9.6 Hz, H7), 8.13 (2H, d, J = 8.5 Hz, H10), 8.09 (1H, d, J = 9.6 Hz, H8), 8.00 – 7.96 
(1H, m, H5), 7.86 (1H, t, J = 7.9 Hz, H4), 3.33 (6H, s, H6, H11); 
13C-NMR δC (101 MHz; DMSO-
d6) 150.20, 142.63, 142.04, 140.26, 140.07, 135.36, 131.32, 130.51, 129.90, 128.49 (2C), 
128.17 (2C), 127.33, 126.10, 126.38, 124.60, 116.99, 44.08, 43.90; HPLC-MS, APCI+: m/z [M 
+ H]+ = 428.0, calculated exact mass = 427.0660, purity: 95.8%, tr = 2.588 min. 
 
6-(4-(Methylsulfinyl)phenyl)-3-(3-(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazine (52) 
Purified by prep-TLC (developed in 4% CH3OH/DCM). 
Crystallized in diethyl ether. Yellow solid (0.0441 g, 
45%), m.p. 218.6 – 221.0 °C; Rf (CH3OH : CH2Cl2 4 : 96) 
0.32; 1H-NMR δH (400 MHz; CDCl3) 9.09 (1H, d, J = 1.9 
Hz, H2), 8.35 (1H, d, J = 7.9 Hz, H6), 8.33 – 8.19 (4H, m, 
H1, H7, H9), 8.03 – 7.97 (1H, m, H4), 7.88 (2H, d, J = 8.1 Hz, H10), 7.81 – 7.68 (2H, m, H5, H8), 
3.16 (3H, s, H3), 2.83 (3H, s, H11);
 13C-NMR δC (101 MHz; CDCl3) 150.81, 148.32, 141.42, 
137.76, 131.20, 130.03, 129.88, 128.01 (4C), 126.63, 126.37, 125.34, 124.48 (3C), 116.07, 
44.58, 43.94; HPLC-MS, APCI+: m/z [M + H]+ = 412.0, calculated exact mass = 411.0711, 
purity: 97.9%, tr = 2.619 min. 
 
3-(3-(Methylsulfinyl)phenyl)-6-(4-(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazine (53) 
Purified by prep-TLC (developed in 4% CH3OH/DCM). 
Crystallized in diethyl ether. Yellow solid (0.0436 g, 
37%), m.p. 218.0 – 221.5 °C; Rf (CH3OH : CH2Cl2 4 : 96) 
0.29; 1H-NMR δH (400 MHz; CDCl3) 8.72 (1H, d, J = 1.7 
Hz, H2), 8.34 – 8.25 (4H, m, H1, H7, H9), 8.23 (1H, d, J = 
7.9 Hz, H3), 8.17 (2H, d, J = 8.4 Hz, H10), 7.75 – 7.66 (2H, m, H4, H8), 7.63 (1H, dt, J = 8.0, 
1.2 Hz, H5), 3.15 (3H, s, H11), 2.84 (3H, s, H6); 
13C-NMR δC (101 MHz; CDCl3) 150.22, 149.15, 
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123.00, 121.56, 115.90, 44.48, 44.18; HPLC-MS, APCI+: m/z [M + H]+ = 412.0, calculated 
exact mass = 411.0711, purity: 99.6%, tr = 2.578 min. 
 
3-(3-(Methylsulfinyl)phenyl)-6-(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazine (54) 
Purified by prep-TLC (developed in 4% CH3OH/DCM). 
Crystallized in diethyl ether. Yellow solid (0.0666 g, 58%), 
m.p. 174.0 – 176.2 °C; Rf (CH3OH : CH2Cl2 4 : 96) 0.14; 
1H-NMR δH (400 MHz; CDCl3) 8.74 – 8.68 (1H, m, H3), 
8.30 – 8.18 (5H, m, H1, H2, H7, H10), 7.87 (2H, d, J = 8.8 
Hz, H9), 7.74 – 7.66 (2H, m, H4, H8), 7.66 – 7.62 (1H, m, H5), 2.84 (3H, s, H6), 2.83 (3H, s, 
H11); 
13C-NMR δC (101 MHz; CDCl3) 150.82, 148.20, 146.80, 137.97, 133.59, 129.90, 129.68 
(2C), 128.91, 128.06 (3C), 126.47, 124.43 (2C), 122.86, 121.53, 115.96, 44.15, 43.95; HPLC-




Purified by flash chromatography (0 – 5% CH3OH/DCM). 
Crystallized in diethylether. Yellow solid (0.5453g, 51%); 1H-NMR 
δH (300 MHz; CDCl3) 8.37 – 8.32 (3H, m, H2, H10), 8.28 (1H, d, J = 
9.5 Hz, H5), 8.24 – 8.18 (2H, m, H1, H7), 7.85 (2H, d, J = 8.7 Hz, H3), 
7.79 – 7.72 (3H, m, H6, H8, H9), 2.84 (6H, m, H4, H11); HPLC-MS, 
APCI+: m/z [M + H]+ = 396.0, calculated exact mass = 395.0762, 
purity: 99.9%, tr = 2.601 min. 
 
6.1.2.5 Procedure for Synthesis of 2-fluoro-5-nitrobenzyl 4-methylbenzenesulfonate (5b)2 
To a solution of NaOH (0.534 g, 13 mmol) in 3.8 mL deionized 
water cooled to ~ 0 °C was added a solution of 2-fluoro-5-
nitrobenzyl alcohol (5a) (1.00 g, 5.8 mmol) in tetrahydrofuran 
(THF) (17 mL). p-Toluenesulfonyl chloride (1.89 g, 9.9 mmol) 
dissolved in THF (5.0 mL) was then added dropwise. The 
reaction mixture was left to stir at 0 – 11 °C for 2 hours. After completion of reaction as 
signalled by TLC (ionisation not observed on HPLC-MS), the reaction mixture was diluted 
with deionized water (50 mL) and extracted with DCM (100 mL × 3). The organic layer was 
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crystallized and purified by trituration in methanol to afford 5b as a cream white solid (1.25 g, 
66%); 1H-NMR δH (300 MHz; CDCl3) 8.29 – 8.16 (2H, m, H6, H7), 7.84 (2H, d, J = 8.4 Hz, 
H2), 7.38 (2H, d, J = 8.0 Hz, H1), 7.22 (1H, t, J = 8.7 Hz, H5), 5.20 (2H, s, H4), 2.48 (3H, s, 
H3). 
 
6.1.2.6 Procedure for Synthesis of N-ethyl-N-(2-fluoro-5-nitrobenzyl)ethanamine (5c)2 
Diethylamine (0.600 mL, 5.9 mmol) and triethylamine (0.800 mL, 5.9 
mmol) were added to a solution of 2-fluoro-5-nitrobenzyl 4-
methylbenzenesulfonate (5b) (1.28 g, 3.9 mmol) in anhydrous 1,4-
dioxane (7.8 mL). The reaction mixture was heated to 55 °C and stirred 
for 5 hours. The solvent was removed in vacuo and the resulting 
yellowish residue taken up in DCM (150 mL) before washing with deionized water (60 mL × 
1), and saturated aqueous solution of NaCl (50 mL × 1). The organic layer was dried (MgSO4) 
before removing the solvent in vacuo to give 5c as a yellow oil (0.771 g, 87%); 1H-NMR δH 
(300 MHz; CDCl3) 8.48 (1H, dd, J = 6.2, 2.9 Hz, H4), 8.14 (1H, ddd, J = 9.0, 4.4, 3.0 Hz, H5), 
7.17 (1H, t, J = 8.9 Hz, H6), 3.71 (2H, s, H3), 2.62 (4H, q, J = 7.1 Hz, H2), 1.10 (6H, t, J = 7.1 
Hz, H1). 
 
6.1.2.7 Procedure for Synthesis of 3-((diethylamino)methyl)-4-fluoroaniline (5d)2 
A solution of stannous chloride (SnCl2) (2.58 g, 13.6 mmol) in 1 M 
aqueous HCl (10.2 mL, 10.2 mmol) was added to a suspension of N-
ethyl-N-(2-fluoro-5-nitrobenzyl)ethanamine (5c) (0.771 g, 3.4 mmol) in 
15 mL THF. The reaction mixture was refluxed at 66 °C for 29 hours. 
THF was removed in vacuo where after the pH of the remaining 
aqueous mixture was adjusted to ~ 8 by gradual addition of saturated aqueous NaHCO3. The 
resulting turbidy emulsion was extracted with DCM (150 mL × 6). The combined organic 
layers were dried (MgSO4) after which the solvent was removed in vacuo to obtain the aniline 
compound 5d as a yellow oil (0.661 g, quantitative); 1H-NMR δH (300 MHz; CDCl3) 6.86 – 
6.78 (2H, m, H4, H6), 6.53 (1H, ddd, J = 8.6, 4.1, 3.0 Hz, H5), 3.58 (2H, s, H3), 2.59 (4H, q, J 
= 7.1 Hz, H2), 1.09 (6H, t, J = 7.1 Hz, H1); HPLC-MS, ESI
+/APCI+: m/z [M + H]+ = 197.1, 
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6.1.2.8 Procedure for Synthesis of N-(4-hydroxyphenyl)acetamide (5f)  
A solution of 4-aminophenol 5e (1.50 g, 13.7 mmol) and acetic anhydride (1.30 
mL, 13.7 mmol) in THF (20 mL) was refluxed at 60 °C for 1.75 hours. The 
solvent was then removed in vacuo and the resulting brown residue purified by 
trituration in diethyl ether for 30 minutes to give the acetylated compound, 5f, as 
a cream white solid (1.81 g, 87%); 1H-NMR δH (300 MHz; CD3OD) 7.31 (2H, d, 
J = 9.0 Hz, H2), 6.74 (2H, d, J = 9.1 Hz, H3), 2.10 (3H, s, H1); HPLC-MS, 
ESI+/APCI+: m/z [M + H]+ = 152.1, calculated exact mass = 151.0633, tr = 1.0 min. 
 
6.1.2.9 Procedure for Synthesis of N-(3-((diethylamino)methyl)-4-
hydroxyphenyl)acetamide (5g) 
Diethylamine (0.800 mL, 7.94 mmol) and 37% aqueous formaldehyde 
(0.600 mL, 7.94 mmol) were added to a solution of N-(4-
hydroxyphenyl)acetamide (5f) (0.600 g, 3.97 mmol) in 5.0 mL absolute 
ethanol. The reaction mixture was heated to 80 °C under microwave 
irradiation for 1.5 hours after which the solvent was removed in vacuo. 
The brown residue was taken up in 40 mL DCM and extracted with 1 
M HCl (35 mL × 1). The pH of the acidic aqueous layer was then adjusted to ~ 12 by gradual 
addition of a saturated aqueous solution of NaOH. The resultant basic mixture was then 
extracted with DCM (50 mL × 3). The combined organic layers were dried (MgSO4) before 
removing the solvent in vacuo to afford 5g as a brown oil, which subsequently crystallized 
upon standing (0.987 g, quantitative); 1H-NMR δH (300 MHz; CDCl3) 7.35 (1H, d, J = 2.4 Hz, 
H5), 7.15 (1H, br s, H2), 7.07 (1H, dd, J = 8.5, 2.6 Hz, H3), 6.76 (1H, d, J = 8.6 Hz, H4), 3.77 
(2H, s, H6), 2.64 (4H, q, J = 7.2 Hz, H7), 2.15 (3H, s, H1), 1.12 (6H, t, J = 7.2 Hz, H8); HPLC-
MS, ESI+/APCI+: m/z [M + H]+ = 237.2, calculated exact mass = 236.1525, tr = 0.58 min. 
 
6.1.2.10 Procedure for Synthesis of 4-amino-2-((diethylamino)methyl)phenol (5h) 
N-(3-((Diethylamino)methyl)-4-hydroxyphenyl)acetamide (5g) (0.987 g, 
4.18 mmol) was refluxed at 80 °C in 6 M aqueous HCl (4.20 mL , 25.1 
mmol) for 2 hours. The reaction mixture was left to cool to room 
temperature before adjusting the pH to ~ 8 by gradual addition of a saturated 
aqueous solution of NaHCO3. The black solution obtained was extracted 
with DCM (100 mL × 5). The combined organic layers were dried (MgSO4), 
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chromatography on silica (4% CH3OH/DCM) to give the phenolic compound 5h as a brown 
oil (0.352 g, 43%); 1H-NMR δH (300 MHz; CDCl3) 6.67 (1H, d, J = 8.4 Hz, H3), 6.56 (1H, dd, 
J = 8.4, 2.8 Hz, H2), 6.41 (1H, d, J = 2.7 Hz, H1),  3.70 (2H, s, H4), 2.64 (4H, q, J = 7.2 Hz, 
H5), 1.12 (6H, t, J = 7.2 Hz, H6); HPLC-MS, ESI
+/APCI+: m/z [M + H]+ = 195.2, calculated 
exact mass = 194.1419, tr = 0.57 min. 
 
6.1.2.11 Procedure for Synthesis of 3-(4-(methylsulfinyl)phenyl)-N-(3-
(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazin-6-amine (36)3–6 
A mixture of 6-chloro-3-(4-
(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazine (4a) 
(0.100 g, 0.34 mmol), 3-(methylsulfonyl)aniline (0.0640 g, 
0.37 mmol), Pd2(dba)3 (0.0249 g, 0.027 mmol), BrettPhos 
(0.0219 g, 0.041 mmol) and Cs2CO3 (0.222 g, 0.68 mmol) in 
1.5 mL anhydrous 1,4-dioxane in a sealed tube was flashed 
with nitrogen for 25 minutes. The reaction mixture was then heated to 120 °C and stirred at 
this temperature for 24 hours. The solvent was removed in vacuo and the resulting black residue 
taken up in DCM (50 mL), washed with deionized water (30 mL × 1), saturated aqueous 
solutions of NaHCO3 (30 mL × 2) and NaCl (30 mL × 1). The organic layer was dried (MgSO4), 
after which the solvent was removed in vacuo. The yellowish residue was then subjected to 
prep-TLC (developed in 5% CH3OH/DCM) to afford 36 as a brown solid (0.0228 g, 16%); Rf 
(CH3OH : CH2Cl2 6 : 94) 0.24; 
1H-NMR δH (400 MHz; DMSO-d6) 9.89 (1H, s, H7), 8.32 – 
8.24 (3H, m, H2, H8), 8.10 – 8.02 (2H, m, H1, H5), 7.99 (1H, dd, J = 8.2, 1.2 Hz, H9), 7.85 (2H, 
d, J = 8.5 Hz, H3), 7.66 (1H, t, J = 7.9 Hz, H10), 7.57 (1H, d, J = 7.8 Hz, H11), 7.03 (1H, d, J = 
9.7 Hz, H6), 3.19 (3H, s, H12), 2.81 (3H, s, H4); 
13C-NMR δC (101 MHz; DMSO-d6) 151.01, 
145.41, 142.07, 141.40, 138.32, 132.42, 131.55, 130.59, 127.51, 127.36, 127.25 (2C), 124.77 
(2C), 123.68, 120.34, 116.42, 113.82, 44.10, 43.72; HPLC-MS, APCI+: m/z [M + H]+ = 427.0, 
calculated exact mass = 426.0820, purity: 99.9%, tr = 2.635 min. 
 
6.1.2.12 General Procedure for Synthesis of Aminated Analogues (37, 38, 40 and 43)3–6  
A suspension of 6-chloro-3-(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazine (4a) (1.0 eq), 
an appropriate amine (1.1 eq), Pd2(dba)3 (0.08 eq), XPhos (0.12 eq) and sodium tert-butoxide 
(2.0 eq) in anhydrous 1,4-dioxane (6.0 mL/mmol of 4a) in a sealed tube was flashed with 
nitrogen for 20 minutes. The reaction mixture was then heated to 120 °C and stirred for 6 - 20 
hours. The solvent was removed in vacuo after which the resulting residue was taken up in 
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DCM, washed with saturated aqueous solutions of NaHCO3 (2 ×) and NaCl (2 ×). The organic 
layer was dried (MgSO4) (Na2SO4 for 38), where after the solvent was removed in vacuo and 




Purified by prep-TLC (developed twice in 6% 
CH3OH/DCM). Brown solid (0.0175 g, 18%); Rf (CH3OH : 
CH2Cl2 6 : 94) 0.19; 
1H-NMR δH (400 MHz; DMSO-d6) 
9.81 (1H, s, H7), 8.28 (2H, d, J = 8.5 Hz, H2), 8.11 (1H, s, 
H11), 8.05 (1H, s, H1), 8.03 (1H, d, J = 9.7 Hz, H5), 7.85 (2H, 
d, J = 8.5 Hz, H3), 7.77 (1H, dd, J = 8.1, 1.3 Hz, H8), 7.57 
(1H, t, J = 7.9 Hz, H9), 7.31 (1H, d, J = 7.7 Hz, H10), 7.02 (1H, d, J = 9.7 Hz, H6), 2.82 (3H, s, 
H4), 2.73 (3H, s, H12); 
13C-NMR δC (101 MHz; DMSO-d6) 151.09, 147.73, 145.44, 141.43, 
138.21, 132.23, 131.62, 130.32, 127.41 (2C), 127.34 (2C), 124.69 (2C), 121.14, 117.01, 
113.89, 113.50, 43.83, 43.73; HPLC-MS, APCI+: m/z [M + H]+ = 411.0, calculated exact mass 
= 410.0871, purity: 98.9%, tr = 2.636 min. 
 
N,3-Bis(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-amine (38) 
Purified by prep-TLC (developed once in 6% CH3OH/DCM, 
then once in 7% CH3OH/DCM), trituration in ethyl acetate 
for 20 h. Grey solid (0.0111 g, 8%); Rf (CH3OH : CH2Cl2 4 
: 96) 0.045; 1H-NMR δH (400 MHz; DMSO-d6) 9.84 (1H, s, 
H7), 8.31 (2H, d, J = 8.5 Hz, H2), 8.07 (1H, s, H1), 8.03 (1H, 
d, J = 9.7 Hz, H5), 7.91 (2H, d, J = 8.7 Hz, H9), 7.86 (2H, d, 
J = 8.5 Hz, H3), 7.70 (2H, d, J = 8.7 Hz, H8), 7.04 (1H, d, J = 9.7 Hz, H6), 2.83 (3H, s, H4), 
2.75 (3H, s, H10); 
13C-NMR δC (101 MHz; DMSO-d6) 150.98, 145.52, 142.95, 138.55, 138.18, 
132.22, 131.59, 127.29 (2C), 127.18, 126.80, 125.30 (2C), 124.53 (2C), 119.27 (2C), 113.89, 
43.70 (2C); HPLC-MS, APCI+: m/z [M + H]+ = 411.1, calculated exact mass = 410.0871, 











Purified by prep-TLC (developed in 5% CH3OH/DCM). Light 
yellow solid (0.0242 g, 29%); Rf (CH3OH : CH2Cl2 6 : 94) 0.3; 
1H-NMR δH (400 MHz; DMSO-d6) 10.43 (1H, s, H7), 9.23 (1H, 
d, J = 1.3 Hz, H8), 8.38 (1H, dd, J = 2.6, 1.5 Hz, H9), 8.35 (2H, 
d, J = 8.5 Hz, H2), 8.26 (1H, d, J = 2.6 Hz, H10), 8.16 – 8.09 (2H, 
m, H1, H5), 7.83 (2H, d, J = 8.5 Hz, H3), 7.43 (1H, d, J = 9.7 Hz, 
H6), 2.82 (3H, s, H4); 
13C-NMR δC (101 MHz; DMSO-d6) 150.20, 149.95, 145.70, 142.75, 
138.50, 137.91, 135.82, 132.81, 131.46, 127.50, 127.35 (2C), 127.09, 124.45 (2C), 113.48, 
43.68; HPLC-MS, APCI+: m/z [M + H]+ = 351.1, calculated exact mass = 350.0950, purity: 




Purified by prep-TLC (developed once in 4% CH3OH/DCM, 
then twice in 5% CH3OH/DCM). Brown solid (0.022 g, 
30%); Rf (CH3OH : CH2Cl2 6 : 94) 0.36; 
1H-NMR δH (400 
MHz; DMSO-d6) 8.41 (2H, d, J = 8.6 Hz, H2), 8.04 (1H, s, 
H1), 7.87 – 7.74 (3H, m, H3, H5), 7.16 (1H, d, J = 6.5 Hz, 
H7), 6.76 (1H, d, J = 9.7 Hz, H6), 3.90 – 3.75 (1H, m, H8), 
3.68 – 3.55 (2H, m, H10e), 3.07 – 2.97 (2H, m, H10a), 2.94 (3H, s, H11), 2.80 (3H, s, H4), 2.26 – 
2.13 (2H, m, H9e), 1.69 – 1.52 (2H, m, H9a); 
13C-NMR δC (101 MHz; DMSO-d6) 153.21, 
144.72, 138.10, 132.18, 131.40, 126.38, 126.27 (2C), 126.12, 124.54 (2C), 113.10, 48.00, 
44.76 (2C), 43.62, 35.15, 30.82 (2C); HPLC-MS, APCI+: m/z [M + H]+ = 434.1, calculated 
exact mass = 433.1242, purity: 98.6%, tr = 2.488 min. 
 
6.1.2.13 Procedure for Synthesis of 3-(4-(methylsulfinyl)phenyl)-N-(4-
(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazin-6-amine (39)3–6 
A mixture of 6-chloro-3-(4-
(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazine (4a) (0.130 
g, 0.45 mmol), 4-(methylsulfonyl)aniline (0.0925 g, 0.54 
mmol), Pd2(dba)3 (0.020 g, 0.022 mmol), (R)-BINAP (0.0168 
g, 0.027 mmol) and K2CO3 (1.24 g, 9.00 mmol) in 1.8 mL 
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stirred at this temperature for 17 hours. However, no significant amount of product was 
detected on HPLC-MS. At this point, anhydrous 1,4-dioxane (3.5 mL) was added and the 
reaction mixture stirred for another 17 hours where after a significant formation of the product 
was observed on HPLC-MS. The reaction mixture was then diluted with deionised water (40 
mL) followed by extraction with DCM (70 mL). The solvents were removed in vacuo and the 
resulting residue taken up in DCM (70 mL), washed with a saturated aqueous solution of NaCl 
(40 mL × 3) and dried (MgSO4). The solvent was then removed in vacuo. The obtained crude 
mixture was subjected to prep-TLC (developed in 5.5% CH3OH/DCM) to afford the aminated 
target compound 39 as a brown solid (0.0251 g, 13%), m.p. 296.7 – 299.2 °C; Rf (CH3OH : 
CH2Cl2 6 : 94) 0.25; 
1H-NMR δH (300 MHz; DMSO-d6) 10.05 (1H, s, H7), 8.30 (2H, d, J = 8.5 
Hz, H2), 8.13 – 8.04 (2H, m, H1, H5), 7.98 – 7.86 (6H, m, H3, H8, H9), 7.07 (1H, d, J = 9.7 Hz, 
H6), 3.19 (3H, s, H10), 2.84 (3H, s, H4); 
13C-NMR δC (100.6 MHz; DMSO-d6) 150.7, 145.8, 
145.2, 138.3, 135.9, 133.3, 132.5, 131.5, 128.8 (2C), 127.6, 127.4 (2C), 124.6 (2C), 118.4 (2C), 
113.9, 44.5, 43.7; HPLC-MS, ESI+/APCI+: m/z [M + H]+ = 427.0, calculated exact mass = 
426.0820, purity: 98.0%, tr = 2.650 min. 
 
6.1.2.14 Procedure for Synthesis of 4-((3-(4-(methylsulfinyl)phenyl)imidazo[1,2-
b]pyridazin-6-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide (41)3–6 
A suspension of 6-chloro-3-(4-
(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazine (4a) (0.0700 
g, 0.24 mmol), 4-aminotetrahydro-2H-thiopyran 1,1-dioxide 
hydrochloride (0.0483 g, 0.26 mmol), Pd2(dba)3 (0.0176 g, 
0.019 mmol), XPhos (0.0137 g, 0.029 mmol), sodium tert-
butoxide (0.0461 g, 0.48 mmol) and triethylamine (TEA) (0.2 
mL, 0.96 mmol) in 1.5 mL anhydrous 1,4-dioxane in a sealed tube was flashed with nitrogen 
for 30 minutes. The reaction mixture was then heated to 120 °C and stirred at this temperature 
for 17 hours. Only small quantities of the desired product were detected on HPLC-MS. At this 
point, the reaction mixture was charged with additional amounts of the amine hydrochloride 
(1.1 eq), Pd2(dba)3 (0.08 eq), TEA (8.0 eq), sodium tert-butoxide (2.0 eq) and 0.5 mL 
anhydrous 1,4-dioxane. The reaction mixture was again purged with nitrogen for 2 minutes 
after which it was heated to 120 °C and stirred for another 9 hours. The solvent was removed 
in vacuo and the resulting black residue taken up in DCM (50 mL), washed with saturated 
aqueous solutions of NaHCO3 (30 mL × 3) and NaCl (30 mL × 3). The organic layer was dried 
(MgSO4) where after the solvent was removed in vacuo. The crude mixture was then subjected 
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to prep-TLC (developed once in 5% CH3OH/DCM, then twice in 6% CH3OH/DCM) to afford 
the aminated target compound 41 as a brown solid (0.0142 g, 15%); m.p. 273.1 – 274.5 °C; Rf 
(CH3OH : CH2Cl2 6 : 94) 0.38; 
1H-NMR δH (400 MHz; DMSO-d6) 8.42 (2H, d, J = 8.5 Hz, 
H2), 8.05 (1H, s, H1), 7.87 – 7.76 (3H, m, H3, H5), 7.25 (1H, d, J = 6.7 Hz, H7), 6.74 (1H, d, J 
= 9.7 Hz, H6), 4.15 – 3.98 (1H, m, H8), 3.46 – 3.27 (2H, m, H10e), 3.25 – 3.14 (2H, m, H10a), 
2.80 (3H, s, H4), 2.48 – 2.35 (2H, m, H9e), 2.16 – 1.98 (2H, m, H9a); 
13C-NMR δC (101 MHz; 
DMSO-d6) 153.01, 144.71, 138.08, 132.05, 131.42, 126.51, 126.36 (2C), 126.18, 124.60 (2C), 
113.00, 49.06 (2C), 46.84, 43.68, 29.08 (2C); HPLC-MS, APCI+: m/z [M + H]+ = 405.1, 
calculated exact mass = 404.0977, purity: 97.2%, tr = 2.434 min. 
 
6.1.2.15 Procedure for Synthesis of N-(1-methylpiperidin-4-yl)-3-(4-
(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-amine (42)3–6 
A suspension of 6-chloro-3-(4-
(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazine (4a) (0.0700 
g, 0.24 mmol), Pd2(dba)3 (0.0176 g, 0.019 mmol), XPhos 
(0.0137 g, 0.029 mmol), and sodium tert-butoxide (0.0461 g, 
0.48 mmol) in 1.5 mL of anhydrous 1,4-dioxane in a sealed tube 
was flashed with nitrogen for 20 minutes. 4-Amino-1-
methylpiperidine (0.06 mL, 0.48 mmol) was then added and the reaction mixture heated to 100 
°C and stirred at this temperature for 22 hours. The solvent was removed in vacuo and the 
resulting black residue taken up in DCM (50 mL), washed with saturated aqueous solutions of 
NaHCO3 (30 mL × 3) and NaCl (30 mL × 3). The organic layer was dried (MgSO4) after which 
the solvent was removed in vacuo. The resulting residue was subjected to flash column 
chromatography (0 – 14% CH3OH/DCM). Further purification by prep-TLC (developed once 
in 20% CH3OH/DCM, then once in 25% CH3OH/DCM) furnished the target compound 20 as 
a brown solid (0.0121 g, 14%); Rf (CH3OH : CH2Cl2 10 : 90) 0.076; 
1H-NMR δH (400 MHz; 
DMSO-d6) 8.43 (2H, d, J = 8.6 Hz, H2), 8.02 (1H, s, H1), 7.87 – 7.66 (3H, m, H3, H5), 7.07 
(1H, d, J = 6.7 Hz, H7), 6.75 (1H, d, J = 9.7 Hz, H6), 3.75 – 3.56 (1H, m, H8), 2.92 – 2.72 (5H, 
m, H4, H10e), 2.24 (3H, s, H11), 2.19 – 2.02 (4H, m, H9e, H10a), 1.65 – 1.43 (2H, m, H9a); 
13C-
NMR δC (101 MHz; DMSO-d6) 153.28, 144.68, 138.05, 132.23, 131.26, 126.19 (3C), 125.99, 
124.30 (2C), 113.18, 54.54 (2C), 48.56, 46.36, 43.66, 31.37 (2C); HPLC-MS, APCI+: m/z [M 
+ H]+ = 370.1, calculated exact mass = 369.1623, purity: 99.9%, tr = 0.230 min. 
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6.1.2.16 Procedure for Synthesis of N-(3-((diethylamino)methyl)-4-fluorophenyl)-3-(4-
(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-amine (44)3–6 
A mixture of 6-chloro-3-(4-
(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazine (4a) 
(0.070 g, 0.24 mmol), 3-((diethylamino)methyl)-4-
fluoroaniline (0.0518 g, 0.26 mmol), Pd2(dba)3 (0.0088 g, 
0.0096 mmol), BrettPhos (0.0077 g, 0.014 mmol), and 
Cs2CO3 in anhydrous 1,4-dioxane (1.7 mL) in a sealed 
tube was flashed with nitrogen for 25 minutes. The reaction mixture was then heated to 120 °C 
and stirred for 12 hours. Significant amounts of starting material, as monitored by HPLC-MS, 
were detected. At this point, an extra 0.04 eq of Pd2(dba)3 were added and the reaction mixture 
left to stir for another 4 hours under nitrogen atmosphere. The solvent was removed in vacuo. 
The resulting dark-brown residue was taken up in 100 mL DCM, washed with deionized water 
(50 mL × 2), saturated aqueous solutions of NaHCO3 (50 mL × 2) and NaCl (50 mL × 2). After 
drying the organic layer (MgSO4), the solvent was removed in vacuo. The obtained crude 
mixture was subjected to prep-TLC (developed in 5 : 94.5 : 0.5% CH3OH/DCM/25% aq 
NH4OH). The obtained target compound, 44, was further purified by automated flash column 
chromatography (0 – 4% CH3OH/DCM) followed by trituration in diethyl ether to give the title 
compound as a yellow solid (0.0158 g, 10%); m.p. 118.0 – 120.0 °C; Rf (CH3OH : CH2Cl2 6 : 
94) 0.1; 1H-NMR δH (300 MHz; CDCl3) 8.24 (2H, d, J = 8.5 Hz, H2), 7.92 (1H, s, H1), 7.84 – 
7.63 (4H, m, H3, H5, H9), 7.58 – 7.51 (1H, m, H7), 7.33 (1H, s, H13), 7.04 (1H, t, J = 9.1 Hz, 
H8), 6.79 (1H, d, J = 9.5 Hz, H6), 3.72 (2H, s, H10), 2.81 (3H, s, H4), 2.65 (4H, q, J = 7.0 Hz, 
H11), 1.10 (6H, t, J = 7.1 Hz, H12); HPLC-MS, ESI
+/APCI+: m/z [M + H]+ = 452.2, calculated 
exact mass = 451.1842, purity: 98.0%, tr = 2.549 min. 
 
6.1.2.17 Procedure for Synthesis of 2-((diethylamino)methyl)-4-((3-(4-
(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)phenol (45)3–6 
A suspension of 6-chloro-3-(4-
(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazine (4a) 
(0.100 g, 0.34 mmol), 4-amino-2-
((diethylamino)methyl)phenol (0.0733 g, 0.38 mmol), 
Pd2(dba)3 (0.0250 g, 0.028 mmol), BrettPhos (0.0220 g, 
0.04 mmol) and Cs2CO3 (0.222 g, 0.68 mmol) in anhydrous 1,4-dioxane (1.3 mL) in a sealed 
tube was purged with nitrogen for 30 minutes. The reaction mixture was then heated to 120 °C 
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and stirred under nitrogen for 18 hours after which the solvent was removed in vacuo. The 
resulting black residue was taken up in DCM (50 mL), washed with deionized water (30 mL × 
2), saturated aqueous solutions of NaHCO3 (30 mL × 2) and NaCl (30 mL × 1). After drying 
(MgSO4) the organic layer, the solvent was removed in vacuo where after the crude mixture 
obtained was subjected to prep-TLC (developed in 8% CH3OH/DCM) to deliver the aminated 
compound, 45, as a brown solid (0.0275 g, 18%); Rf (CH3OH : CH2Cl2 8 : 92) 0.12; Rf (CH3OH 
: CH2Cl2 8 : 92) 0.12; 
1H-NMR δH (400 MHz; CD3OD) 8.32 (2H, d, J = 8.5 Hz, H2), 7.89 (1H, 
s, H1), 7.80 (2H, d, J = 8.5 Hz, H3), 7.74 (1H, d, J = 9.7 Hz, H5), 7.54 (1H, d, J = 2.5 Hz, H9), 
7.33 (1H, dd, J = 8.6, 2.7 Hz, H7), 6.91 (1H, d, J = 9.7 Hz, H6), 6.75 (1H, d, J = 8.7 Hz, H8), 
3.82 (2H, s, H10), 2.87 (3H, s, H4), 2.71 (4H, q, J = 7.1 Hz, H11), 1.15 (6H, t, J = 7.2 Hz, H12); 
13C-NMR δC (100.6; CD3OD) 153.3, 151.7, 143.3, 137.8, 132.3, 131.9, 129.9, 127.2 (2C), 
124.9, 123.8 (2C), 121.9, 120.5 (2C), 116.7, 115.5, 114.0, 56.3, 46.4 (2C), 42.3, 10.2 (2C); 
HPLC-MS, ESI+/APCI+: m/z [M + H]+ = 450.2, calculated exact mass = 449.1885, purity: 
95.0%, tr = 2.40 min. 
 
6.1.2.18 General Procedure for Synthesis of Diarylated Imidazopyridazines (25 and 50)1,7–
9 
A suspension of 6-chloro-3-iodoimidazo[1,2-b]pyridazine (3a) (1.0 eq), an appropriate boronic 
acid (2.2 eq), and Pd(PPh3)2Cl2 (0.10 eq) in anhydrous DMF (2.6 mL) was purged with nitrogen 
for 30 minutes. A 1 M aqueous solution of K2CO3 (2.1 eq) was then added. The reaction 
mixture was heated to 100 °C and left to magnetically stir at this temperature for 24 hours (28) 
and 15 hours (3). The reaction mixture was then diluted with DCM (60 mL), washed with 
deionized water (40 mL × 7), saturated aqueous solutions of NaHCO3 (40 mL × 3), NH4Cl (40 
mL × 3), and NaCl (40 mL × 1). The organic layer was dried (Na2SO4), after which the solvent 
was removed in vacuo. The resulting crude mixture was subjected to prep-TLC purification to 
get the title compounds. 
 
3,6-Bis(3-(methylsulfonyl)phenyl)imidazo[1,2-b]pyridazine (50) 
Purified by prep-TLC (developed in 4% CH3OH/DCM). 
Crystallized in diethyl ether. Yellow solid (0.114 g, 62%); m.p. 
228.7 – 230.8 °C; Rf (CH3OH : CH2Cl2 4 : 96) 0.20; 1H-NMR δH 
(400 MHz; CDCl3) 9.17 (1H, s, H2), 8.71 (1H, s, H12), 8.55 – 8.21 
(4H, m, H1, H5, H7, H11), 8.17 (1H, d, J = 7.6 Hz, H3), 8.04 (1H, 
d, J = 7.4 Hz, H9), 7.94 – 7.74 (3H, m, H4, H8, H10), 3.24 (3H, s, H6), 3.22 (3H, s, H13); 
13C-
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NMR δC (101 MHz; CDCl3) 151.08, 142.30, 141.61, 136.18, 132.12 (3C), 131.56, 130.55, 
130.11, 129.33 (2C), 127.04 (2C), 126.47, 126.20, 125.47, 117.29, 44.76, 44.53; HPLC-MS, 
APCI+: m/z [M + H]+ = 428.0, calculated exact mass = 427.0660, purity: 95.9%, tr = 2.586 min. 
 
3,6-Bis(4-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazine (25) 
Purified by prep-TLC (developed twice in 5% CH3OH/DCM). 
Crystallized in diethyl ether. Yellow solid (0.0665 g, 39%); m.p. 
180.4 – 182.3 °C; Rf (CH3OH : CH2Cl2 4 : 96) 0.21; 1H-NMR δH 
(400 MHz; DMSO-d6) 8.48 (2H, d, J = 8.8 Hz, H7), 8.45 (1H, s, 
H1), 8.39 (1H, d, J = 9.6 Hz, H5), 8.35 (2H, d, J = 8.7 Hz, H2), 
7.99 (1H, d, J = 9.6 Hz, H6), 7.91 (2H, d, J = 8.6 Hz, H3), 7.89 
(2H, d, J = 8.8 Hz, H8), 2.84 (3H, s, H9), 2.83 (3H, s, H4); 
13C-NMR δC (101 MHz; DMSO-d6) 
151.04, 148.96, 145.89, 140.15, 137.75, 135.09, 131.10, 128.43 (2C), 127.23 (3C), 127.13, 
124.91 (2C), 124.68 (2C), 116.98, 43.67 (2C); HPLC-MS, APCI+: m/z [M + H]+ = 396.0, 
calculated exact mass = 395.0762, purity: 98.5%, tr = 2.563 min. 
 
6.1.2.19 Procedure for Synthesis of 6-(3-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazine 
(6a)1,7–9 
A suspension of 6-chloroimidazo[1,2-b]pyridazine (2a) (1.50 g, 9.8 
mmol), 3-methylsulfinylphenylboronic acid (1.78 g, 9.8 mmol), and 
Pd(PPh3)2Cl2 (0.344 g, 0.49 mmol) in anhydrous DMF (30 mL) was 
purged with nitrogen for 30 minutes. A 1 M aqueous solution of K2CO3 
(1.42 g, 10.29 mmol) was then added. The reaction mixture was heated 
to 100 °C and magnetically stirred at this temperature for 3.25 hours. The black reaction 
mixture was then diluted with DCM (150 mL), washed with deionized water (75 mL × 8), 
saturated aqueous solutions of NaHCO3 (75 mL × 3), NH4Cl (75 mL × 1) and NaCl (50 mL × 
5). After drying (MgSO4) the organic layer, the solvent was removed in vacuo and the resulting 
crude mixture subjected to flash column chromatography (0 – 5% CH3OH/DCM) to afford the 
phenylated intermediate, 6a which was further crystallized in diethyl ether to obtain a yellow 
solid (1.20 g, 48%); 1H-NMR δH (400 MHz; CDCl3) 8.36 (1H, td, J = 1.8, 0.6 Hz, H7), 8.25 
(1H, d, J = 9.6 Hz, H2), 8.15 (1H, dt, J = 7.7, 1.7 Hz, H4), 8.10 (1H, d, J = 1.3 Hz, H9), 7.89 
(1H, d, J = 1.4 Hz, H1), 7.78 (1H, dt, J = 7.8, 1.5 Hz, H6), 7.74 (1H, td, J = 7.6, 0.6 Hz, H5), 
7.69 (1H, d, J = 9.5 Hz, H3), 2.84 (3H, s, H8); HPLC-MS, ESI
+: m/z [M + H]+ = 258.1, 
calculated exact mass = 257.0623, tr = 3.1 min. 
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6.1.2.20 Procedure for Synthesis of 3-bromo-6-(3-(methylsulfinyl)phenyl)imidazo[1,2-
b]pyridazine (6b)1,9 
A brown solution of 6-(3-(methylsulfinyl)phenyl)imidazo[1,2-
b]pyridazine (6a) (1.20 g, 4.7 mmol) in anhydrous DMF (4 mL) was 
purged with nitrogen for 30 minutes. NBS (0.912 g, 5.1 mmol) was 
added where after the reaction mixture was stirred at room temperature 
(23 °C) for 22 hours. The reaction mixture, containing a yellow 
precipitate at this point, was taken up in 100 mL DCM and washed with deionized water (75 
mL × 8), saturated aqueous solutions of NaHCO3 (75 mL × 2), NH4Cl (75 mL × 2) and NaCl 
(75 mL × 1). The organic layer was dried (MgSO4) after which the solvent was removed in 
vacuo. The obtained oily residue was crystallized and triturated with ethyl acetate for 30 
minutes. The solid was filtered and washed with ethyl acetate to give 6b as a yellow solid 
(0.939 g, 59%); 1H-NMR δH (300 MHz; CDCl3) 8.44 – 8.35 (2H, m, H2, H7), 8.29 – 8.23 (1H, 
m, H4), 7.93 (1H, s, H1), 7.90 – 7.73 (3H, m, H3, H5, H6), 2.85 (3H, s, H8); HPLC-MS, ESI
+: 
m/z [M + H]+ = 336.0 & 338.0, calculated exact mass = 334.9728, tr = 3.9 min. 
 
6.1.2.21 Procedure for Synthesis of 3,6-bis(3-(methylsulfinyl)phenyl)imidazo[1,2-
b]pyridazine (35)1,7–9 
A suspension of 3-bromo-6-(3-
(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazine (6b) (0.100 g, 
0.30 mmol), 3-methylsulfinylphenylboronic acid (0.0602 g, 
0.33 mmol), and Pd(PPh3)2Cl2 (0.0105 g, 0.015 mmol) in 
anhydrous DMF (2.0 mL) was purged with nitrogen for 30 
minutes. A 1 M aqueous solution of K2CO3 (0.0435 g, 0.32 mmol) was then added. The reaction 
mixture was heated to 100 °C and magnetically stirred at this temperature for 20 hours. The 
reaction mixture was then diluted with DCM (60 mL), washed with deionized water (40 mL × 
6), saturated aqueous solutions of NaHCO3 (40 mL × 3), NH4Cl (40 mL × 3) and NaCl (40 mL 
× 1). The organic layer was dried (MgSO4), where after the solvent was removed in vacuo. The 
resulting crude mixture was subjected to prep-TLC (developed twice in 4% CH3OH/DCM) to 
get 35 as an oil. Crystallization with diethyl ether gave 35 as a yellow solid (0.0481 g, 40%); 
Rf (CH3OH : CH2Cl2 4 : 96) 0.17; 1H-NMR δH (400 MHz; DMSO-d6) 8.80 (1H, m, H2), 8.48 – 
8.42 (2H, m, H1, H12), 8.42 – 8.35 (2H, m, H7, H9), 8.33 (1H, dt, J = 7.6, 1.6 Hz, H5), 8.03 (1H, 
d, J = 9.5 Hz, H8), 7.94 – 7.88 (1H, m, H11), 7.82 (1H, t, J = 7.7 Hz, H10), 7.76 (1H, t, J = 7.7 
Hz, H4), 7.73 – 7.69 (1H, m, H3), 2.88 (3H, s, H6), 2.86 (3H, s, H13);
 13C-NMR δC (101 MHz; 
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DMSO-d6) 150.75, 148.34, 147.67, 140.06, 136.44, 134.81, 130.65, 130.14, 129.89, 129.73, 
128.72, 127.15, 127.08, 125.63, 123.28, 122.60, 121.19, 116.75, 43.97, 43.82; HPLC-MS, 
APCI+: m/z [M + H]+ = 396.0, calculated exact mass = 395.0762, purity: 99.8% tr = 2.525 min. 
 
6.1.2.22 General Procedure for Synthesis of Aminated Analogues (46 - 49)3–6 
A suspension of 3-bromo-6-(3-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazine (6b) (1.0 eq), 
an appropriate amine (1.3 eq), Pd2(dba)3 (0.2 eq), BrettPhos (0.12 eq) and Cs2CO3 (2.0 eq) in 
anhydrous 1,4-dioxane (2 mL) in a sealed tube was flashed with nitrogen for 20 minutes. The 
reaction mixture was then heated to 120 °C and stirred for 5 - 39 hours. The solvent was 
removed in vacuo after which the resulting black residue was taken up in DCM (60 mL), 
washed with saturated aqueous solutions of NaHCO3 (40 mL × 3) and NaCl (40 mL × 1). The 
organic layer was dried (Na2SO4), after which the solvent was removed in vacuo and the crude 




Purified by prep-TLC (developed thrice in 2.5% 
CH3OH/DCM). Crystallized in diethyl ether. Brown solid 
(0.0121 g, 9%); m.p. 105.0 – 107.2 °C; Rf (CH3OH : CH2Cl2 
4 : 96) 0.23; 1H-NMR δH (400 MHz; DMSO-d6) 9.13 (1H, s, 
H2), 8.32 – 8.25 (2H, m, H6, H12), 8.18 (1H, d, J = 7.7 Hz, 
H8), 7.91 – 7.80 (3H, m, H1, H7, H10), 7.78 – 7.68 (3H, m, H3, H9), 6.99 (2H, d, J = 8.4 Hz, H4), 
3.11 (3H, s, H5), 2.80 (3H, s, H11); 
13C-NMR δC (101 MHz; DMSO-d6) 150.57, 149.91, 148.01, 
136.65, 135.99, 130.46, 130.33, 129.64, 129.31 (2C), 127.66, 127.04, 126.95, 125.62, 122.61, 
115.86, 114.13 (2C), 44.75, 43.63; HPLC-MS, APCI+: m/z [M + H]+ = 427.0, calculated exact 














Purified by flash column chromatography (0 - 4% 
CH3OH/DCM), trituration in diethyl ether. Brown solid (0.0127 
g, 10%); m.p. 150.4 – 152.0 °C; Rf (CH3OH : CH2Cl2 4 : 96) 
0.19; 1H-NMR δH (400 MHz; DMSO-d6) 9.09 (1H, s, H2), 8.38 
(1H, d, J = 9.5 Hz, H8), 8.29 (1H, s, H13), 8.22 (1H, d, J = 7.9 
Hz, H10), 8.05 (1H, d, J = 9.6 Hz, H9), 8.02 (1H, s, H1), 7.86 (1H, d, J = 7.8 Hz, H12), 7.77 (1H, 
t, J = 7.8 Hz, H11), 7.50 (1H, t, J = 7.9 Hz, H5), 7.45 (1H, s, H3), 7.36 (1H, d, J = 7.6 Hz, H6), 
7.24 (1H, dd, J = 8.1, 2.3 Hz, H4), 3.16 (3H, s, H7), 2.81 (3H, s, H14); 
13C-NMR δC (101 MHz; 
DMSO-d6) 151.43, 148.10, 145.50, 142.26, 136.13, 134.94, 130.83, 130.55, 129.79, 128.30, 
125.97, 125.83, 122.75 (2C), 119.50, 117.75 (2C), 112.76, 44.03, 43.62; HPLC-MS, APCI+: 
m/z [M + H]+ = 427.1, calculated exact mass = 426.0820, purity: 95.1%, tr = 2.555 min. 
 
N,6- Bis(3-(methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (48) 
Purified by prep-TLC (developed in 4% CH3OH/DCM). 
Crystallized in diethyl ether. Brick-red solid (0.0186 g, 15%); 
m.p. 110.0 – 113.5 °C; Rf (CH3OH : CH2Cl2 4 : 96) 0.15; 1H-
NMR δH (400 MHz; DMSO-d6) 8.90 (1H, s, H2), 8.35 – 8.27 
(2H, m, H8, H13), 8.23 (1H, d, J = 7.9 Hz, H10), 8.00 – 7.90 (2H, 
m, H1, H9), 7.86 (1H, d, J = 7.8 Hz, H12), 7.76 (1H, t, J = 7.7 Hz, H11), 7.41 (1H, t, J = 7.9 Hz, 
H5), 7.24 (1H, s, H3), 7.07 (2H, m, H4, H6), 2.81 (3H, s, H14), 2.69 (3H, s, H7); 
13C-NMR δC 
(101 MHz; DMSO-d6) 150.92, 148.05 (2C), 145.68, 136.37, 135.03, 130.50 (2C), 129.73, 
128.59, 126.18, 125.77, 123.92, 122.72, 116.94, 116.61, 114.38, 109.29, 43.81, 43.62; HPLC-





Purified by prep-TLC (developed twice in 6% CH3OH/DCM), 
trituration in diethyl ether. Brown solid (0.0204 g, 17%); m.p. 
161.6 – 163.7 °C; 1H-NMR δH (400 MHz; DMSO-d6) 8.83 (1H, 
s, H2), 8.29 (1H, d, J = 1.8 Hz, H11), 8.25 (1H, d, J = 9.6 Hz, 
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H10), 7.75 (1H, t, J = 7.8 Hz, H9), 7.53 (2H, d, J = 8.6 Hz, H3), 7.03 (2H, d, J = 8.4 Hz, H4), 
2.81 (3H, s, H12), 2.69 (3H, s, H5); 
13C-NMR δC (101 MHz; DMSO-d6) 150.41, 147.99, 147.68, 
136.69, 135.60, 135.32, 130.45, 129.64, 127.95, 126.83, 126.71, 125.84 (2C), 125.56, 122.63, 
115.43, 114.92 (2C), 43.75, 43.63; HPLC-MS, APCI+: m/z [M + H]+ = 411.1, exact mass = 
410.0871, purity: 99.9%, tr = 2.450 min. 
 
6.1.2.23 Procedure for Synthesis of 4-(6-chloroimidazo[1,2-b]pyridazin-3-yl)benzoic acid 
(7a)1,7–9 
A suspension of 6-chloro-3-iodoimidazo[1,2-b]pyridazine (3a) (1.00 g, 
3.6 mmol), 4-carboxylphenylboronic acid (0.657 g, 4.0 mmol) and 
Pd(PPh3)2Cl2 (0.126 g, 0.18 mmol) in DMF (10 mL) was purged with 
nitrogen for 20 minutes. A 1 M aqueous solution of K2CO3 (0.522 g, 3.8 
mmol) was added after which the reaction mixture was heated to 80 °C 
and left to stir for 27 hours. DMF was then removed under reduced pressure and the resulting 
yellow residue subjected to automated flash chromatography (silica, 0 – 8% CH3OH/DCM) to 
afford the carboxylic acid intermediate, 7a, as a yellow solid (0.555 g, 56%); 1H-NMR δH (300 
MHz; DMSO-d6) 8.45 (1H, s, H1), 8.34 (1H, d, J = 9.5 Hz, H5), 8.26 (2H, d, J = 8.6 Hz, H3), 
8.09 (2H, d, J = 8.6 Hz, H2), 7.48 (1H, d, J = 9.5 Hz, H4); HPLC-MS, ESI
+/APCI+: m/z [M + 
H]+ = 274.0, calculated exact mass = 273.0305. 
 
6.1.2.24 General Procedure for Synthesis of Carboxylic Acid Intermediates (7b - d)1,7–9 
A suspension of 4-(6-chloroimidazo[1,2-b]pyridazin-3-yl)benzoic acid (7a) (1.0 eq), the 
appropriate substituted arylboronic acid (1.5 eq) and Pd(PPh3)2Cl2 (0.05 eq) in DMF (3 
mL/mmol of halogenated starting material) was flashed with nitrogen for 20 minutes. A 1 M 
aqueous solution of K2CO3 (1.05 eq) was then added. The reaction mixture was heated to 100 
°C and left to stir for 22 hours. DMF was removed under reduced pressure and the resulting 
crude reaction mixture subjected to manual glass tube column chromatography (silica, 0 – 10% 
CH3OH/DCM) to give carboxy-substituted intermediates 7b and 7c. For intermediate 7d, a 
bromo-substituted starting material (see scheme 2.5 in chapter 2) was used as opposed to the 
chloro-substituted derivative. For this intermediate, the reaction mixture was stirred at 100 °C 
for 30 hours. DMF was removed in vacuo and the resulting residue subjected to manual glass 
tube column chromatography employing two separate sets of mobile phase solvent systems. 
Impurities were eluted from the column using a 50% EtOAc/hexane mobile phase after which 
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a 4% CH3OH/DCM mobile phase was employed to elute the carboxy-substituted compound 
7d. 
 
4-(6-(3-(Methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)benzoic acid (7b) 
Manual glass tube column chromatography (silica, 0 - 10% 
CH3OH/DCM). Yellow solid (0.159 g, 95%); 1H-NMR δH (300 
MHz; CD3OD) 8.48 (1H, t, J = 1.5 Hz, H7), 8.36 (2H, d, J = 8.8 Hz, 
H3), 8.33 – 8.28 (2H, m, H6, H9), 8.24 (1H, s, H1), 8.19 (2H, d, J = 
8.8 Hz, H2), 7.95 (1H, d, J = 9.6 Hz, H4), 7.91 - 7.86 (1H, m, H8), 
7.84 (1H, d, J = 9.5 Hz, H5), 2.92 (3H, s, H10); HPLC-MS, ESI
+/APCI+: m/z [M + H]+ = 378.1, 
calculated exact mass = 377.0834. 
 
4-(6-(3-(Trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)benzoic acid (7c) 
Manual glass tube column chromatography (silica, 1.5 - 4% 
CH3OH/DCM). Yellow solid (0.152 g, 54%); 1H-NMR δH (300 MHz; 
DMSO-d6) 8.53 – 8.44 (3H, m, H1, H4, H6), 8.43 – 8.35 (3H, m, H3, 
H5), 8.14 – 8.06 (3H, m, H2, H7), 7.96 (1H, d, J = 8.6 Hz, H9), 7.87 
(1H, t, J = 7.7 Hz, H8); HPLC-MS, ESI
+/APCI+: m/z [M + H]+ = 
384.0, calculated exact mass = 383.0882, tr = 4.6 min. 
 
4-(6-(3-(Methylsulfonyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)benzoic acid (7d) 
Manual glass tube column chromatography (silica, 50% 
EtOAc/hexane, then 4% CH3OH/DCM). Yellow solid (0.108 g, 
39%); 1H-NMR δH (400 MHz; DMSO-d6) 8.67 (1H, t, J = 1.7 Hz, H9), 
8.56 – 8.51 (1H, m, H8), 8.49 (1H, s, H1), 8.46 – 8.39 (3H, m, H3, H4), 
8.17 – 8.10 (3H, m, H2, H6), 8.08 (1H, d, J = 9.5 Hz, H5), 7.91 (1H, t, 
J = 7.9 Hz, H7), 3.35 (3H, s, H10); HPLC-MS, ESI
+/APCI+: m/z [M + H]+ = 394.1, calculated 
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6.1.2.25 Procedure for Synthesis of 4-(6-(3-(methylsulfinyl)phenyl)imidazo[1,2-
b]pyridazin-3-yl)-N-((trimethylsilyl)methyl)benzamide (55)10 
EDCI (0.162 g, 0.84 mmol) was added to a suspension of 
4-(6-(3-(Methylsulfinyl)phenyl)imidazo[1,2-b]pyridazin-
3-yl)benzoic acid (7b) (0.159 g, 0.42 mmol) and DMAP 
(0.103 g, 0.84 mmol) in DCM (4 mL). The resulting 
mixture was left to stir for 30 minutes under nitrogen 
before adding (trimethylsilyl)methylamine (0.100 mL, 
0.75 mmol). The resulting reaction mixture was then left to stir for another 20 hours with no 
significant amount of the product being detected on HPLC-MS. The reaction appeared 
inhibited by poor solubility of the carboxylic acid starting material in DCM. DMF (0.6 mL) 
was, therefore, added and the reaction mixture stirred for another 40 hours after which a drastic 
improvement of conversion to the product was observed. The reaction mixture was then 
washed with saturated aqueous solutions of NaHCO3 (1 ×), NH4Cl (1 ×) and NaCl (1 ×). The 
organic layer was dried (MgSO4) and concentrated in vacuo where after the obtained residue 
was subjected to prep-TLC (developed in 4% CH3OH/DCM) to furnish 55 as a yellow solid 
(0.0191 g, 10%); m.p. 130.9 – 132.0 °C; Rf (CH3OH : CH2Cl2 6 : 94) 0.45; 
1H-NMR δH (300 
MHz; CD3OD) 8.48 (1H, s, H1), 8.42 – 8.19 (5H, m, H3, H4, H7, H8), 8.11 - 7.76 (6H, m, H2, 
H9, H10, H11, H12), 3.00 (2H, s, H5), 2.91 (3H, s, H13), 0.17 (9H, s, H6); 
13C-NMR δC (100.6 
MHz; CD3OD) 168.5, 152.0, 146.5, 137.3, 134.5, 132.0, 130.2, 129.7, 129.0, 127.3 (3C), 126.5 
(2C), 125.4 (3C), 122.1, 118.0, 30.5, 22.6, -3.6 (3C); HPLC-MS, ESI+/APCI+: m/z [M + H]+ = 
463.1, calculated exact mass = 462.1546, purity: 96.7%, tr = 2.820 min. 
 
6.1.2.26 Procedure for Synthesis of 4-(6-(3-(methylsulfonyl)phenyl)imidazo[1,2-
b]pyridazin-3-yl)-N-((trimethylsilyl)methyl)benzamide (57)10 
EDCI (0.105 g, 0.55 mmol) was added to a suspension of 
4-(6-(3-(Methylsulfonyl)phenyl)imidazo[1,2-b]pyridazin-
3-yl)benzoic acid (7d) (0.108 g, 0.27 mmol) and DMAP 
(0.067 g, 0.55 mmol) in DCM (3 mL). The resulting 
mixture was left to stir for 30 minutes under nitrogen before 
adding (trimethylsilyl)methylamine (0.200 mL, 1.4 mmol). 
The resulting reaction mixture was then left to stir for another 16 hours with no significant 
amount of the product being detected on HPLC-MS. DMF (0.5 mL) was added followed by 
5.0 eq of (trimethylsilyl)methylamine. The reaction flask was then sealed and heated to 36 °C. 
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The reaction was allowed to proceed at this temperature for another 21 hours. The reaction 
mixture was diluted with DCM before washing with saturated aqueous solutions of NaHCO3 
(3 ×), NH4Cl (2 ×) and NaCl (1 ×). The organic layer was dried (Na2SO4) and concentrated in 
vacuo. The obtained residue was subjected to manual glass tube column chromatography (1.5% 
CH3OH/DCM) to deliver 57 as a yellow solid (0.0248 g, 19%); m.p. 209.8 – 211.0 °C; Rf 
(CH3OH : CH2Cl2 6 : 94) 0.48; 
1H-NMR δH (300 MHz; CDCl3) 8.56 (1H, t, J = 1.6 Hz, H9), 
8.35 (1H, d, J = 8.2 Hz, H12), 8.26 – 8.15 (4H, m, H1, H3, H7), 8.10 (1H, d, J = 8.3 Hz, H10), 
7.92 (2H, d, J = 8.5 Hz, H2), 7.79 (1H, t, J = 7.8 Hz, H11), 7.62 (1H, d, J = 9.5 Hz, H8), 6.18 
(1H, t, J = 5.5 Hz, H4), 3.16 (3H, s, H13), 3.03 (2H, d, J = 5.8 Hz, H5), 0.18 (9H, s, H6); HPLC-
MS, ESI+/APCI+: m/z [M + H]+ = 479.1, calculated exact mass = 478.1495, purity: 97.1%, tr = 
2.903 min. 
 
6.1.2.27 Procedure for Synthesis of 4-(6-(3-(trifluoromethyl)phenyl)imidazo[1,2-
b]pyridazin-3-yl)-N-((trimethylsilyl)methyl)benzamide (56)10 
EDCI (0.153 g, 0.80 mmol) was added to a suspension of 4-
(6-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-
yl)benzoic acid (7c) (0.152 g, 0.40 mmol) and DMAP 
(0.0977 g, 0.80 mmol) in DMF (4 mL). The resulting mixture 
was left to stir for 30 minutes under nitrogen before adding 
(trimethylsilyl)methylamine (0.270 mL, 2.0 mmol). The 
reaction mixture was then left to stir for another 20 hours. The reaction mixture was diluted 
with DCM and washed with saturated aqueous solutions of NaHCO3 (2 ×), NH4Cl (1 ×) and 
NaCl (2 ×). The organic layer was dried over Na2SO4, concentrated in vacuo after which the 
obtained residue was chromatographed using a manual glass tube column (1.0% 
CH3OH/DCM). Further purification by trituration in diethyl ether afforded 56 as a yellow solid 
(0.028 g, 15%); m.p. 174.2 °C; Rf (CH3OH : CH2Cl2 6 : 94) 0.41; 
1H-NMR δH (300 MHz; 
CDCl3) 8.31 – 8.17 (6H, m, H1, H3, H7, H8, H9), 7.92 (2H, d, J = 8.2 Hz, H2), 7.81 (1H, d, J = 
7.6 Hz, H10), 7.72 (1H, d, J = 7.6 Hz, H12), 7.69 – 7.60 (1H, m, H11), 6.15 (1H, t, J = 5.8 Hz, 
H4), 3.04 (2H, d, J = 5.7 Hz, H5), 0.18 (9H, s, H6); 
13C-NMR δC (100.6 MHz; CDCl3) 167.1, 
150.8, 136.3, 134.5, 133.3, 131.8 (q, J = 32.7 Hz), 130.9, 130.3, 129.8 (2C). 127.3 (2C), 126.9, 
126.7 (2C), 126.4, 125.2, 123.9, 122.5, 116.0, 30.5, -2.5 (3C); HPLC-MS, ESI+/APCI+: m/z [M 
+ H]+ = 469.2, calculated exact mass = 468.1593, purity: 98.1%, tr = 3.190 min. 
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6.1.3 Synthetic Methods for Aminopyrazines 
6.1.3.1 Procedure for Synthesis of 5-bromo-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-
amine (7g)11 
A yellow solution of 5-bromo-3-iodopyrazin-2-amine (7f) (1.00 g, 3.3 
mmol) and 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester 
(0.991 g, 3.6 mmol) in 13 mL anhydrous 1,4-dioxane was degassed with 
nitrogen for 20 minutes. Pd(PPh3)2Cl2 (0.116 g, 0.17 mmol) and a 1 M 
aqueous solution of K2CO3 (1.37 g, 9.9 mmol) were then added. The reaction mixture was 
heated to 110 °C and left to stir for 20 hours. The reaction mixture was diluted with water (70 
mL) and extracted with EtOAc (100 mL × 3). The pooled organic layers were then washed 
with saturated aqueous NaCl (100 mL × 3). The organic layer was dried (Na2SO4) where after 
the solvent was removed in vacuo. The obtained residue was subjected to flash column 
chromatography (0 - 15% EtOAc/hexane) to deliver 7g as a yellow solid (0.4564 g, 43%); 1H-
NMR δH (300 MHz; CDCl3)
 9.16 (1H, s, H3), 8.30 (1H, d, J = 7.8 Hz, H4), 8.20 (1H, s, H1), 
7.85 (1H, d, J = 8.2 Hz, H5), 4.84 (2H, s, H2); HPLC-MS, APCI
-: m/z [M - H]- = 317.0 & 319.9, 
calculated exact mass = 317.9728, tr = 3.0 min. 
 
6.1.3.2 Procedure for Synthesis of tert-butyl 4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-
yl)pyrazin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (59)11 
A suspension of 5-bromo-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-
amine (7g) (0.162 g, 0.51 mmol), 3,6-dihydro-2H-pyridine-1-N-boc-4-
boronic acid pinacol ester (0.173 g, 0.56 mmol) and Pd(PPh3)2Cl2 (0.0179 
g, 0.026 mmol) in 3 mL anhydrous 1,4-dioxane was degassed with 
nitrogen for 20 minutes. A 1 M aqueous solution of K2CO3 (0.212 g, 1.53 
mmol) was then added. The reaction mixture was heated to 110 °C and 
left to stir for 13 hours. The solvent was removed in vacuo. The remaining 
residue was taken up in DCM (70 mL) and washed with deionized water (40 mL × 1) and 
saturated aqueous NaCl (40 mL × 3). The organic layer was dried (Na2SO4) after which the 
solvent was removed in vacuo. The obtained residue was subjected to flash column 
chromatography (0 - 3% MeOH/DCM). Further purification by trituration in diethyl ether 
delivered 59 as a yellow solid (0.1289 g, 21%); m.p. 193 – 195 °C; Rf (CH3OH : CH2Cl2 8 : 
92) 0.49; 1H-NMR δH (400 MHz; CDCl3) 9.19 (1H, d, J = 2.0 Hz, H8), 8.36 – 8.31 (1H, m, H9), 
8.16 (1H, s, H2), 7.86 (1H, dd, J = 8.1, 0.8 Hz, H10), 6.57 (1H, br s, H7), 5.25 (2H, br s, H1), 
4.15 (2H, d, J = 3.1 Hz, H6), 3.67 (2H, t, J = 5.7 Hz, H4), 2.63 (2H, br s, H3), 1.51 (9H, s, H5); 
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13C-NMR δC (101 MHz; CDCl3) 154.79, 149.95, 149.50, 148.45 (q, J = 34.94 Hz), 143.74, 
137.21, 135.57, 135.52, 132.05 (2C), 123.26 (2C), 120.65, 79.86, 43.68, 39.61, 28.47 (3C), 
25.47; HPLC-MS, APCI-: m/z [M - H]- = 420.1, calculated exact mass = 421.1726, purity: 
99.9%, tr = 2.919 min. 
 
6.1.3.3 Procedure for Synthesis of tert-butyl 4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-
yl)pyrazin-2-yl)piperidine-1-carboxylate (60)12 
A suspension of tert-butyl 4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-
yl)pyrazin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (59) (0.0602 g, 
0.14 mmol), ammonium formate (NH4HCO2) (0.0631 g, 7.7 mmol) and 
10% carbon-supported palladium (Pd/C) (0.0149 g, 0.14 mmol) in 2 mL 
anhydrous methanol in a sealed tube was evacuated. The reaction mixture 
was then left to stir at room temperature (24 °C) under an atmosphere of 
hydrogen captured in a balloon for 2.5 hours. The reaction mixture was filtered through a filter 
paper to remove the Pd/C catalyst after which the filtrate was concentrated in vacuo. The 
obtained residue was taken up in DCM (50 mL) and washed with deionized water (30 mL) and 
saturated aqueous NaCl (30 mL × 1). The organic layer was dried (Na2SO4) and concentrated 
under reduced pressure. The obtained residue was subjected to prep-TLC (silica, developed 
once in 2% CH3OH/DCM) to give 60 which was crystallized in diethyl ether to furnish a yellow 
solid (0.054 g, 68%); m.p. 151 – 154 °C; Rf (CH3OH : CH2Cl2 8 : 92) 0.46;
 1H-NMR δH (400 
MHz; CDCl3) 9.19 – 9.15 (1H, m, H7), 8.32 (1H, d, J = 8.0 Hz, H8), 7.95 (1H, s, H2), 7.85 (1H, 
d, J = 8.0 Hz, H9), 5.12 (2H, br s, H1), 4.38 – 4.17 (2H, m, H4e), 2.96 – 2.78 (3H, m, H4a, H6), 
2.00 – 1.87 (2H, m, H3e), 1.84 – 1.68 (2H, m, H3a), 1.49 (9H, s, H5); 
13C-NMR δC (101 MHz; 
CDCl3) 154.76, 150.06, 149.96, 149.41, 148.52, 137.65, 137.27, 136.00, 135.69, 120.63, 
119.99, 79.58, 43.91 (2C), 40.94, 31.39 (2C), 28.47 (3C); HPLC-MS, APCI-: m/z [M - H]- = 
422.1, calculated exact mass = 423.1882, purity: 99.6%, tr = 2.824 min.    
 
6.1.3.4 Procedure for Synthesis of 5-(piperidin-4-yl)-3-(6-(trifluoromethyl)pyridin-3-
yl)pyrazin-2-amine (61)13  
A solution of 4 M HCl in 1,4-dioxane (6.0 mL, 24 mmol) was added to 
tert-butyl 4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-
yl)piperidine-1-carboxylate (60) (0.3170 g, 0.75 mmol). The reaction 
mixture was then stirred at room temperature (24 °C) for 30 minutes after 
which excess HCl and the solvent were removed in vacuo. The yellow 
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residue was dissolved in deionized water (30 mL) followed by basification to pH 12 by adding 
4 M aqueous NaOH. The aqueous mixture was then extracted with DCM (40 mL × 3). The 
pooled organic layers were then washed with saturated aqueous NaCl (40 mL × 1) and dried 
(MgSO4). The organic layer was concentrated in vacuo and subjected to prep-TLC (silica, 
developed once in 30% CH3OH/DCM, developed once in 40% CH3OH/DCM, developed once 
in 40% CH3OH : 1% triethylamine : 59% DCM) to give 61 which was further crystallized in 
diethyl ether to give a yellow solid (0.0606 g, 25%); m.p. 127 – 129 °C; Rf (CH3OH : CH2Cl2 
8 : 92) 0.0; 1H-NMR δH (400 MHz; CD3OD) 9.10 (1H, d, J = 2.1 Hz, H6), 8.44 (1H, ddt, J = 
8.2, 2.1, 0.7 Hz, H7), 7.96 (1H, d, J = 0.4 Hz, H1), 7.93 (1H, dd, J = 8.2, 0.9 Hz, H8), 3.22 – 
3.13 (2H, m, H4e), 2.85 (1H, tt, J = 11.8, 3.9 Hz, H2), 2.77 (2H, td, J = 12.4, 2.9 Hz, H4a), 1.96 
– 1.88 (2H, m, H3e), 1.80 (2H, dtd, J = 13.3, 12.0, 4.0 Hz, H3a); 
13C-NMR δC (101 MHz; 
CD3OD) 151.91, 149.46, 149.00, 146.83 (q, J = 34.70 Hz), 139.54, 137.32, 136.97, 134.48, 
123.00, 120.23, 45.63 (2C), 40.49, 31.69 (2C); HPLC-MS, APCI-: m/z [M - H]- = 321.8, 
calculated exact mass = 323.1358, purity: 97.1%, tr = 0.566 min. 
 
6.1.3.5 Procedure for Synthesis of 5-(1-(methylsulfonyl)piperidin-4-yl)-3-(6-
(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine (62)14 
To a solution of 5-(piperidin-4-yl)-3-(6-(trifluoromethyl)pyridin-3-
yl)pyrazin-2-amine (61) (0.0450 g, 0.14 mmol) and triethylamine (0.1 
mL, 0.7 mmol) in 1 mL DCM cooled to 0 °C, methanesulfonyl chloride 
(0.012 mL, 0.15 mmol) was added dropwise. The reaction mixture was 
then left to warm to room temperature (23 °C) and stirred for 1 hour. The 
reaction mixture was diluted with 30 mL DCM and washed with 
deionized water (20 mL × 1), saturated aqueous solutions of NaHCO3 (20 mL × 3), NH4Cl (20 
mL × 2) and NaCl (20 mL × 1). The organic layer was dried (MgSO4) after which the solvent 
was removed in vacuo. The obtained residue was triturated in diethyl ether to deliver 62 as a 
white solid (0.0369 g, 66%); m.p. 193 – 196 °C; Rf (CH3OH : CH2Cl2 8 : 92) 0.45;
 1H-NMR 
δH (600 MHz; CDCl3) 9.16 (1H, d, J = 1.8 Hz, H7), 8.34 – 8.30 (1H, m, H8), 7.94 (1H, s, H2), 
7.87 (1H, d, J = 8.1 Hz, H9), 5.61 (2H, br s, H1), 4.01 – 3.93 (2H, m, H5e), 2.95 – 2.74 (6H, m, 
H3, H5a, H6), 2.14 – 2.04 (2H, m, H4e), 2.02 – 1.92 (2H, m, H4a); 
13C-NMR δC (151 MHz; 
CDCl3) 149.54, 149.33, 148.79, 148.64, 148.55, 137.39 (2C), 135.22, 134.99, 120.76, 46.00 
(2C), 40.10, 35.21, 30.93 (2C); HPLC-MS, APCI+: m/z [M + H]+ = 402.1, calculated exact 
mass = 401.1133, purity: 95.5%, tr = 2.517 min. 
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6.1.3.6 Procedure for Synthesis of tert-butyl 4-(3-amino-6-(4-
(methylsulfonyl)phenyl)pyrazin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (63) 
A suspension of 3-bromo-5-(4-(methylsulfonyl)phenyl)pyrazin-2-
amine (7h) (0.6 g, 1.8 mmol), 3,6-dihydro-2H-pyridine-1-N-boc-4-
boronic acid pinacol ester (0.6784 g, 2.2 mmol) and Pd(PPh3)2Cl2 
(0.0632 g, 0.09 mmol) in 6 mL anhydrous 1,4-dioxane was degassed 
with nitrogen for 20 minutes. A 1 M aqueous solution of K2CO3 (0.7463 
g, 5.4 mmol) was then added. The reaction mixture was heated to 110 
°C in a sealed tube and left to stir for 2 hours. The solvent was removed 
in vacuo. The remaining residue was taken up in DCM (70 mL) and washed with deionized 
water (50 mL × 4) and saturated aqueous NaCl (50 mL × 4). The organic layer was dried 
(MgSO4) after which the solvent was removed in vacuo. The obtained residue was subjected 
to flash column chromatography (silica, 0 - 3% MeOH/DCM). Further purification by 
trituration in a mixture of EtOAc and diethyl ether delivered 63 as a maroon solid (0.617 g, 
80%); m.p. 175 – 177 °C; Rf (CH3OH : CH2Cl2 8 : 92) 0.44;
 1H-NMR δH (600 MHz; CDCl3) 
8.36 (1H, s, H2), 8.10 (2H, d, J = 8.5 Hz, H3), 8.01 (2H, d, J = 8.5 Hz, H4), 6.39 (1H, br s, H6), 
5.63 (2H, br s, H1), 4.17 (2H, d, J = 3.3 Hz, H7), 3.71 (2H, t, J = 5.7 Hz, H8), 3.08 (3H, s, H5), 
2.73 (2H, br s, H9), 1.51 (9H, s, H10); 
13C-NMR δC (151 MHz; CDCl3) 154.74, 150.19, 141.55, 
139.96, 139.50, 134.35 (2C), 133.96, 128.00 (2C), 126.96, 126.18 (2C), 80.14, 44.59 (2C), 
43.11, 28.48 (3C), 27.39; HPLC-MS, APCI-: m/z [M - H]- = 429.1, calculated exact mass = 
430.1675, purity: 98.5%, tr = 2.703 min. 
 
6.1.3.7 Procedure for Synthesis of tert-butyl 4-(3-amino-6-(4-
(methylsulfonyl)phenyl)pyrazin-2-yl)piperidine-1-carboxylate (64)  
A suspension of tert-butyl 4-(3-amino-6-(4-
(methylsulfonyl)phenyl)pyrazin-2-yl)-3,6-dihydropyridine-1(2H)-
carboxylate (63) (0.5706 g, 1.3 mmol), NH4HCO2 (0.5850 g, 9.3 mmol) 
and 10% carbon-supported palladium (Pd/C) (0.1383 g, 1.3 mmol) in 15 
mL anhydrous methanol in a sealed tube was evacuated. The reaction 
mixture was then left to stir at room temperature (24 °C) under an 
atmosphere of hydrogen captured in a balloon for 1 hour. The reaction mixture was filtered 
through a filter paper to remove the Pd/C catalyst after which the filtrate was concentrated in 
vacuo. The obtained residue was taken up in DCM (60 mL) and washed with deionized water 
(40 mL × 1) and saturated aqueous NaCl (40 mL × 4). The organic layer was dried (MgSO4) 
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after which the solvent was removed to afford 64 as a cream white solid (0.3968 g, 71%); m.p. 
180 – 183 °C; Rf (CH3OH : CH2Cl2 8 : 92) 0.41;
 1H-NMR δH (400 MHz; CDCl3) 8.34 (1H, s, 
H2), 8.13 (2H, d, J = 8.7 Hz, H3), 8.04 (2H, d, J = 8.5 Hz, H4), 6.06 (2H, br s, H1), 4.31 (2H, d, 
J = 13.3 Hz, H8e), 3.11 (3H, s, H5), 3.05 – 2.93 (3H, m, H6, H8a), 2.03 – 1.87 (4H, m, H7), 1.52 
(9H, s, H9); 
13C-NMR δC (101 MHz; CDCl3) 154.78, 149.59, 147.14, 141.40, 140.16, 139.52, 
132.11, 128.02 (2C), 126.16 (2C), 79.76, 44.56, 43.67, 38.96 (2C), 29.40 (2C), 28.48 (3C); 
HPLC-MS, APCI-: m/z [M - H]- = 431.1, calculated exact mass = 432.1831, purity: 99.6%, tr 
= 2.806 min. 
 
6.1.3.8 Procedure for Synthesis of 5-(4-(methylsulfonyl)phenyl)-3-(piperidin-4-
yl)pyrazin-2-amine (65)13  
A solution of 4 M HCl in 1,4-dioxane (5.0 mL, 20 mmol) was added to a 
suspension of tert-butyl 4-(3-amino-6-(4-(methylsulfonyl)phenyl)pyrazin-2-
yl)piperidine-1-carboxylate (64) (0.2654 g, 0.61 mmol) in 3 mL DCM. The 
reaction mixture was then stirred for 1 hour at room temperature (24 °C) after 
which excess HCl and the solvent were removed in vacuo. The white residue 
obtained was taken up in 60 mL EtOAc and basified to pH 11 by slowly adding 
15% aqueous NaOH while vigorously stirring the mixture. The aqueous phase 
was removed using a separatory funnel. The organic layer was then dried (Na2SO4) where after 
the solvent was removed in vacuo. The obtained residue was triturated in EtOAc to afford 65 
as a brown solid (0.1745 g, 86%); m.p. 125 – 128 °C; Rf (CH3OH : CH2Cl2 8 : 92) 0.0;
 1H-
NMR δH (400 MHz; DMSO-d6) 8.52 (1H, s, H2), 8.20 (2H, d, J = 8.7 Hz, H3), 7.94 (2H, d, J = 
8.6 Hz, H4), 6.63 (2H, s, H1), 3.21 (3H, s, H5), 3.09 (2H, d, J = 12.2 Hz, H7e), 3.03 – 2.93 (1H, 
m, H8), 2.78 – 2.66 (2H, m, H7a), 1.82 – 1.64 (4H, m, H6); 
13C-NMR δC (101 MHz; DMSO-d6) 
153.24, 144.82, 142.82, 139.45, 137.98, 136.82, 127.88 (2C), 125.50 (2C), 46.18 (2C), 44.23, 
37.80, 30.49 (2C); HPLC-MS, APCI+: m/z [M + H]+ = 333.1, calculated exact mass = 332.1307, 
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6.1.3.9 Procedure for Synthesis of 5-(4-(methylsulfonyl)phenyl)-3-(1-
(methylsulfonyl)piperidin-4-yl)pyrazin-2-amine (66)14 
To a solution of 5-(4-(methylsulfonyl)phenyl)-3-(piperidin-4-yl)pyrazin-
2-amine (65) (0.1745 g, 0.52 mmol) and triethylamine (0.36 mL, 2.6 
mmol) in 1 mL DCM cooled to 0 °C, methanesulfonyl chloride (0.045 
mL, 0.58 mmol) was added dropwise. The reaction mixture was then left 
to warm to room temperature (24 °C) and stirred for 1 hour. The reaction 
mixture was diluted with 30 mL DCM and washed with deionized water 
(20 mL × 1), saturated aqueous solutions of NaHCO3 (20 mL × 3), NH4Cl 
(20 mL × 2) and NaCl (20 mL × 1). The organic layer was dried (MgSO4) after which the 
solvent was removed in vacuo to deliver 66 as a white solid; Rf (CH3OH : CH2Cl2 8 : 92) 0.41;
 
1H-NMR δH (300 MHz; DMSO-d6) 8.56 (1H, s, H2), 8.22 (2H, d, J = 8.6 Hz, H3), 7.95 (2H, d, 
J = 8.5 Hz, H4), 6.74 (2H, s, H1), 3.89 – 3.78 (3H, m, H7e, H8), 3.22 – 3.21 (6H, m, H5, H9), 
3.16 – 3.03 (2H, m, H7a), 2.02 – 1.90 (2H, m, H6e), 1.89 – 1.77 (2H, m, H6a); HPLC-MS, APCI
+: 
m/z [M + 2Na]+ = 489.1, calculated exact mass = 410.1082, purity: 95.2%, tr = 2.434 min. 
 
6.1.3.10 Procedure for Synthesis of 4-(3-amino-6-(4-(methylsulfonyl)phenyl)pyrazin-2-
yl)benzoic acid (69) 
A suspension of 3-bromo-5-(4-(methylsulfonyl)phenyl)pyrazin-2-amine 
(7h) (0.3 g, 0.91 mmol), 4-carboxyphenylboronic acid (0.1820 g, 1.1 mmol) 
and Pd(PPh3)2Cl2 (0.0319 g, 0.046 mmol) in 4 mL anhydrous 1,4-dioxane 
was degassed with nitrogen for 20 minutes. A 1 M aqueous solution of 
K2CO3 (0.3773 g, 2.7 mmol) was then added. The reaction mixture was 
heated to 110 °C in a sealed tube and left to stir for 2 hours. The solvent was 
removed in vacuo to obtain a deep brown residue which was directly subjected to flash column 
chromatography (silica, 0 - 12% CH3OH/DCM). The brown solid obtained was triturated in 
EtOAc to deliver 69 as a brown solid (0.2671 g, 79%); m.p. 271 – 274 °C; Rf (CH3OH : CH2Cl2 
8 : 92) 0.16; 1H-NMR δH (400 MHz; DMSO-d6) 8.74 (1H, s, H2), 8.26 (2H, d, J = 8.8 Hz, H6), 
8.09 (2H, d, J = 8.5 Hz, H3), 7.98 (2H, d, J = 8.7 Hz, H7), 7.93 (2H, d, J = 8.5 Hz, H4), 6.66 
(2H, s, H1), 3.24 (3H, s, H5); 
13C-NMR δC (101 MHz; DMSO-d6) 153.32, 142.12, 141.57, 
140.17 (2C), 139.92 (2C), 138.23, 137.79, 130.12 (2C), 128.79 (2C), 127.93 (2C), 125.92 (2C), 
44.17; HPLC-MS, APCI+: m/z [M + H]+ = 370.1, calculated exact mass = 369.0783, purity: 
99.9%, tr = 2.496 min. 
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6.1.3.11 Procedure for Synthesis of di-tert-butyl 4,4'-(3-aminopyrazine-2,6-diyl)bis(3,6-
dihydropyridine-1(2H)-carboxylate) (70) 
A suspension of 5-bromo-3-iodopyrazin-2-amine (7f) (0.3733 g, 1.2 
mmol), 3,6-dihydro-2H-pyridine-1-N-boc-4-boronic acid pinacol ester 
(0.8467 g, 2.7 mmol) and Pd(PPh3)2Cl2 (0.0842 g, 0.12 mmol) in 4 mL 
anhydrous 1,4-dioxane was degassed with nitrogen for 30 minutes. A 
1 M aqueous solution of K2CO3 (0.9951 g, 7.2 mmol) was then added. 
The reaction mixture was heated to 110 °C in a sealed tube and left to 
stir for 4 hours. The solvent was removed in vacuo. The remaining brown residue was taken 
up in DCM (60 mL) and washed with deionized water (40 mL × 1) and saturated aqueous NaCl 
(40 mL × 3). The organic layer was dried (Na2SO4) after which the solvent was removed in 
vacuo. The obtained brown residue was subjected to flash column chromatography (silica, 0 - 
4% CH3OH/DCM). Further purification by prep-TLC (silica, developed once in 3% 
CH3OH/DCM) gave 70 which was crystallized from a mixture of diethyl ether and pentane to 
obtain a faint yellow crystalline solid (0.374 g, 68%); m.p. 90 – 92 °C; Rf (CH3OH : CH2Cl2 8 
: 92) 0.41; 1H-NMR δH (400 MHz; CDCl3) 7.73 (1H, s, H2), 6.59 (1H, br s, H12), 6.50 – 6.32 
(3H, m, H1, H7), 4.19 (2H, d, J = 3.1 Hz, H11), 4.15 (2H, d, J = 3.5 Hz, H6), 3.70 (2H, t, J = 5.6 
Hz, H9), 3.67 (2H, t, J = 5.6 Hz, H4), 2.72 – 2.62 (2H, m, H8), 2.57 – 2.48 (2H, m, H3), 1.53 
(9H, s, H10), 1.51 (9H, s, H5); HPLC-MS, APCI
+: m/z [M + H]+ = 458.2, calculated exact mass 
= 457.2689, purity: 98.1%, tr = 3.007 min. 
 
6.1.3.12 Procedure for Synthesis of di-tert-butyl 4,4'-(3-aminopyrazine-2,6-
diyl)bis(piperidine-1-carboxylate) (71)  
A suspension of di-tert-butyl 4,4'-(3-aminopyrazine-2,6-
diyl)bis(3,6-dihydropyridine-1(2H)-carboxylate) (70) (0.135 g, 0.3 
mmol), NH4HCO2 (0.1324 g, 2.1 mmol) and 10% carbon-supported 
palladium (Pd/C) (0.0319 g, 0.3 mmol) in 5.5 mL anhydrous 
methanol in a sealed tube was evacuated. The reaction mixture was 
then left to stir at room temperature (20 °C) under an atmosphere of 
hydrogen captured in a balloon for 4 hours. The reaction mixture was filtered through a filter 
paper to remove the Pd/C catalyst after which the filtrate was concentrated in vacuo. The 
obtained residue was taken up in DCM (50 mL) and washed with deionized water (25 mL × 1) 
and a saturated aqueous solution of NaCl (25 mL × 4). The organic layer was dried (MgSO4) 
after which the solvent was removed. The obtained residue was subjected to prep-TLC (silica, 
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developed twice in 2% CH3OH/DCM) to afford 71 as a white solid (0.084 g, 61%); m.p. 69 – 
72 °C; Rf (CH3OH : CH2Cl2 8 : 92) 0.43;
 1H-NMR δH (400 MHz; CDCl3) 7.47 (1H, s, H2), 6.55 
(2H, s, H1), 4.34 – 4.10 (4H, m, H4e, H9e), 3.04 – 2.89 (3H, m, H7, H9a), 2.88 – 2.69 (3H, m, 
H4a, H5), 1.93 – 1.75 (6H, m, H3e, H8a, H8e), 1.73 – 1.58 (2H, m, H3a), 1.48 (18H, s, H6, H10); 
13C-NMR δC (101 MHz; CDCl3) 154.78, 154.73, 149.89, 147.51, 146.92, 125.37, 79.68, 79.64, 
43.74 (4C), 40.64, 38.58, 31.03 (2C), 29.32 (2C), 28.46 (6C); HPLC-MS, APCI+: m/z [M – boc 
+ H]+ = 362.2 and m/z [M – 2boc + H]+ = 262.2, calculated exact mass = 461.3002, purity: 
99.9%, tr = 2.940 min. 
 
6.1.3.13 Procedure for Synthesis of 3,5-di(piperidin-4-yl)pyrazin-2-amine (7i)13  
A solution of 4 M HCl in 1,4-dioxane (3.0 mL, 12 mmol) was added to a 
solution of di-tert-butyl 4,4'-(3-aminopyrazine-2,6-diyl)bis(piperidine-1-
carboxylate) (71) (0.3612 g, 0.78 mmol) in 3 mL anhydrous 1,4-dioxane. The 
reaction mixture, containing a white precipitate at this point, was then stirred 
for 1.5 hours at room temperature (23 °C) after which excess HCl and the 
solvent were removed in vacuo. The white residue obtained was resuspended in 45 mL EtOAc 
and basified to pH 11 by slowly adding 15% aqueous NaOH while vigorously stirring the 
mixture. The aqueous phase was removed using a separatory funnel. The organic layer was 
concentrated in vacuo to afford 7i as a white solid (0.1031 g, 50.7%) which was used in the 
next step without further purification; UPLC-MS, ESI+: m/z [M + H]+ = 262.1, calculated exact 
mass = 261.1953, tr = 0.11 min. 
 
6.1.3.14 Procedure for Synthesis of 3,5-bis(1-(methylsulfonyl)piperidin-4-yl)pyrazin-2-
amine (72)14 
To a suspension of 3,5-di(piperidin-4-yl)pyrazin-2-amine (7i) (0.1031 g, 
0.39 mmol) and triethylamine (0.54 mL, 3.9 mmol) in 3.5 mL DCM 
cooled to 0 °C, methanesulfonyl chloride (0.1 mL, 0.87 mmol) was added 
dropwise. The reaction mixture was then left to warm to room temperature 
(21.5 °C) and stirred for 12 hours. The reaction mixture was diluted with 
50 mL DCM and washed with deionized water (15 mL × 1), saturated 
aqueous solutions of NaHCO3 (15 mL × 2) and NaCl (15 mL × 2). The organic layer was dried 
(MgSO4) after which the solvent was removed in vacuo. The obtained residue was subjected 
to prep-TLC (silica, developed twice in 1.5% CH3OH/DCM) to deliver 72 as a white solid 
(0.038 g, 23%); m.p. 95 – 98 °C; Rf (CH3OH : CH2Cl2 8 : 92) 0.54;
 1H-NMR δH (300 MHz; 
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CDCl3) 8.31 (1H, s, H1), 4.06 – 3.94 (4H, m, H3e, H8e), 3.22 – 3.08 (1H, m, H6), 3.04 – 2.75 
(11H, m, H3a, H4, H5, H8a, H9), 2.21 – 1.86 (8H, m, H2a, H2e, H7a, H7e); purity: 98.7%, tr = 2.417 
min. 
 
6.1.3.15 Procedure for Synthesis of 5-(4-(methylsulfonyl)phenyl)-3-(piperazin-1-
yl)pyrazin-2-amine (67) 
A mixture of 3-bromo-5-(4-(methylsulfonyl)phenyl)pyrazin-2-amine (7h) 
(0.05 g, 0.15 mmol), 1-boc-piperazine (0.0426 g, 0.23 mmol) and triethylamine 
(0.1 mL, 0.45 mmol) in a sealed tube was heated to 170 °C and left to stir for 
4 hours. The reaction mixture, which was solid at this point, was suspended in 
60 mL EtOAc and basified to pH 11 by slowly adding a solution of 15% 
aqueous NaOH while stirring vigorously (cloudy mixture clears after about 45 
minutes). The aqueous phase was removed using a separatory funnel where after the organic 
layer was dried (Na2SO4). The solvent was removed in vacuo and the obtained residue triturated 
in ethyl acetate to furnish 67 as a brown solid (0.0787 g, 38.7%); m.p. 158 – 161 °C; Rf (CH3OH 
: CH2Cl2 8 : 92) 0.03;
 1H-NMR δH (400 MHz; DMSO-d6) 8.33 (1H, s, H2), 8.17 (2H, d, J = 8.6 
Hz, H3), 7.92 (2H, d, J = 8.6 Hz, H4), 6.27 (2H, s, H1), 3.21 (3H, s, H5), 3.11 – 3.06 (4H, m, 
H6), 2.93 – 2.87 (4H, m, H7); 
13C-NMR δC (101 MHz; DMSO-d6) 149.15, 145.83, 142.85, 
139.30, 135.36, 133.56, 127.83 (2C), 125.55 (2C), 49.57 (2C), 45.73 (2C), 44.22; HPLC-MS, 
APCI+: m/z [M + H]+ = 334.1, calculated exact mass = 333.1259, purity: 95.7%, tr = 0.170 min. 
 
6.1.3.16 Procedure for Synthesis of 5-(4-(methylsulfonyl)phenyl)-3-(4-
(methylsulfonyl)piperazin-1-yl)pyrazin-2-amine (68)14 
To a solution of 5-(4-(methylsulfonyl)phenyl)-3-(piperazin-1-yl)pyrazin-
2-amine (67) (0.0564 g, 0.17 mmol) and triethylamine (0.12 mL, 0.85 
mmol) in 1 mL DCM cooled to 0 °C, methanesulfonyl chloride (0.014 
mL, 0.19 mmol) was added dropwise. The reaction mixture was then left 
to warm to room temperature (20 °C) and stirred for 30 minutes. The 
reaction mixture was diluted with 40 mL DCM and washed with 
deionized water (5 mL × 2), saturated aqueous solutions of NaHCO3 (15 
mL × 2), and NaCl (15 mL × 2). The organic layer was dried (Na2SO4) after which the solvent 
was removed in vacuo. The crude mixture was subjected to prep-TLC (silica, developed once 
in 5% CH3OH/DCM) to deliver 68 which was crystallized in diethyl ether to give a yellow 
solid (0.0521 g, 74%); m.p. 239 – 242 °C; Rf (CH3OH : CH2Cl2 8 : 92) 0.49;
 1H-NMR δH (400 
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MHz; DMSO-d6) 8.39 (1H, s, H2), 8.19 (2H, d, J = 8.6 Hz, H3), 7.94 (2H, d, J = 8.6 Hz, H4), 
6.45 (2H, s, H1), 3.40 – 3.34 (4H, m, H6), 3.29 – 3.26 (4H, m, H7), 3.22 (3H, s, H5), 2.94 (3H, 
s, H8);
 13C-NMR δC (101 MHz; DMSO-d6) 149.13, 144.65, 142.61, 139.43, 135.40, 134.33, 
127.84 (2C), 125.67 (2C), 47.65 (2C), 45.50 (2C), 44.20, 34.76; HPLC-MS, APCI+: m/z [M + 
H]+ = 412.1, calculated exact mass = 411.1035, purity: 99.9%, tr = 2.447 min. 
 
6.2 Biological Assays 
6.2.1 In Vitro Asexual Blood Stage Antiplasmodial Assay 
Compounds were screened against multidrug resistant (K1) and sensitive (NF54) strains of P. 
falciparum in vitro using the modified [3H]-hypoxanthine incorporation assay.15 P. falciparum 
was cultivated in a variation of the medium previously described,16,17 consisting of RPMI 1640 
supplemented with 0.5% ALBUMAX® II, 25 mM Hepes, 25 mM NaHCO3 (pH 7.3), 0.36 mM 
hypoxanthine and 100 μg/mL neomycin. Human erythrocytes served as host cells. Cultures 
were maintained at 37 °C in an atmosphere of 3% O2, 4% CO2 and 93% N2 in humidified 
modular chambers. Compounds were dissolved by sonication in DMSO (10 mg/mL) and 
diluted in hypoxanthine-free culture medium. Infected erythrocytes (100 μL per well with 2.5% 
hematocrit and 0.3% parasitemia) were added to each drug titrated in 100 μL duplicates over a 
64-fold range. After 48 hours incubation, 0.5 μCi of [3H]hypoxanthine in 50 μL medium was 
added and plates were incubated for an additional 24 hours. Parasites were harvested onto 
glass-fiber filters and radioactivity was counted using a Betaplate liquid scintillation counter 
(Wallac, Zurich). The results were recorded as counts per minute (cpm) per well at each drug 
concentration and expressed as a percentage of the untreated controls. Fifty percent inhibitory 
concentrations (IC50) were estimated by linear interpolation.
18 
 
6.2.2 In Vitro Gametocytocidal Assay 
6.2.2.1 Luciferase Reporter Assay 
Two transgenic parasite lines (NF54-PfS16-GFP-Luc and NF54-Mal8p1.16-GFP-Luc) were 
used in the luciferase assays which facilitated stage-specific determination of gametocytocidal 
activity. Gametocytes were produced according to Reader et al.19 On days 5 and 10 which 
respectively represent > 90% of early stage (I – III) and > 90% of late stage (IV and V) 
gametocytes, drug assays where set up. In both cases, 2 – 3% gametocytaemia and 1.5% 
haematocrit culture were used with a 48 hour drug pressure in a gas chamber (90% N2, 5% O2 
and 5% CO2) at 37ºC. To 20 μL parasite lysates, 50 μL of luciferin substrate (Promega 
Luciferase Assay System) was added at room temperature. Luciferase activity was determined 
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by detection of resulting bioluminescence at an integration constant of 10 seconds using the 
GloMax®-Multi+ Detection System with Instinct® Software. Methylene blue and 
dihydroartemisinin were used as controls. 
 
6.2.2.2 ATP Assay 
In the ATP assay, late stage gametocytes (IV and V, primarily stage V) were enriched using 
density gradient centrifugation and magnetic separation. Dilutions for the compounds were 
prepared in triplicate in 96-well plates. To each well, about 50,000 gametocytes in glucose-rich 
complete medium were added to make a final volume of 100 μL where after the plates were 
incubated at 37 °C in a humidified gas chamber (90% N2, 5% O2 and 5% CO2) for 24 hours. 
The BacTiter-Glo™ assay (Promega) was then carried out in accordance with the 
manufacturer’s guidelines at room temperature in the dark with assay substrate incubated for 
10 minutes to detect ATP levels. The GloMax®-Multi+ Detection System with Instinct® 
Software was used to detect bioluminescence at an integration constant of 0.5 seconds. 
Methylene blue and dihydroartemisinin were used controls. 
 
6.2.3 In Vitro Liver Stage Assay  
Luminescence intensity in Huh7 cells, a human hepatoma cell line, infected with a firefly 
luciferase-expressing P. berghei line, PbGFP-Luccon was used to determine inhibition of liver 
stage infection as previously described.20 A 1640 RPMI medium supplemented with 10% v/v 
fetal calf serum (FCS), 1% v/v non-essential amino acids, 1% v/v penicillin/streptomycin, 1% 
v/v glutamine and 10 mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulphonic acid (HEPES), pH 
7, and maintained at 37 °C with 5% CO2 was used to culture the Huh7 cells. Dulbecco’s 
Modified Eagle Medium (DMEM) (Gibco/Invitrogen) was used to harvest salivary glands from 
female Anopheles stephensi mosquitoes. The salivary glands were then homogenized in a 
grinder after which the resulting homogenate was filtered and centrifuged at 3000 RPM for 5 
minutes. Phase-contrast microscopy was then used to count free sporozoites in a Neubauer 
chamber. DMSO was used to prepare 10 mM stock solutions of test compounds which were 
diluted with 1640 RPMI medium. A day before drug treatment and infection, Huh7 cells (1.2 
× 104 per well) were seeded in 96-well plates. About 1 hour prior to infection with freshly 
obtained sporozoites, the medium in the cells was replaced by medium containing the 
appropriate concentration of each compound. The plates were centrifuged at 1700 RPM for 5 
minutes following sporozoite addition. The AlamarBlue assay (Invitrogen, UK) was used to 
assess the effect of the compounds on the viability of Huh7 cells using the manufacturer’s 
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protocol. A Tecan Infinite M200 spectrometer (Tecan Group, Switzerland) was used to 
measure fluorescence intensity at 530 nm excitation wavelength and 590 nm emission 
wavelength. A Luciferase Assay System Kit (Promega, Netherlands) was used to determine 
parasite load by measuring luminescence 48 hours post-infection according to the 
manufacturer's instructions. Briefly, phosphate buffer was used to wash out the 96-well plate 
after which cells were incubated with 75 μL of lysis buffer for 15 minutes in a shaker at 600 
RPM. After the lysis, debris and membranes were then deposited by centrifuging the 96-well 
plate at 3000 RPM for 5 minutes. The supernatant (30 μL) was then transferred into a white 
96-well plate and the luciferase activity was measured by adding 50 μL of Luciferase Assay 
substrate (1:50 dilution) (Luciferase Assay System Kit, Promega, Netherlands). A Tecan 
Infinite M200 spectrometer (Tecan Group, Switzerland) was used to measure luminescence 
intensity. To fit the normalized results of the dose-response curves, nonlinear regression 
analysis was employed, and IC50 values were determined using GraphPad Prism V 5.0. 
 
6.2.4 In Vitro hERG Inhibition Assay 
A QPatch hERG assay employing a four-point concentration-response format was used to carry 
out hERG inhibition studies by the UK-based Metrion Biosciences Ltd. The hERG gene was 
stably expressed in a CHO cell line which was grown and passaged under standard culture 
conditions. The external (e) and internal (i) recording solutions were of the following 
compositions (mM): NaCl – 140 (e) : 0 (i); KCl – 2 (e) : 70 (i); KF - 0 (e) : 60 (i); HEPES - 10 
(e) : 10 (i); MgCl2 - 1 (e) : 0 (i); CaCl2 - 2 (e) : 0 (i); Glucose - 5 (e) : 0 (i); EGTA - 0 (e) : 5 
(i); Mg2ATP - 0 (e) : 5 (i) and pH – 7.4 (NaOH) (e) : 7.2 (KOH) (i). The external recording 
solution was regularly prepared and kept at 4 °C until required and was maintained at room 
temperature during recording. The internal recording solution was prepared and kept at – 20 
°C until required. 
The QPatch is a chip-based planar patch clamp which is automated. Using suction, cells added 
to each well are drawn across a small aperture creating a Giga-ohm seal between the membrane 
surface and a treated silicon surface. A small volume of bathing solution containing the test 
compound or control bathing solution is added to a reservoir on the chip which perfuses across 
the cell through quartz-lined microfluidic channels. The solution is removed by capillary action 
before the next sample is added. Using the industry +40/-40 voltage protocol, currents were 
triggered from a holding potential of -90 mV at a stimulus frequency of 0.1 Hz. 
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By cumulatively adding four escalating concentrations of the test compounds to an individual 
cell, the concentration response curves were established. This was done by firstly allowing the 
whole-cell configuration to be achieved followed by the addition of the vehicle (0.1% DMSO 
v/v in external recording solution) to each well in two bolus additions allowing a two-minute 
recording time between each addition. This was followed by the addition of four concentrations 
(0.3 – 10 μM) of test compounds in two bolus additions at 2-minute intervals. The effect on the 
hERG tail current amplitude was measured during the 4-minute recording time. The 
concentrations (0.3, 1, 3 and 10 μM) of the test samples were prepared in such a way to have a 
final concentration of 0.1% of DMSO v/v in the external recording solution. For each 
compound, the experiments at each concentration were done in triplicate and using a 
bioinformatics suite developed and running in Pipeline Pilot (Biovia, USA), the percent 
inhibition, as a reduction in mean peak current relative to the value measured at the end of the 
vehicle control period, was calculated. Such percent inhibition data were used to construct the 
concentration-response curves which enabled calculation of the IC50 values. For compounds 
which could not achieve 50% inhibition even at the highest tested concentration of 10 μM, 
extrapolated IC50 values for such are reported. In this regard, all IC50 values above 10 μM 
reported in this thesis were extrapolated and should be treated with caution. 
 
6.2.5 In Vitro Cytotoxicity Assay21 
Cytotoxicity was measured using the MTT-assay which measures cellular growth and survival 
calorimetrically. All growth and chemosensitivity was measured by the formation of 
tetrazolium salt. The test samples were assayed in triplicate on one occasion. Stock solutions 
of 2 mg/mL of test samples in DMSO were prepared with poorly soluble samples being tested 
as suspensions. The test samples were kept at -20 °C until required. In all experiments, emetine 
was used as a reference drug. 10-fold serial dilutions in complete medium to give 6 
concentrations were made from an initial concentration of 100 µg/mL with the lowest 
concentration being 0.001 µg/mL. The cell viability was not affected by the highest 
concentration of the solvent to which the cells were exposed. The full dose-response curves 
plotted using a non-linear dose-response curve fitting analysis via GraphPad Prism V 4 
software enabled the determination of the IC50 values. 
 
6.2.6 Metabolic Stability Assay 
The metabolic stability assay was performed in duplicate in a 96-well micro titre plate. The test 
compounds (0.1 µM) were incubated (37 °C) in mouse, rat and pooled human liver microsomes 
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(final protein concentration of 0.4 mg/mL; XenoTech, Lenexa, KS) suspended in 0.1 M 
phosphate buffer (pH 7.4) for 30 minutes, in the presence and absence of the cofactor NADPH 
(1 mM). The reactions were quenched by the addition of ice cold acetonitrile containing an 
internal standard (carbamazepine, 0.0236 µg/mL). The samples were centrifuged, and the 
supernatant was filtered and analysed by means of HPLC-MS/MS (Agilent Rapid Resolution 
HPLC, AB SCIEX 4500 MS). The relative loss of parent compound over time was monitored 
and plots were prepared for each compound of concentration versus time to determine the first 
order rate constant for compound depletion. This was used to calculate the degradation half-
life, in vitro intrinsic clearance value and subsequently to predict the in vivo hepatic extraction 
ratio (EH). Metabolite searches were not conducted during the metabolic stability assay. 
 
6.3 Solubility Determination 
6.3.1 Kinetic Solubility Employing HPLC 
A miniaturised shake flask method was used to perform the solubility assay.22 From 10 mM 
stock solutions of the test compounds in DMSO, calibration standards (10 - 220 μM in DMSO) 
were prepared. The 10 mM stock solutions were also used to spike (1:50) duplicate aqueous 
samples in phosphate buffered saline (pH 6.5). The DMSO was dried off in a GeneVac (MiVac, 
90 min, 37 °C) after which the samples were incubated while shaking for 20 hours at 25 °C. 
Thereafter, the solutions were filtered, and their absorbance measured using HPLC-DAD 
(Agilent 1200 Rapid Resolution HPLC with a diode array detector). The calibration standards 
were used to plot the calibration curves, which were used to determine the solubility of the 
aqueous samples. 
 
6.3.2 Kinetic (Turbidimetric) Solubility23 
A phosphate buffered saline (PBS) solution comprising 0.14 M NaCl, 0.003 M KCl and 0.01 
M phosphate buffer (pH 7.4) was prepared by dissolving one intact PBS buffer tablet in 1 L of 
water. Particulate contaminants were removed by filtering the solution through a 0.22 μm nylon 
filter and the pH verified using a pH meter. Stock solutions (10 mM) of test compounds were 
prepared by dissolving in DMSO. Using a 96-well plate, serial dilutions of the compounds in 
DMSO were prepared in triplicate starting from 8 mM to 0.25 mM (predilution plate). 
Secondary serial dilutions (5 – 200 μM) in DMSO and PBS buffer, also in triplicate, were 
prepared by pipetting 4 μL aliquots from the predilution plate to corresponding wells in the 
secondary plate containing 196 μL DMSO and PBS buffer (final volume of 200 μL in each 
CHAPTER 6: EXPERIMENTAL 
243 
 
well). The serial dilutions in DMSO acted as controls to make sure the test compounds in 
solution did not absorb electromagnetic radiation at the test wavelength. The plate was covered 
and incubated for 2 hours in an oven maintained at 37 °C. The absorbance values of the wells 
were then measured by a UV-Visible Multiskan Go 1510-05438 spectrometer (Thermo 
Scientific). The values were then corrected by subtracting the absorbance of the blank wells 
containing only DMSO and 2% DMSO in PBS. The corrected absorbance values were plotted 
as a function of concentration using excel. A constant absorbance value of 0 at all 
concentrations indicates the compound is soluble at all concentrations. Insoluble compounds 
will precipitate and cause turbidity the absorbance of which was measured by a UV-Visible 
spectrometer. Solubility was taken to be that concentration above which the test compound 
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